Multisubunit hepacivirus vaccines and therapeutics

Abstract

The present disclosure relates generally to multisubunit nucleic acids comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from a hepacivirus. The multisubunit nucleic acid encodes a multisubunit peptide.

Description

[0001]PVM-00425 (PVX-PAT-2406-WO) Multisubunit Hepacivirus Vaccines and Therapeutics RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application serial number 63 / 663,910, filed on June 25, 2024, the entire contents of which are hereby incorporated herein by reference in its entirety. REFERENCE TO A SEQUENCE LISTING XML This application contains a Sequence Listing which has been submitted electronically in XML format. The Sequence Listing XML is incorporated herein by reference. Said XML file, created on June 20, 2025, is named PVM-00425.xml and is 12,304,384 bytes in size. BACKGROUND Hepatitis C is a viral infection affecting liver caused by hepatitis C virus. According to the World Health Organization (WHO) an estimated 50 million people have chronic hepatitis C virus infection, with about 1.0 million new infections occurring per year. The WHO has estimated approximately 2,42,000 deaths due to hepatitis C in the year 2022. Although antivirals are available, they are unaffordable to a large majority in the low- and middle-income countries. So far there has been no effective vaccine against hepatitis C. Therefore, effective vaccine against hepatitis C is an important necessity. SUMMARY Accordingly, the present disclosure relates to a multisubunit nucleic acid comprising a plurality of polynucleotide sequences, wherein some or all polynucleotide sequences of the plurality comprises either a target sequence, a linker sequence, and a self- assembling sequence or a linker sequence, a target sequence, a linker sequence and a self- assembling sequence or a combination thereof, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence. In some embodiments, the multisubunit nucleic acid PVM-00425 (PVX-PAT-2406-WO) further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality. In some embodiments, the target sequence is obtained or derived from E1 protein, E2 protein, or a combination thereof of a hepacivirus. In some embodiments, the linker sequence comprises a zipper sequence, an amino acid linker sequence, or a combination thereof. In some embodiments, the target sequence, the linker sequence, and the self-assembling sequence or the linker sequence, the target sequence, thelinker sequence, and the self-assembling sequence are in 5 to 3 order.In some embodiments, provided herein is a multisubunit nucleic acid comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence. In some embodiments, the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality. In some embodiments, the target sequence is obtained or derived from E1 protein, E2 protein, or a combination thereof of a hepacivirus. In some embodiments, the linker sequence comprises a zipper sequence, an amino acid linker sequence, or a combination thereof. In some embodiments, the target sequence, the linker sequence, and the self-assemblingsequence are in 5 to 3 order.In some embodiments, provided herein is a multisubunit nucleic acid comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a linker sequence, a target sequence, a linker sequence, and a self- assembling sequence, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence. In some embodiments, the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality. In some embodiments, the target sequence is obtained or derived from E1 protein, E2 protein, PVM-00425 (PVX-PAT-2406-WO) or a combination thereof of a hepacivirus. In some embodiments, the linker sequence comprises a zipper sequence, an amino acid linker sequence, or a combination thereof. In some embodiments, the linker sequence, the target sequence, the linker sequence, and theself-assembling sequence are in 5 to 3 order.In another aspect, provided herein is a vaccine comprising a multisubunit nucleic acid, wherein the multisubunit nucleic acid comprises a plurality of polynucleotide sequences, wherein some or all polynucleotide sequences of the plurality comprises either a target sequence, a linker sequence, and a self-assembling sequence or a linker sequence, a target sequence, a linker sequence and a self-assembling sequence or a combination thereof, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence. In some embodiments, the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality. In some embodiments, the target sequence is obtained or derived from E1 protein, E2 protein, or a combination thereof of a hepacivirus. In some embodiments, the linker sequence comprises a zipper sequence, an amino acid linker sequence, or a combination thereof. In some embodiments, the target sequence, the linker sequence, and the self-assembling sequence or the linker sequence, the target sequence, the linker sequence, and the self-assembling sequence are in 5 to 3 order.In some embodiments, provided herein is a vaccine comprising a multisubunit nucleic acid, wherein the multisubunit nucleic acid comprises a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence. In some embodiments, the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality. In some embodiments, the target sequence is PVM-00425 (PVX-PAT-2406-WO) obtained or derived from E1 protein, E2 protein, or a combination thereof of a hepacivirus. In some embodiments, the linker sequence comprises a zipper sequence, an amino acid linker sequence, or a combination thereof. In some embodiments, the target sequence, thelinker sequence, and the self-assembling sequence are in 5 to 3 order.In some embodiments, provided herein is a vaccine comprising a multisubunit nucleic acid, wherein the multisubunit nucleic acid comprises a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence. In some embodiments, the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality. In some embodiments, the target sequence is obtained or derived from E1 protein, E2 protein, or a combination thereof of a hepacivirus. In some embodiments, the linker sequence comprises a zipper sequence, an amino acid linker sequence, or a combination thereof. In some embodiments, the linker sequence, the target sequence, the linker sequence, and the self-assembling sequence are in5 to 3 order.In another aspect, provided herein is a multisubunit nucleic acid encoding a plurality of polypeptides, wherein some or all polypeptides of the plurality comprises either a target peptide, a linker peptide, and a self-assembling peptide or a linker peptide, a target peptide, a linker peptide and a self-assembling peptide or a combination thereof, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide. In some embodiments, the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of one or more of the polypeptides of the plurality. In some embodiments, the target peptide is obtained or derived from E1 protein, E2 protein, or a combination thereof of a hepacivirus. In some embodiments, the linker peptide comprises a zipper motif, an amino acid linker or a combination thereof. In PVM-00425 (PVX-PAT-2406-WO) some embodiments, the cleavage peptide comprises one or more cleavage peptides. In some embodiments, the target peptide, the linker peptide, and the self-assembling peptide or the linker peptide, the target peptide, the linker peptide and the self-assembling peptide are in N-terminus to C-terminus order. In some embodiments, provided herein is a multisubunit nucleic acid encoding a plurality of polypeptides, wherein each polypeptide of the plurality comprises a target peptide, a linker peptide, and a self-assembling peptide, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide. In some embodiments, the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of one or more of the polypeptides of the plurality.. In some embodiments, the target peptide is obtained or derived from E1 protein, E2 protein, or a combination thereof of a hepacivirus. In some embodiments, the linker peptide comprises a zipper motif, an amino acid linker or a combination thereof. In some embodiments, the cleavage peptide comprises one or more cleavage peptides. In some embodiments, the target peptide, the linker peptide, and the self-assembling peptide are in N-terminus to C-terminus order. In some embodiments, provided herein is a multisubunit nucleic acid encoding a plurality of polypeptides, wherein each polypeptide of the plurality comprises a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide. In some embodiments, the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of one or more of the polypeptides of the plurality. In some embodiments, the target peptide is obtained or derived from E1 protein, E2 protein, or a combination thereof of a hepacivirus. In some embodiments, the linker peptide comprises a zipper motif, an amino acid linker or a combination thereof. In some embodiments, the cleavage peptide comprises one or more cleavage peptides. In some PVM-00425 (PVX-PAT-2406-WO) embodiments, the linker peptide, the target peptide, the linker peptide, and the self- assembling peptide are in N-terminus to C-terminus order. In another aspect, provided herein is a vaccine comprising a multisubunit nucleic acid encoding a plurality of polypeptides, wherein some or all polypeptides of the plurality comprises either a target peptide, a linker peptide, and a self-assembling peptide or a linker peptide, a target peptide, a linker peptide and a self-assembling peptide or a combination thereof, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide. In some embodiments, the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of one or more of the polypeptides of the plurality. In some embodiments, the target peptide is obtained or derived from E1 protein, E2 protein, or a combination thereof of a hepacivirus. In some embodiments, the linker peptide comprises a zipper motif, an amino acid linker or a combination thereof. In some embodiments, the cleavage peptide comprises one or more cleavage peptides. In some embodiments, the target peptide, the linker peptide, and the self-assembling peptide or the linker peptide, the target peptide, the linker peptide and the self-assembling peptide are in N-terminus to C-terminus order. In some embodiments, provided herein is a vaccine comprising a multisubunit nucleic acid encoding a plurality of polypeptides, wherein each polypeptide of the plurality comprises a target peptide, a linker peptide, and a self-assembling peptide, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide. In some embodiments, the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of one or more of the polypeptides of the plurality. In some embodiments, the target peptide is obtained or derived from E1 protein, E2 protein, or a combination thereof of a hepacivirus. In some embodiments, the linker peptide comprises a zipper motif, an amino acid linker or a combination thereof. In some embodiments, the cleavage peptide comprises one or more cleavage peptides. In PVM-00425 (PVX-PAT-2406-WO) some embodiments, the target peptide, the linker peptide, and the self-assembling peptide are in N-terminus to C-terminus order. In some embodiments, provided herein is a vaccine comprising a multisubunit nucleic acid encoding a plurality of polypeptides, wherein each polypeptide of the plurality comprises a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide. In some embodiments, the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of one or more of the polypeptides of the plurality. In some embodiments, the target peptide is obtained or derived from E1 protein, E2 protein, or a combination thereof of a hepacivirus. In some embodiments, the linker peptide comprises a zipper motif, an amino acid linker or a combination thereof. In some embodiments, the cleavage peptide comprises one or more cleavage peptides. In some embodiments, the linker peptide, the target peptide, the linker peptide, and the self- assembling peptide are in N-terminus to C-terminus order. In some embodiments, total number of the polynucleotide sequences are not more than 100. In some embodiments, total number of the polynucleotide sequences are between 2-5, 2-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, or 90-99. In some embodiments, the multisubunit nucleic acid is a DNA or an RNA. In some embodiments, the RNA is an mRNA. In some embodiments, the mRNA is obtained or synthesized through a single IVT process or step. In some embodiments, the linker sequence encodes a linker peptide. In some embodiments, the linker peptide is an amino acid linker, a zipper motif, a foldon, a scaffold, or a combination thereof. In some embodiments, the linker peptide is an amino acid linker. In some embodiments, the linker peptide is a zipper motif. In some embodiments, the linker peptide is a foldon. In some embodiments, the linker peptide is a scaffold. In some embodiments, the linker peptide comprises an amino acid linker and a zipper motif. In some embodiments, the linker peptide comprises an amino acid linker and a foldon. In some embodiments, the linker peptide comprises an amino acid linker and a scaffold. In some embodiments, the linker peptide comprises a zipper motif and a scaffold. In some embodiments, the linker peptide comprises a foldon and a scaffold. In some PVM-00425 (PVX-PAT-2406-WO) embodiments, the linker peptide comprises an amino acid linker, a zipper motif, and a scaffold. In some embodiments, the linker peptide comprises an amino acid linker, a foldon, and a scaffold. In some embodiments, the amino acid linker comprises 2 to 49 amino acids. In some embodiments, the amino acid linker is a glycine serine linker, a glycine proline linker, a glycine threonine linker, an alanine serine linker, any combination of two amino acids, or a combination thereof. In some embodiments, the linker peptide has an amino acid sequence of any one of SEQ ID NOs: 12-51 or 12116-12120. In some embodiments, the self-assembling sequence encodes a self-assembling peptide. In some embodiments, the self-assembling peptide is lumazine synthase, MS2 coat protein, hepatitis B surface antigen (HBsAg) from Hepatitis B Virus, hepatitis B core antigen (HBcAg) from Hepatitis B virus, human papillomavirus L1 (HPV L1) protein, matrix protein M1 from influenza A virus, ferritin, riboflavin synthase, dihydrolipoyl acetyltransferase (E2p), or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, comparable equivalents or functional analogs thereof. In some embodiments, the ferritin comprises of ferritin subunit or ferritin peptide. In some embodiments, the ferritin peptide is obtained or derived from Listeria innocua or Helicobacter pylori. In some embodiments, the ferritin peptide is obtained or derived from Listeria innocua ferritin, or its fragment, mutant, variant, comparable equivalent, or functional analogs thereof. In some embodiments, the ferritin peptide is obtained or derived from Helicobacter pylori ferritin, or its fragment, mutant, variant, comparable equivalent, or functional analogs thereof. In some embodiments, the dihydrolipoyl acetyltransferase (E2p) is obtained or derived from Bacillus stearothermophilus, or its fragment, mutant, variant, comparable equivalent, or functional analogs thereof. In some embodiments, the lumazine synthase is obtained or derived from Aquifex species (for example, Aquifex aeolicus) or Bacillus species (for example, Bacillus subtilis), or its fragment, mutant, variant, comparable equivalent, or functional analogs thereof. In some embodiments, the MS2 coat protein is obtained or derived from Emesvirus zinderi, or its fragment, mutant, variant, comparable equivalent, or functional analogs thereof. In some embodiments, the self-assembling peptide has an amino acid sequence of any one of SEQ ID NOs: 1-11 or 12112-12115. PVM-00425 (PVX-PAT-2406-WO) In some embodiments, the cleavage sequence encodes a cleavage peptide. In some embodiments, the cleavage sequence encodes one or more cleavage peptides. In some embodiments, the cleavage peptide comprises one or more cleavage peptides, for example, cleavage peptide-1, cleavage peptide-2, and so on. In some embodiments, the one or more cleavage peptides are optionally connected to each other by a linker peptide. In some embodiments, the cleavage peptide is a golgi specific cleavage peptide or self cleaving peptide. In some embodiments, the cleavage peptide has an amino acid sequence of any one of SEQ ID NOs: 52-66. In some embodiments, the signal sequence encodes a signal peptide. In some embodiments, the signal peptide is present on the amino-terminus of the first polypeptide. In some embodiments, the multisubunit nucleic acid further encodes a second signal peptide on the amino-terminus of all or some polypeptides. In some embodiments, the signal peptide has an amino acid sequence of any one of SEQ ID NOs: 67-86. In some embodiments, the target sequence encodes a target peptide. In some embodiments, the target peptide is encoded by a codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the target peptide is a core protein of a hepacivirus, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the core protein has an amino acid sequence of any one of SEQ ID NOs: 88-353, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the target peptide is an E1 protein of a hepacivirus, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the E1 protein has an amino acid sequence of any one of SEQ ID NOs: 354-959 or 12121, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. PVM-00425 (PVX-PAT-2406-WO) In some embodiments, the target peptide is an E2 protein of a hepacivirus, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the E2 protein has an amino acid sequence of any one of SEQ ID NOs: 960-1582 or 12122, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the target peptide is a P7 protein of a hepacivirus, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the P7 protein has an amino acid sequence of any one of SEQ ID NOs: 1583-2026, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the target peptide is an NS2 protein of a hepacivirus, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the NS2 protein has an amino acid sequence of any one of SEQ ID NOs: 2027-2651, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the target peptide is an NS3 protein of a hepacivirus, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the NS3 protein has an amino acid sequence of any one of SEQ ID NOs: 2652-3284, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the target peptide is an NS4A protein of a hepacivirus, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the NS4A protein has an amino acid sequence of any one of SEQ ID NOs: 3285-3462, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the target peptide is an NS4B protein of a hepacivirus, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the NS4B PVM-00425 (PVX-PAT-2406-WO) protein has an amino acid sequence of any one of SEQ ID NOs: 3463-4004, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the target peptide is an NS5A protein of a hepacivirus, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the NS5A protein has an amino acid sequence of any one of SEQ ID NOs: 4005-4627, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the target peptide is an NS5B protein of a hepacivirus, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the NS5B protein has an amino acid sequence of any one of SEQ ID NOs: 4628-5247, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the target peptide is a B cell epitope of a hepacivirus, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the B cell epitope has an amino acid sequence of any one of SEQ ID NOs: 5248-10039, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the target peptide is a T cell epitope of a hepacivirus, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the T cell epitope has an amino acid sequence of any one of SEQ ID NOs: 10040-12111, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the target peptide has an amino acid sequence of any one of SEQ ID NOs: 88-12111 or 12121-12122, including its codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In another aspect, provided herein is a lipid nanoparticle composition comprising a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid PVM-00425 (PVX-PAT-2406-WO) according to any of the preceding embodiments or paragraphs. In some embodiments, the cationic lipid comprises an ionizable lipid. In some embodiments, the cationic lipid is present in an amount from 10 mol percent to 70 mol percent. In some embodiments, the phospholipid is present in an amount from 2 mol percent to 65 mol percent. In some embodiments, the sterol is present in an amount from 20 mol percent to 65 mol percent. In some embodiments, the PEG-lipid is present in an amount from 0.2 mol percent to 2.0 mol percent. In some embodiments, the lipid nanoparticle composition additionally comprises an ionizable polymer. In some embodiments, the ionizable polymer is present in an amount from 1 mol percent to 25 mol percent. In some embodiments, the ionizable polymer is selected from the group comprising a chitosan, chitosan derivatives, cellulose derivatives, a poly-L-lysine (PLL), a protamine, a polyethyleneimine, and / or their derivatives or a combination thereof. In some embodiments, the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), or formula (VIII), or SM-102, or ALC-0315, or a combination thereof. In some aspects, provided herein is a vaccine comprising a lipid nanoparticle, wherein the lipid nanoparticle comprises a cationic lipid, a phospholipid, a sterol, a PEG- lipid, and the multisubunit nucleic acid according to any of the preceding embodiments or paragraphs. In some embodiments, the cationic lipid comprises an ionizable lipid. In some embodiments, the cationic lipid is present in an amount from 10 mol percent to 70 mol percent. In some embodiments, the phospholipid is present in an amount from 2 mol percent to 65 mol percent. In some embodiments, the sterol is present in an amount from 20 mol percent to 65 mol percent. In some embodiments, the PEG-lipid is present in an amount from 0.2 mol percent to 2.0 mol percent. In some embodiments, the lipid nanoparticle composition additionally comprises an ionizable polymer. In some embodiments, the ionizable polymer is present in an amount from 1 mol percent to 25 mol percent. In some embodiments, the ionizable polymer is selected from the group comprising a chitosan, chitosan derivatives, cellulose derivatives, a poly-L-lysine (PLL), a protamine, a polyethyleneimine, and / or their derivatives or a combination thereof. In some embodiments, the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), or formula (VIII), or SM-102, or ALC-0315, or a combination thereof. PVM-00425 (PVX-PAT-2406-WO) In another aspect, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof the multisubunit nucleic acid disclosed herein. In another aspect, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof the multisubunit peptide disclosed herein. In another aspect, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof the lipid nanoparticle or the lipid nanoparticle composition disclosed herein. In another aspect, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof, the vaccine comprising the multisubunit nucleic acid disclosed herein. In another aspect, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof, the vaccine comprising the multisubunit peptide disclosed herein. In another aspect, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof, the vaccine comprising the lipid nanoparticle or the lipid nanoparticle composition disclosed herein. In another aspect, provided herein is use of the multisubunit nucleic acid disclosed herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject. In another aspect, provided herein is use of the lipid nanoparticle composition disclosed herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject. In another aspect, provided herein is use of the vaccine comprising the multisubunit nucleic acid disclosed herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject. In another aspect, provided herein is use of the vaccine comprising the lipid nanoparticle composition disclosed herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject. In another aspect, provided herein is a multisubunit peptide encoded by the multisubunit nucleic acid disclosed herein. PVM-00425 (PVX-PAT-2406-WO) In another aspect, provided herein is a multisubunit peptide comprising two or more polypeptides, wherein some or all polypeptides comprises either a target peptide, a linker peptide, and a self-assembling peptide, or a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, or a combination thereof, wherein one polypeptide is connected to another polypeptide by a cleavage peptide, wherein the multisubunit peptide includes a signal peptide upstream (amino-terminus) of one or more of the polypeptides, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the signal peptide is present on the amino-terminus of the first polypeptide. In some embodiments, the signal peptide is present on the amino- terminus of some or each of the polypeptides. In another aspect, provided herein is a polypeptide nanoparticle comprising at least 2 or up to 500 polypeptides disclosed herein. In some embodiments, the polypeptides are homologous polypeptides, heterologous polypeptides, oligomeric complexes, polypeptide clusters, or combination thereof. In some embodiments, the polypeptide nanoparticle is icosahedral, helical, spherical, rod-like or a combination thereof. In another aspect, provided herein is a multisubunit nucleic acid sequence comprising two or more polynucleotide sequences, wherein some or all polynucleotide sequences comprises either a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein one polynucleotide sequence is connected to another polynucleotide sequence by a cleavage sequence, wherein the multisubunit nucleic acid sequence includes a signal sequence upstream of one or more of the polynucleotide sequences, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the linker sequence connects the signal sequence with the first polynucleotide sequence. In some embodiments, the signal sequence is present upstream of all or some of the polynucleotide sequences. In some embodiments, the signal sequence is present upstream of the first polynucleotide sequence. In some embodiments, the signal sequence is present upstream of all polynucleotide sequences. In some embodiments, the linker sequence connects the target sequence with the self-assembling PVM-00425 (PVX-PAT-2406-WO) sequence in a polynucleotide sequence. In some embodiments, one linker sequence connects the cleavage sequence with the target sequence and another linker sequence connects the target sequence with the self-assembling sequence in a polynucleotide sequence. In some embodiments, the multisubunit nucleic acid sequence is a DNA or an RNA. In some embodiments, the multisubunit nucleic acid sequence is an mRNA. In some embodiments, the multisubunit nucleic acid sequence encodes a multisubunit peptide. In some embodiments, the multisubunit nucleic acid sequence is formulated or encapsulated in a lipid nanoparticle composition. In some embodiments, the multisubunit nucleic acid sequence is obtained or synthesized through one or more in vitro transcription (IVT) process. In some embodiments, the multisubunit nucleic acid sequence (for example mRNA) is synthesized or obtained through a single in vitro transcription (IVT) process or step. In some embodiments, the disclosure relates to a multisubunit nucleic acid sequence encoding a multisubunit peptide described herein. In some embodiments, the disclosure relates to a vaccine comprising a multisubunit nucleic acid sequence encoding a multisubunit peptide described herein. In some embodiments, the disclosure relates to a multisubunit nucleic acid sequence encoding a multisubunit peptide comprising two or more polypeptides, wherein some or all polypeptides comprises either a target peptide, a linker peptide, and a self- assembling peptide, or a linker peptide, a target peptide, a linker peptide, and a self- assembling peptide, or a combination thereof, wherein one polypeptide is connected to another polypeptide by a cleavage peptide, wherein the multisubunit peptide includes a signal peptide upstream of one or more of the polypeptides, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, a signal peptide is present upstream (amino-terminus) of all or some of the polypeptides. In some embodiments, a signal peptide is present upstream (amino-terminus) of the first polypeptide. In some embodiments, a signal peptide is present upstream (amino-terminus) of all polypeptides. In some embodiments, the disclosure relates to a vaccine comprising a multisubunit nucleic acid sequence encoding a multisubunit peptide, wherein multisubunit peptide comprises two or more polypeptides, wherein some or all polypeptides comprises either a PVM-00425 (PVX-PAT-2406-WO) target peptide, a linker peptide, and a self-assembling peptide, or a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, or a combination thereof, wherein one polypeptide is connected to another polypeptide by a cleavage peptide, wherein the multisubunit peptide includes a signal peptide upstream of one or more of the polypeptides, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, a signal peptide is present upstream (amino-terminus) of all or some of the polypeptides. In some embodiments, a signal peptide is present upstream (amino-terminus) of the first polypeptide. In some embodiments, a signal peptide is present upstream (amino-terminus) of all polypeptides. In some embodiments, the disclosure also relates to a multisubunit peptide comprising two or more polypeptides, wherein some or all polypeptides comprises either a target peptide, a linker peptide, and a self-assembling peptide, or a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, or a combination thereof, wherein one polypeptide is connected to another polypeptide by a cleavage peptide, wherein the multisubunit peptide includes a signal peptide upstream (amino-terminus) of one or more of the polypeptides, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, signal peptide is present upstream (amino-terminus) of all or some of the polypeptides. In some embodiments, a signal peptide is present upstream (amino-terminus) of the first polypeptide. In some embodiments, a signal peptide is present upstream (amino-terminus) of all the polypeptides. In some embodiments, the disclosure also relates to a vaccine comprising a multisubunit peptide, wherein the multisubunit peptide comprises two or more polypeptides, wherein some or all polypeptides comprises either a target peptide, a linker peptide, and a self-assembling peptide, or a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, or a combination thereof, wherein one polypeptide is connected to another polypeptide by a cleavage peptide, wherein the multisubunit peptide includes a signal peptide upstream (amino-terminus) of one or more of the polypeptides, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, PVM-00425 (PVX-PAT-2406-WO) NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, a signal peptide is present upstream (amino-terminus) of all or some of the polypeptides. In some embodiments, a signal peptide is present upstream (amino-terminus) of the first polypeptide. In some embodiments, a signal peptide is present upstream (amino-terminus) of all the polypeptides In some embodiments, the linker peptide connects the signal peptide with the first polypeptide in a multisubunit peptide. In some embodiments, the linker peptide connects the target peptide with the self-assembling peptide in a polypeptide. In some embodiments, one linker peptide connects the cleavage peptide with the target peptide and another linker peptide connects the target peptide with the self-assembling peptide in a polypeptide. In some embodiments, the multisubunit peptide comprises homologous polypeptides. In some embodiments, the multisubunit peptide comprises heterologous polypeptides. In some embodiments, the multisubunit peptide comprises homologous polypeptides, or heterologous polypeptides. In some embodiments, the disclosure relates to a polypeptide nanoparticle comprising one or more homologous polypeptides, one or more heterologous polypeptides, one or more oligomeric complexes, one or more polypeptide clusters, or a combination thereof. In some embodiments, the homologous polypeptides, heterologous polypeptides, oligomeric complexes, or polypeptide clusters comprise either a target peptide, a linker peptide, and a self-assembling peptide, or a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, or a combination thereof, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the polypeptides in a polypeptide nanoparticle may also have some residues (amino acids) of the cleavage peptide. In some embodiments, the disclosure relates to a polypeptide nanoparticle formed from the self-assembly of two or more polypeptides, wherein some or all polypeptides comprises either a target peptide, a linker peptide, and a self-assembling peptide, or a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide or a combination thereof, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the polypeptides in the polypeptide PVM-00425 (PVX-PAT-2406-WO) nanoparticle may also have some residues (amino acids) of the cleavage peptide. In some embodiments, the polypeptide nanoparticle comprises of homologous polypeptides, heterologous polypeptides, oligomeric complexes, polypeptide clusters, or combination thereof. In some aspects, provided herein is the multisubunit nucleic acid sequence described herein, formulated or encapsulated in a lipid nanoparticle composition. In some aspects, the lipid nanoparticle composition comprises a cationic lipid, a phospholipid, a sterol, a PEG lipid and the multisubunit nucleic acid sequence described herein. In some embodiments, the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some aspects, provided herein is a vaccine comprising the multisubunit nucleic acid sequence described herein, formulated or encapsulated in a lipid nanoparticle composition. In some aspects, the lipid nanoparticle composition comprises a cationic lipid, a phospholipid, a sterol, a PEG lipid and the multisubunit nucleic acid sequence described herein. In some embodiments, the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some other aspects, the lipid nanoparticle composition comprises an ionizable polymer, a cationic lipid, a phospholipid, a sterol, a PEG-lipid and the multisubunit nucleic acid sequence described herein. In some embodiments, the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof the multisubunit nucleic acid sequence as described herein. In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof a vaccine comprising the multisubunit nucleic acid sequence as described herein. In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof a lipid nanoparticle composition comprising a cationic lipid, a phospholipid, a sterol, a PEG-lipid and the multisubunit nucleic acid sequence as described herein. In some embodiments, the cationic lipid is PVM-00425 (PVX-PAT-2406-WO) represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof a lipid nanoparticle composition comprising an ionizable polymer, a cationic lipid, a phospholipid, a sterol, a PEG-lipid and the multisubunit nucleic acid sequence as described herein. In some embodiments, the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (VII), formula (V), formula (VI), formula (VIII), or a combination thereof. In some aspects, the disclosure relates to use of a lipid nanoparticle composition comprising a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid sequence as described herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject. In some embodiments, the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some aspects, the disclosure relates to use of a vaccine comprising a lipid nanoparticle composition, wherein the lipid nanoparticle composition comprises a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid sequence as described herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject. In some embodiments, the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some embodiments, the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus, including the codon optimized sequences, fragments, variants, mutants, comparable equivalent, or functional analog thereof. In some embodiments, the target sequence is modified or unmodified. In some embodiments, the target sequence encodes a target peptide obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the target sequence or target peptide is modified or unmodified. In some embodiments, the target peptide regulates or modulates cellular functions. In some embodiments, the target peptide has immunostimulatory or immunomodulatory effect. PVM-00425 (PVX-PAT-2406-WO) In some embodiments, the self-assembling sequence encodes a self-assembling peptide. In some embodiments, the self-assembling peptide includes, but not limited to, lumazine synthase, MS2 coat protein, hepatitis B surface antigen (HBsAg) from Hepatitis B Virus, hepatitis B core antigen (HBcAg) from hepatitis B virus, human papillomavirus L1 (HPV L1) protein, matrix protein M1 from influenza A virus, ferritin peptide, riboflavin synthase, dihydrolipoyl acetyltransferase (E2p), or a combination thereof, including their fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the ferritin peptide is obtained or derived from Listeria innocua or Helicobacter pylori. In some embodiments, the ferritin peptide is a Listeria innocua ferritin or its fragment, mutant, variant, comparable equivalent, or functional analogs thereof. In some embodiments, the ferritin peptide is a Helicobacter pylori ferritin or its fragment, mutant, variant, comparable equivalent, or functional analogs thereof. In some embodiments, the dihydrolipoyl acetyltransferase (E2p) is obtained or derived from Bacillus stearothermophilus, or its fragment, mutant, variant, comparable equivalent, or functional analogs thereof. In some embodiments, the lumazine synthase is obtained or derived from Aquifex species (for example, Aquifex aeolicus) or Bacillus species (for example, Bacillus subtilis), or its fragment, mutant, variant, comparable equivalent, or functional analogs thereof. In some embodiments, the MS2 coat protein is obtained or derived from Emesvirus zinderi, or its fragment, mutant, variant, comparable equivalent, or functional analogs thereof. In some embodiments, the linker sequence encodes a linker peptide. In some embodiments, the linker peptide connects the target peptide with the self-assembling peptide in a polypeptide. In some embodiments, the linker peptide connects the signal peptide with the first polypeptide. In some embodiments, one linker peptide connects the cleavage peptide with the target peptide and another linker peptide connects the target peptide with the self-assembling peptide in a polypeptide. In some embodiments, the linker peptide connects two signal peptides. In some embodiments, the linker peptide connects two cleavage peptides. The linker peptide may be an amino acid linker, a zipper motif, a foldon, a scaffold or a combination thereof. In some embodiments, the cleavage sequence encodes a cleavage peptide. In some embodiments, the cleavage peptide comprises one or more cleavage peptides. The cleavage peptide connects one polypeptide with another polypeptide, for example, adjacent PVM-00425 (PVX-PAT-2406-WO) polypeptide. The cleavage peptide carries a cleavage site. In some embodiments, the cleavage peptide carries one or more cleavage sites. In some embodiments, the cleavage peptide facilitates the action of cellular proteases to cleave the multisubunit peptide into individual polypeptides. In some embodiments, the cleavage peptide self cleaves into individual polypeptides. In some embodiments, the cleavage peptide comprises two or more cleavage peptides (for example, cleavage peptide-1, cleavage peptide-2 and so on), optionally connected via a linker. In some embodiments, the cleavage peptide self cleaves into individual polypeptides or is cleaved by the action of cellular proteases. In some embodiments, the cleavage peptide is a substrate for cellular proteases. In some embodiments, the cleavage peptide is a substrate for golgi specific proteases. In some embodiments, the cleavage peptide is a self cleaving peptide. In some embodiments, the cleavage peptide comprises two or more cleavage peptides (for example, cleavage peptide- 1, cleavage peptide-2 and so on), optionally linked by a linker peptide, wherein one cleavage peptide is a substrate for cellular proteases and the other cleavage peptide is a self cleaving peptide. In some embodiments, the signal sequence encodes a signal peptide. The signal peptide is present upstream (amino-terminus) of one or more polypeptides in a multisubunit peptide. In some embodiments, the signal peptide is present upstream (amino- terminus) of the first polypeptide. In some embodiments, the signal peptide is present upstream (amino-terminus) of some polypeptides. In some embodiments, the signal peptide is present upstream (amino-terminus) of all polypeptides. In some embodiments, the signal peptide transports the multisubunit peptide to cell organelles. In some embodiments, the signal peptide transports the multisubunit peptide to golgi body or golgi apparatus. In some embodiments, the signal peptide is a golgi targeting signal peptide. In some aspects, the present disclosure also includes a method of transforming a cell with the multisubunit nucleic acid sequence as described herein. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 – shows representative schematic illustration of multisubunit nucleic acid sequence wherein each polynucleotide sequence (PS) comprises a target sequence (TS), a linker sequence (LS), and a self-assembling sequence (SAS) or a linker sequence (LS), a target sequence (TS), a linker sequence (LS), and a self-assembling sequence (SAS), wherein the target sequence is obtained or derived from core protein, E1 protein, E2 PVM-00425 (PVX-PAT-2406-WO) protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. Multiple polynucleotide sequences are connected through a cleavage sequence (CS) such that between any two polynucleotide sequences there is present a cleavage sequence. The multisubunit nucleic acid sequence has a signal sequence (SS) upstream of the first polynucleotide sequence. The letter ‘n’ in figure 1 represents any number between 1 to 98. The multisubunit nucleic acid sequence may additionally have 5’ cap and 3’ poly(A) tail. This multisubunit nucleic acid sequence encodes corresponding multisubunit peptide depicted in Figure 2. Figure 2 – shows representative schematic illustration of multisubunit peptide wherein each polypeptide (PP) comprises a target peptide (TP), a linker peptide (LP), and a self-assembling peptide (SAP) or a linker peptide (LP), a target peptide (TP), a linker peptide (LP), and a self-assembling peptide (SAP), wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. Multiple polypeptides are connected through a cleavage peptide (CP) such that between any two polypeptides there is present a cleavage peptide. The multisubunit peptide has a signal peptide (SP) on the N-terminus of the first polypeptide. The letter ‘n’ represents any number between 1 to 98. Figure 3 – shows western blot of cell lysate (lane 2) showing expression of multisubunit peptide (SEQ ID NO: 12123) encoded by the multisubunit nucleic acid sequence of example 2 using anti-ferritin antibody. Lane 1 is protein ladder and lane 3 is control. Figure 4 – shows generation of antibodies (IgG), detected using ELISA, against the target peptides (E1 protein and / or E2 protein) encoded by the multisubunit nucleic acid sequence of example 2. DESCRIPTION The present disclosure relates to multisubunit nucleic acid sequences, multisubunit peptides, polypeptide nanoparticle, and their compositions for vaccine and therapeutic purpose against hepacivirus. PVM-00425 (PVX-PAT-2406-WO) Unless defined otherwise, technical, and scientific terms used herein have the same meaning as commonly understood by one of person skill in the art. Some of the terms are defined briefly here below; the definitions should not be construed in a limiting sense. The singular forms “a”, “an” and “the” as used in the specification also include plural aspects unless the context dictates otherwise. Similarly, any singular term used in the specification also mean plural or vice versa unless the context dictates otherwise. As used herein in the claim(s), when used in conjunction with the word “comprising”, the words “a” or “an” may mean one or more than one. As used herein “another” may mean at least a second or more. It must be noted that the words “comprising” or any of its form such as “comprise” or “comprises”, “having” or any of its forms such as “have” or “has”, “including” or any of its forms such as “include” or “includes”, or “containing” or any of its forms such as “contain” or “contains” are open-ended and do not exclude additional unrecited elements or method steps. Wherever any quantity or range is stated one skilled in the art will recognize that quantity or range within 10 or 20 percent of the stated values can also be expected to be appropriate and reasonable and included within the scope of the invention. Unless otherwise defined herein, scientific, and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skilled in the art. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, protein, adjuvant, pharmaceutical biotechnology, and biopharmaceutical manufacturing described herein are those well known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. The term “composition”, “formulation”, “lipid nanoparticle composition”, or “lipid nanoparticle” has been used interchangeably to mean a nanoparticle, nanostructure, vesicle, liposome, composition or formulation comprising one or more lipid components (for example, a cationic lipid, a phospholipid, a sterol, and a PEG-lipid), and / or an ionizable polymer component. In some embodiments, the lipid nanoparticle comprises a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and a multisubunit nucleic acid. In some embodiments, the cationic lipid is represented by any one of formula (I), formula PVM-00425 (PVX-PAT-2406-WO) (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some embodiments, the lipid nanoparticle comprises one or more lipid components, an ionizable polymer component, and a multisubunit nucleic acid. In some embodiments, the multisubunit nucleic acid associated with the lipid nanoparticle is a DNA, an mRNA, a micro-RNA, a small interfering RNA, a small nucleolar RNA, a small nuclear RNA, a long non-coding RNA or a combination thereof. In some embodiments, the lipid nanoparticle composition contains one or more pharmaceutical carriers or excipients, such as but not limited to, buffering agents, stabilizers, tonicity modifiers, surfactants, chelating agents, salts, anti-oxidants, diluents, and / or preservatives or a combination thereof. The term lipid nanoparticle also denotes lipid nanoparticles that are devoid of any encapsulated multisubunit nucleic acid (empty lipid nanoparticles or ghost lipid nanoparticles). In some embodiments, the lipid nanoparticle composition comprises lipid nanoparticles with encapsulated multisubunit nucleic acid as well as empty lipid nanoparticles. The term “therapeutic”, “therapeutic agent”, “prophylactic”, “prophylactic agent”, or “drug” has been used interchangeably to mean a compound (such as multisubunit nucleic acid sequence) or composition (such as a lipid nanoparticle composition described herein) having a biological effect or a combination of biological effects that prevents, inhibits, eliminates or prevents the progression of a disease or other aberrant biological processes in a subject, for example, an animal or human. The term “preventing” is art-recognized, and when used in relation to a condition, such as an infection is well understood in the art, and includes administration of a composition, which reduces the frequency or severity, or delays the onset, of one or more symptoms of the medical condition in a subject relative to a subject who does not receive the composition. Thus, the prevention of a condition, such as an infection, includes, for example, the reduction of the frequency or severity of one or more symptoms of the medical condition in a population of patients receiving a therapy relative to a control population that did not receive the therapy, e.g., by a statistically and / or clinically significant amount. Similarly, the prevention of an infection includes reducing the likelihood that a patient receiving a therapy will develop the infection or related symptoms, relative to a patient who does not receive the therapy. The term “molar percent”, “mol percent”, “molar %”, or “mol %” have been used interchangeably to mean number of moles of a component expressed as percentage relative PVM-00425 (PVX-PAT-2406-WO) to total moles of all lipid components present in the lipid nanoparticle compositions described herein. For example, 50 mol % cationic lipid means, 50 mol % of cationic lipid is present in the lipid nanoparticle composition and other lipid components together constitute remaining 50 mol % such that the total amount of all the lipid components constitute 100 mol %. In some embodiments, mol % also denotes to mean number of moles of a component expressed as percentage relative to total moles of all lipid components (such as cationic lipid, phospholipid, sterol and PEG-lipid) and ionizable polymer component(s) present in the lipid nanoparticle composition described herein. For example, 50 mol % of cationic lipid means, 50 mol % of cationic lipid is present in the lipid nanoparticle composition and other lipids components and ionizable polymer components together constitute the remaining 50 mol % such that the total amount of all the lipid components and ionizable polymer components constitute 100 mol %. The term “N / P ratio”, “N:P ratio”, “lipid to nucleic acid ratio”, or “cationic lipid to nucleic acid ratio” have been used interchangeably herein and means the ratio (molar ratio) of the positive charges in the cationic lipid relative to the negative charges in the nucleic acid (such as the multisubunit nucleic acid sequence disclosed herein) in a lipid nanoparticle. In some embodiments, the N / P ratio refers to the ratio of protonable nitrogen present in the cationic lipid relative to the phosphate present in the nucleic acid in a lipid nanoparticle. In some embodiments, the N / P ratio is between 1 to 18 (i.e., 1:1 to 18:1). For example, a N / P ratio of 18 refers to the presence of 18 protonable nitrogen of the cationic lipid relative to 1 phosphate of the nucleic acid in a lipid nanoparticle. The terms “antibody” and “antibodies” have been used interchangeably herein and means any antibody or antibody fragment (whether produced naturally or recombinantly) which retains antigen binding activity. This includes a monoclonal or polyclonal antibody, a single chain antibody, a Fab fragment of a monoclonal or polyclonal antibody, a chimeric antibody, a humanized antibody, a human antibody, a bispecific antibody, a multispecific antibody, or a nanobody. The term “buffer” as used herein means those agents that maintains the pH of a solution in a desired range. The term “cell” as used herein means a single cell or a population of cells or plurality of cells. The term “biologically effective amount” or “therapeutically effective amount” as used herein means an amount of an agent, for example, a therapeutic, drug, therapeutic PVM-00425 (PVX-PAT-2406-WO) agent, prophylactic agent, diagnostic agent, composition, etc., that is sufficient, when administered to a subject suffering from or susceptible to an infection, disease, disorder, and / or condition, to treat, prevent, diagnose, improve symptoms of, and / or delay the onset of the infection, disease, disorder, and / or condition. A therapeutically effective amount herein may vary according to factors such as the disease state, age, sex, and weight of the patient. As used herein, the term “treating” or “treatment” includes reducing, arresting, or reversing the symptoms, clinical signs, or underlying pathology of a condition to stabilize or improve a subject's condition or to reduce the likelihood that the subject’s condition will worsen as much as if the subject did not receive the treatment. Treatment may be administered to a subject who does not exhibit signs of a disease and / or exhibits only early signs of the disease for the purpose of decreasing the risk of developing pathology associated with the disease. The term “subject” as used herein refers to an animal or human, for example, a living mammal and may be interchangeably used with the term “patient”. Examples of mammals include, but are not limited to, any member of the mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, ferrets, and guinea pigs, and the like. The term does not denote a particular age or gender. As used herein, an individual “at risk” of developing a particular disease, disorder, or condition may or may not have detectable disease or symptoms of disease, and may or may not have displayed detectable disease or symptoms of disease prior to the treatment methods described herein. “At risk” denotes that an individual has one or more risk factors, which are measurable parameters that correlate with development of a particular disease, disorder, or condition, as known in the art. An individual having one or more of these risk factors has a higher probability of developing a particular disease, disorder, or condition than an individual without one or more of these risk factors. The term “disease” as used herein, means an interruption, cessation, or disorder of body function, system, or organ. Non limiting examples of disease include malignant diseases, autoimmune diseases, inherited diseases, metabolic disorders, or infectious diseases. PVM-00425 (PVX-PAT-2406-WO) The term “vaccine” as used herein means a substance or composition comprising an antigen or immunogen for eliciting an immune response in a subject against the antigen or the immunogen. The term vaccine is also understood to mean a substance or composition comprising an antigen or immunogen that activates or stimulates an immune cell. In some cases, the antigen or immunogen is a peptide, a protein, a polysaccharide, or a combination thereof. In some cases, the antigen or immunogen is encoded by a nucleic acid, for example, a DNA, an RNA, or an mRNA. In some embodiments, the vaccine comprises a nucleic acid that encodes an antigen or an immunogen. In some embodiments, the vaccine comprises a multisubunit nucleic acid as described herein. As used herein, administration “conjointly” with another compound or composition includes simultaneous administration and / or administration at different times. Conjoint administration also encompasses administration as a co-formulation or administration as separate compositions, including at different dosing frequencies or intervals, and using the same route of administration or different routes of administration. The term “multisubunit nucleic acid sequence” or “multisubunit nucleic acid” have been used interchangeably herein and means two or more polynucleotide sequences wherein some or all polynucleotide sequences comprises either a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, or a combination thereof, wherein one polynucleotide sequence is connected to another polynucleotide sequence by a cleavage sequence, wherein the multisubunit nucleic acid sequence includes a signal sequence upstream of one or more polynucleotide sequences, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the signal sequence is present upstream of the first polynucleotide sequence. In some embodiments, the signal sequence is present upstream of some polynucleotide sequences. In some embodiments, the signal sequence is present upstream of each of the polynucleotide sequences. In some embodiments, the polynucleotide sequence comprises a target sequence, a linker sequence, and a self-assembling sequence, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the PVM-00425 (PVX-PAT-2406-WO) polynucleotide sequence comprises a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. Thus, in some embodiments, one linker sequence connects the cleavage sequence with the target sequence and another linker sequence connects the target sequence with the self-assembling sequence in a polynucleotide sequence. In some embodiments, the linker sequence connects the signal sequence with the polynucleotide sequence. As illustrated in figure 1 multisubunit nucleic acid sequence comprises multiple repeats of polynucleotide sequences wherein each polynucleotide sequence may comprise either a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence and a self-assembling sequence, or a combination thereof, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus, such that total number of polynucleotide sequences in a multisubunit nucleic acid sequence are not more than 100. In some embodiments, the linker sequence connects signal sequence with the first polynucleotide sequence. In some embodiments, the signal sequence is present upstream of each of some or all of the polynucleotide sequences. In some embodiments, the multisubunit nucleic acid sequence is obtained or synthesized through single in vitro transcription (IVT) process or step. The multisubunit nucleic acid sequence encodes multisubunit peptide. The terms “multisubunit peptide” as used herein means two or more polypeptides wherein some or all polypeptides comprises either a target peptide, a linker peptide, and a self-assembling peptide, or a linker peptide, a target peptide, a linker peptide and a self- assembling peptide, or a combination thereof, wherein one polypeptide is connected to another polypeptide by a cleavage peptide, wherein the multisubunit peptide includes a signal peptide upstream (amino-terminus) of one or more polypeptides, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the signal peptide is present on the amino-terminus of the first polypeptide. In some embodiments, the signal peptide is present on the amino-terminus of some polypeptides. In PVM-00425 (PVX-PAT-2406-WO) some embodiments, the signal peptide is present on the amino-terminus of each of the polypeptides. In some embodiments, the polypeptide comprises a target peptide, a linker peptide, and a self-assembling peptide, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the polypeptide comprises a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. Thus, in some embodiments, one linker peptide connects the cleavage peptide with the target peptide and another linker peptide connects the target peptide with the self-assembling peptide in a multisubunit peptide. In some embodiments, the multisubunit peptide either comprises a target peptide, a linker peptide, and a self-assembling peptide, or a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, or a combination thereof, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus, such that the total number of polypeptides in a multisubunit peptide are not more than 100. In some embodiments, the linker peptide connects the signal peptide with the polypeptide. In some embodiments, the signal peptide is present on the amino-terminus of each of some or all polypeptides. The multisubunit peptide may comprise homologous polypeptides or heterologous polypeptides. The term “polynucleotide sequence” as used herein means a sequence of nucleotides that encodes a polypeptide. The terms “protein” or “peptide” have been used interchangeably herein and mean a polymer of amino acids linked through peptide bonds but do not imply any specific length. The term also includes fusion proteins, muteins, analogs or modified forms. The term “polypeptide” as used herein means a sequence of amino acids that comprises either a target peptide, a linker peptide, and a self-assembling peptide or a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell PVM-00425 (PVX-PAT-2406-WO) epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the polypeptide comprises a target peptide, a linker peptide, and a self-assembling peptide, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the polypeptide comprises a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the polypeptide may have some residues (amino acids) of cleavage peptide. In some embodiments, the polypeptide comprises a signal peptide. The term “target sequence” as used herein means a sequence of nucleotides that encodes a target peptide obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. The term “target peptide” as used herein means a sequence of amino acids obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the target peptides in two or more polypeptides are identical i.e., homologous polypeptides. In some other embodiments, the target peptides in two or more polypeptides are different i.e., heterologous polypeptides. The term “signal sequence” as used herein means a sequence of nucleotides that encodes a signal peptide. The term “signal peptide” as used herein means a sequence of amino acids that transports the multisubunit peptide to specific cell organelles. In some embodiments the signal peptide transports the multisubunit peptide to golgi apparatus or golgi body. The signal peptide is present on the N-terminus (amino-terminus) of one or more polypeptides. In some embodiments, the signal peptide is present on the N-terminus of some or all polypeptides. In some embodiments, the signal peptide is present on the N-terminus of the first polypeptide. In some embodiments, the signal peptide is present on the N-terminus of some polypeptides. In some embodiments, the signal peptide is present on the N-terminus PVM-00425 (PVX-PAT-2406-WO) of all polypeptides. In some embodiments, the signal peptide is encoded by signal sequence. In some embodiments, the signal peptide is a golgi targeting signal peptide. The term “cleavage sequence” as used herein means a sequence of nucleotides that encodes a cleavage peptide. The term “cleavage peptide” as used herein means a sequence of amino acids that facilitates the action of cellular proteases to cleave the multisubunit peptide into individual polypeptides or self cleaves into individual polypeptides. The cleavage peptide is present between any two polypeptides. It connects one polypeptide with another polypeptide, for example, adjacent polypeptide. The cleavage peptide carries one or more cleavage sites. In some embodiments, the cleavage peptide is a substrate for proteases. In some embodiments, cleavage peptide undergoes self cleavage to result in individual polypeptides. In some embodiments, the cleavage peptide is a substrate for golgi specific proteases. In some embodiments, the cleavage peptide comprises one or more cleavage peptides, for example, cleavage peptide-1, cleavage peptide-2 and so on. In some embodiments, the cleavage peptide optionally comprises a linker peptide between two cleavage peptides. In some embodiments, the cleavage peptide self cleaves into individual polypeptides or is cleaved by the action of cellular proteases. In some embodiments, the cleavage peptide is a substrate for cellular proteases. In some embodiments, the cleavage peptide is a substrate for golgi specific proteases. In some embodiments, the cleavage peptide is a self cleaving peptide. In some embodiments, the cleavage peptide comprises two or more cleavage peptides (for example, cleavage peptide-1, cleavage peptide-2 and so on), optionally linked by a linker peptide, wherein one cleavage peptide is a substrate for cellular proteases and the other cleavage peptide is a self cleaving peptide. The term “linker sequence” as used herein means a sequence of nucleotides that encodes a linker peptide. The term “linker peptide” or “peptide linker” have been used interchangeably to mean a sequence of amino acids that either connects the target peptide with the self- assembling peptide, connects the signal peptide with the target peptide, connects the cleavage peptide with the target peptide, connects the signal peptide with the polypeptide, or connects two cleavage peptides. In some embodiments, the linker peptide connects the signal peptide with the polypeptide. In some embodiments, the linker peptide connects the target peptide with the self-assembling peptide in a polypeptide. In some embodiments, one linker peptide connects the cleavage peptide with the target peptide and another linker PVM-00425 (PVX-PAT-2406-WO) peptide connects the target peptide with the self-assembling peptide in a polypeptide. In some embodiments, one linker peptide connects the cleavage peptide with the target peptide and another linker peptide connects the target peptide with the self-assembling peptide. In some embodiments, one linker peptide connects the cleavage peptide with the target peptide and another linker peptide connects the signal peptide with the target peptide. In some embodiments, the linker peptide connects two cleavage peptides. In some embodiments, the linker peptide is an amino acid linker, a zipper motif, a foldon, a scaffold or a combination thereof. In some embodiments, the linker peptide is an amino acid linker. In some embodiments, the linker peptide is a foldon. In some embodiments, the linker peptide is a zipper motif. In some embodiments, the linker peptide is a scaffold. In some embodiments, the linker peptide comprises an amino acid linker and a foldon. In some embodiments, the linker peptide comprises an amino acid linker and a zipper motif. In some embodiments, the linker peptide comprises an amino acid linker and a scaffold. In some embodiments, the linker peptide comprises a zipper motif and a scaffold. In some embodiments, the linker peptide comprises a foldon and a scaffold. In some embodiments, the linker peptide comprises an amino acid linker, a zipper motif, and a scaffold. In some embodiments, the linker peptide comprises an amino acid linker, a foldon, and a scaffold. The term “amino acid linker sequence” as used herein means a sequence of nucleotides that encodes an amino acid linker. The term “amino acid linker” as used herein means a sequence of amino acids that provides structural integrity to polypeptide such that the components of the polypeptide remain, as far as possible, in their native or stable conformation. In some embodiments, amino acid linker also helps in orientation of a polypeptide such that the domains or epitopes on the target peptide are exposed or displayed for interaction or communication with cells or biomolecules or immune system in the absence of foldon or scaffold. In some embodiments, the amino acid linker connects two cleavage peptides. Some of the non- limiting examples of amino acid linkers includes, glycine serine linker, glycine proline linker, glycine threonine linker, alanine serine linker, any combination of two amino acids or a combination thereof. In some embodiments, amino acid linker is about 2-49 amino acid long. The term “glycine serine linker sequence” as used herein means a sequence of nucleotides that encodes a glycine serine linker. PVM-00425 (PVX-PAT-2406-WO) The term “glycine serine linker” as used herein means a sequence of amino acid comprising one or more glycine (G) and serine (S) in any combinations without any preference of order or limitation on number of appearances of either glycine or serine. In some embodiments, the glycine serine linker is few amino acids in length to several amino acids in length. The term “zipper sequence” as used herein means a sequence of nucleotides that encodes a zipper motif. The term “zipper motif” or “zipper peptide” as used herein means a sequence of amino acids that facilitates homologous polypeptides or heterologous polypeptides to come together or associate to form a polypeptide cluster. The term “foldon sequence” as used herein means a sequence of nucleotides that encodes a foldon. The term “foldon” as used herein means a sequence of amino acids that enables two or more homologous polypeptides to organise to form an oligomeric complex. In some embodiments, the foldon also helps in orientation of a polypeptide such that the domains or epitopes on the target peptide are exposed or displayed for interaction or communication with cells or biomolecules or immune system. The term “scaffold sequence” as used herein means a sequence of nucleotides that encodes a scaffold. The term “scaffold” as used herein means a sequence of amino acids that provides structural and / or functional integrity or support to the target peptide and helps in orientation of target peptide such that the domains or epitopes of the target peptide are exposed or displayed for interaction or communication with cells or biomolecules or immune system. The term “oligomeric complex” as used herein means a complex formed by two or more homologous polypeptides. In some embodiments, the oligomeric complex has at least two homologous polypeptides, at least three homologous polypeptides, at least four homologous polypeptides, at least five homologous polypeptides, or at least six homologous polypeptides and so on. The term “polypeptide cluster” as used herein means a complex formed by interaction of protein domains of two or more homologous polypeptides or two or more heterologous polypeptides orchestrated by the zipper motif. In some embodiments, the PVM-00425 (PVX-PAT-2406-WO) polypeptide cluster has at least two, at least three, at least four, at least five, at least six homologous polypeptides, heterologous polypeptides, or combination thereof. The term “self-assembling sequence” as used herein means a sequence of nucleotides that encodes a self-assembling peptide. The term “self-assembling peptide” as used herein means a sequence of amino acids that enables the polypeptides to self-assemble into a polypeptide nanoparticle. The term “self-assembly” or “self-assemble” or “self-assembling” has been used interchangeably to means the ability of polypeptides to undergo multimerization to form a polypeptide nanoparticle. In some embodiments, the polypeptide nanoparticle has at least two polypeptides (dimer or 2-mer), at least three polypeptides (trimer or 3-mer), at least four polypeptides (tetramer or 4-mer), at least five polypeptides (pentamer or 5-mer), at least six polypeptides (hexamer or 6-mer), at least seven polypeptides (heptamer or 7-mer), at least eight polypeptides (octamer or 8-mer), and so on. In some embodiments, the polypeptide nanoparticle is up to 500-mers. In some embodiments, hydrogen bonds, disulfide bonds, hydrophobic interactions, electrostatic interactions, and / or Van der Waals forces combine to maintain self-assembled structure. The term “multimerization” as used herein means association of two or more units of homologous polypeptides, heterologous polypeptides, oligomeric complexes, polypeptide clusters, or their combination. The term “polypeptide nanoparticle” as used herein means a nanoparticle formed by self-assembly of polypeptides. In some embodiments, the polypeptide nanoparticle comprises two or more homologous polypeptides, two or more heterologous polypeptides, one or more oligomeric complexes, one or more polypeptide clusters, or a combination thereof. The term “homologous polypeptides” as used herein means polypeptides in a multisubunit peptide that have identical target peptides. For example, if two polypeptides in the multisubunit peptide have identical target peptides they are considered to be homologous polypeptides. The term “heterologous polypeptide” as used herein means polypeptides in a multisubunit peptide that have different target peptides. For example, if two polypeptides in the multisubunit peptide have different or non-identical target peptides, they are considered to be heterologous polypeptides. PVM-00425 (PVX-PAT-2406-WO) The term “upstream”, “amino-terminus”, or “N-terminus” has been used interchangeably in the context of amino acid sequences (protein, peptide, polypeptide, or any other sequence composed of amino acids) or the nucleic acid sequences (DNA, RNA or any other sequence composed of nucleotides) to mean amino end of an amino acid sequence or the 5-prime end of a nucleic acid sequence respectively. The term “fragment” as used herein, whether in the context of a nucleic acid, nucleotide, protein, polypeptide, or peptide, means any length of the nucleic acid, protein, polypeptide, or peptide sequence except the full length of the respective nucleic acid, protein, polypeptide, or peptide sequence. Fragment includes such portions of nucleic acid, protein, polypeptide, or peptide that are capable of treating, preventing, diagnosing, improving symptoms of, and / or delay the onset of an infection, disease, disorder, and / or condition. A fragment is also understood to mean an immunogenic fragment of the protein, polypeptide or peptide, or a fragment of nucleic acid encoding an immunogenic fragment of the protein, peptide, or polypeptide. The term “variant” as used herein, whether in the context of a nucleic acid, nucleotide, protein, polypeptide, or peptide sequence, means homologs, orthologs, paralogs, mutants or analogs of respective nucleic acid, protein, polypeptide, or peptide sequence. The term “mutant” as used herein, whether in the context of a nucleic acid, nucleotide, protein, polypeptide, or peptide sequence, means a sequence which is not a wild type sequence. A mutant is also understood to mean a nucleic acid, nucleotide, protein, polypeptide, or peptide sequence that carries a mutation. The term “mutation” as used herein means, a change or modification in the sequence of nucleic acid or amino acid in comparison to a reference sequence and includes insertion, deletion, substitution, or a combination thereof. Mutations are introduced to impart desirable properties upon the nucleic acid, nucleotide, protein, polypeptide, or peptide sequence. This includes, for example, enabling the nucleic acid, nucleotide, protein, polypeptide, or peptide sequence to elicit an immune response while ensuring that any undesirable or deleterious effects are minimized or entirely removed. The term “sequence” as used herein means nucleic acid sequences, nucleic acids, polynucleotides, amino acid sequences, proteins, polypeptides, or peptides, depending upon the context in which the term sequence is used, to mean a sequence of nucleotides or amino acids. In the context of nucleic acid, polynucleotide, or nucleotide sequence, the PVM-00425 (PVX-PAT-2406-WO) sequence is represented by a single letter code representing the nitrogenous base, for example A, T, G, C, or U. In the context of amino acid sequences, proteins, polypeptides, or peptides the sequence is represented by a single letter amino acid code as generally understood by persons skilled in the art. If the single letter amino acid code is represented by the letter “X”, it means the amino acid at that position is either absent or substituted by any other amino acid. In some embodiments, the sequences representing target sequence or target peptide, may contain a tag, for example, histidine tag, streptavidin tag etc, which may be deleted or removed from the respective sequence before employing the sequence in accordance with the present disclosure. In some embodiments, the sequences representing target sequence or target peptide may contain a signal sequence or signal peptide respectively, which may be deleted or removed from the respective sequence before employing the sequence in accordance with the present disclosure. The deleted or removed signal sequence or signal peptide may be employed in accordance with the present disclosure. The presence of tags, signal sequence or signal peptide, or other similar elements, may easily be recognized by those skilled in the art. The term “percentage identity”, “percent identity”, “% age identity”, or “% identity” have been used interchangeably and means the extent of identity between two sequences (e.g. nucleic acid sequences or amino acid sequences). Percent identity can be determined by aligning two sequences, introducing gaps to maximize identity between the sequences. Percent identity should generally be calculated between the same types of sequences for example nucleic acids, i.e. for DNA sequences or RNA sequences or amino acid sequences. The alignment of sequences (nucleic acid or amino acid) can be performed with the appropriate pair wise sequence alignment programs. Identity can be calculated between two sequences by multiplying the number of matches in the pair by 100 and dividing by the length of the aligned region, including gaps. Gaps at the end of sequencesare not included, and internal gaps are included in the length. In some embodiments, thenucleic acid sequence or the amino acid sequence, as the case may be, shares at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with the sequences disclosed herein. In some embodiments, the nucleic acid sequence or the amino acid sequence, as the case may be, shares at least 50% to 60%, at least 60% to 70%, PVM-00425 (PVX-PAT-2406-WO) at least 70% to 80%, at least 80% to 90%, or at least 90% to 100% identity with the sequences disclosed herein. The term “functional analog” or “functional analogue” have been used interchangeably, whether in the context of nucleic acid sequence or amino acid (protein or peptide) sequence, and mean all sequences which essentially performs similar function compared to the sequence being referred. For example, functional analogs of a target peptide include all sequences, irrespective of their percentage identity, which essentially perform at least one function similar to the function the target peptide performs. The term “comparable equivalent” in the context of nucleic acid sequences, amino acid sequences, proteins, polypeptides, or peptides, as disclosed herein, means structurally or functionally similar or identical nucleic acid sequences, amino acid sequences, proteins, polypeptides, or peptides compared to the nucleic acid sequences or amino acid sequences being referred. The term “structural protein” as used herein means proteins that are components of the viral particle or structure, for example, capsid proteins, membrane or envelope proteins, proteins packaged within the virus particle etc. The term “envelope protein” as used herein means a protein associated with the viral envelope, for example, anchored into, projecting from, or across the lipid layer of the viral envelope. Envelope proteins mediate attachment and fusion. In some embodiments, envelope proteins are glycosylated. The term “non-structural protein” as used herein means proteins that are encoded by the virus, but are not the component or part of the mature viral particle or structure, for example, enzymes, transcription factors etc. The term “matrix protein” as used herein means a protein that is found beneath the viral envelope, often acting as a bridge between nucleocapsid or core and the envelope. The term “capsid protein” or “nucleocapsid protein” as used herein means a protein that encapsidates or packages the viral genetic material or genome. The term is also understood to mean those proteins which are involved or participate in one or more of the following functions or activities, such as virus assembly, budding or release of virus, mediating attachment to and penetration into the host cells (especially in case of non- enveloped viruses), packaging the genome, etc. The capsid protein or nucleocapsid proteins are the proteins associated with viral capsid or viral nucleocapsid or viral core. PVM-00425 (PVX-PAT-2406-WO) The term “B cell epitope” as used herein means a protein determinant that is recognized by B cell receptors (BCR) and capable of specific binding to an antibody or immunoglobulin. The term “T cell epitope” as used herein means a protein determinant derived from an antigen which is presented by an antigen presenting cell (APC) through major histocompatibility complex (MHC) for recognition by a T cell receptor (TCR). The term hepatitis “C virus”, “hepacivirus C”, or “HCV” has been used interchangeably to mean a member of hepacivirus genus, and includes all hepatitis C virus genotypes viz., genotype 1, genotype 2, genotype 3, genotype 4, genotype 5, genotype 6, genotype 7, and genotype 8. The term “core protein” as used herein means a region spanning amino acids 1 to 191 of the HCV polyprotein (reference amino acid sequence as described herein as SEQ ID NO: 87), including any other comparable equivalents in other hepacivirus polyprotein (for example, homologous region) that are involved in viral capsid formation, RNA binding etc., and not necessarily starting at the same amino acid position in other hepaciviruses. The core protein also includes any fragments, mutants, derivatives, variants, comparable equivalents, or functional analogs thereof. The term “E1 protein”, “E1”, “E1 glycoprotein”, or “envelope glycoprotein E1 protein” have been used interchangeably and means a region spanning amino acids 192 to 383 of the HCV polyprotein (reference amino acid sequence as described herein as SEQ ID NO: 87), including any other comparable equivalents in other hepacivirus polyprotein (for example, homologous region) that are involved in E1-E2 heterodimer formation, endosome-lipid membrane fusion, assembly during the HCV replication cycle, assisting E2 in receptor binding etc., and not necessarily starting at the same amino acid position in other hepaciviruses. The E1 protein also includes any fragments, mutants, derivatives, variants, comparable equivalents, or functional analogs thereof. The term “E2 protein”, “E2”, “E2 glycoprotein”, or “envelope glycoprotein E2 protein” have been used interchangeably and means a region spanning amino acids 384 to 746 of the HCV polyprotein (reference amino acid sequence as described herein as SEQ ID NO: 87), including any other comparable equivalents in other hepacivirus polyprotein (for example, homologous region) that are involved in E1-E2 heterodimer formation, host receptor binding, entry, and fusion with the endosomal membrane etc., and not necessarily starting at the same amino acid position in other hepaciviruses. The E2 protein also PVM-00425 (PVX-PAT-2406-WO) includes any fragments, mutants, derivatives, variants, comparable equivalents, or functional analogs thereof. The term “P7 protein”, or “P7” have been used interchangeably and means a region spanning amino acids 747 to 809 of the HCV polyprotein (reference amino acid sequence as described herein as SEQ ID NO: 87), including any other comparable equivalents in other hepacivirus polyprotein (for example, homologous region) that are involved in ion channel formation, viral assembly etc., and not necessarily starting at the same amino acid position in other hepaciviruses. The P7 protein also includes any fragments, mutants, derivatives, variants, comparable equivalents, or functional analogs thereof. The term “NS2 protein”, or “NS2” have been used interchangeably and means a region spanning amino acids 810 to 1026 of the HCV polyprotein (reference amino acid sequence as described herein as SEQ ID NO: 87), including any other comparable equivalents in other hepacivirus polyprotein (for example, homologous region) that are involved in viral assembly, protease activity etc., and not necessarily starting at the same amino acid position in other hepaciviruses. The NS2 protein also includes any fragments, mutants, derivatives, variants, comparable equivalents, or functional analogs thereof. The term “NS3 protein”, or “NS3” have been used interchangeably and means a region spanning amino acids 1027 to 1657 of the HCV polyprotein (reference amino acid sequence as described herein as SEQ ID NO: 87), including any other comparable equivalents in other hepacivirus polyprotein (for example, homologous region) that functions as serine protease, RNA helicase, and forms NS3-4A complex etc., and not necessarily starting at the same amino acid position in other hepaciviruses. The NS3 protein also includes any fragments, mutants, derivatives, variants, comparable equivalents, or functional analogs thereof. The term “NS4A protein”, or “NS4A” have been used interchangeably and means a region spanning amino acids 1658 to 1711 of the HCV polyprotein (reference amino acid sequence as described herein as SEQ ID NO: 87), including any other comparable equivalents in other hepacivirus polyprotein (for example, homologous region) that acts as a cofactor for NS3 protein and forms NS3-4A complex etc., and not necessarily starting at the same amino acid position in other hepaciviruses. The NS4A protein also includes any fragments, mutants, derivatives, variants, comparable equivalents, or functional analogs thereof. PVM-00425 (PVX-PAT-2406-WO) The term “NS4B protein”, or “NS4B” have been used interchangeably and means a region spanning amino acids 1712 to 1972 of the HCV polyprotein (reference amino acid sequence as described herein as SEQ ID NO: 87), including any other comparable equivalents in other hepacivirus polyprotein (for example, homologous region) that plays a role in the formation of replication complex etc., and not necessarily starting at the same amino acid position in other hepaciviruses. The NS4B protein also includes any fragments, mutants, derivatives, variants, comparable equivalents, or functional analogs thereof. The term “NS5A protein”, or “NS5A” have been used interchangeably and means a region spanning amino acids 1973 to 2420 of the HCV polyprotein (reference amino acid sequence as described herein as SEQ ID NO: 87), including any other comparable equivalents in other hepacivirus polyprotein (for example, homologous region) that plays a role in viral replication and assembly, modulation of signalling pathways, response to interferon etc., and not necessarily starting at the same amino acid position in other hepaciviruses. The NS5A protein also includes any fragments, mutants, derivatives, variants, comparable equivalents, or functional analogs thereof. The term “NS5B protein”, or “NS5B” have been used interchangeably and means a region spanning amino acids 2421 to 3011 of the HCV polyprotein (reference amino acid sequence as described herein as SEQ ID NO: 87), including any other comparable equivalents in other hepacivirus polyprotein (for example, homologous region) performing the key function of viral replication by acting as an RNA dependent RNA polymerase (RdRp), and not necessarily starting at the same amino acid position in other hepaciviruses. The NS5B protein also includes any fragments, mutants, derivatives, variants, comparable equivalents, or functional analogs thereof. Multisubunit nucleic acid sequence and multisubunit peptide In the present disclosure, a multisubunit nucleic acid sequence includes two or more polynucleotide sequences wherein some or all polynucleotide sequences comprises either a target sequence, a linker sequence, and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, wherein one polynucleotide sequence is connected to the another polynucleotide sequence by a cleavage sequence, wherein the multisubunit nucleic acid sequence includes a signal sequence upstream of one or more polynucleotide sequences, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, PVM-00425 (PVX-PAT-2406-WO) NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the signal sequence is present upstream of all or some polynucleotide sequences. In some embodiments, the signal sequence is present upstream of the first polynucleotide sequence. In some embodiments, the signal sequence is present upstream of some polynucleotide sequences. In some embodiments, the signal sequence is present upstream of each of the polynucleotide sequences. In some embodiments, the polynucleotide sequence comprises a target sequence, a linker sequence, and a self-assembling sequence, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the polynucleotide sequence comprises a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the multisubunit nucleic acid sequence comprises one polynucleotide sequence comprising a target sequence, a linker sequence and a self-assembling sequence, and another polynucleotide sequence comprising a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the multisubunit nucleic acid sequence either comprises a target sequence, a linker sequence and a self-assembling sequence, or a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence or a combination thereof, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus, such that the total number of polynucleotide sequences in a multisubunit nucleic acid sequence are not more than 100. In some embodiments, the linker sequence connects the signal sequence with the polynucleotide sequence. In some embodiments, one linker sequence connects the cleavage sequence with the target sequence and another linker sequence connects the target sequence with the self- PVM-00425 (PVX-PAT-2406-WO) assembling sequence in a polynucleotide sequence. Some exemplary illustrations of the multisubunit nucleic acid sequences are provided in figure 1, and their representative encoded multisubunit peptides are provided in figure 2 respectively. The term “nucleic acid” as used herein means a polymer comprising two or more nucleotides for example, deoxyribonucleotides or ribonucleotides, either in an unmodified or modified form. The nucleic acid may be either single stranded or double stranded, linear, or circular. The term nucleic acid also encompasses fragments, variants, mutants, or codon optimized sequences of deoxyribonucleotides, ribonucleotides, or functional analogs thereof. The term “nucleotide” as used herein means a ribonucleotide or deoxyribonucleotide. If the term nucleotide is used in the context of RNA, it refers to ribonucleotide, and if it is used in the context of DNA, it refers to deoxyribonucleotide. In some embodiments, the multisubunit nucleic acid sequence is a DNA, an RNA, or an mRNA. The multisubunit nucleic acid sequence may be few nucleotides long to several thousand nucleotides long. Deoxyribonucleic acid (DNA) The term “deoxyribonucleic acid” or “DNA” has been used interchangeably herein and means a polymer of deoxyribonucleotides. The DNA may be either single stranded or double stranded, linear, or circular. In some embodiments, the multisubunit nucleic acid sequence is a DNA. In some embodiments, the DNA encodes a multisubunit peptide described herein. Ribonucleic acid (RNA) The term “ribonucleic acid” or “RNA” has been used interchangeably herein and means a polymer of ribonucleotides. The RNA may be either single stranded or double stranded, linear, or circular. The term RNA also includes messenger RNA (mRNA). In some embodiments, the multisubunit nucleic acid sequence is an mRNA. In some embodiments, the mRNA encodes a multisubunit peptide as described herein. In some embodiments, the mRNA is unmodified or modified or a combination of both. The modification may be in the nucleobase of the nucleotide, or sugar moiety of the nucleotide, or the phosphate of the nucleotide. PVM-00425 (PVX-PAT-2406-WO) In some embodiments, mRNA is produced using recombinant expression system, or chemically synthesized or obtained through in vitro transcription. In some embodiments, the mRNA is obtained through a single in vitro transcription (IVT) process or step. In vitro transcription (IVT) is a laboratory process used to synthesize RNA molecules (for example, mRNA) from a DNA template enzymatically outside of a cell or in a cell free system. A single IVT process or step is understood to mean one complete cycle of an IVT reaction which produces mRNA molecules, each comprising at least two polynucleotide sequences, as described herein, as against multiple IVT reactions that produces separate mRNA molecules, each comprising a single polynucleotide sequence. In some embodiments, the mRNA is circular. In other embodiments, the mRNA is linear. In some embodiments, the mRNA is self-amplifying or self-replicating. Self- amplifying or self-replicating mRNA as used herein means an mRNA that self-replicate upon delivery into the cells. Such mRNAs typically contain a replicase sequence, usually obtained or derived from an alphavirus, which enables amplification of the original strand of mRNA encoding the protein of interest upon delivery into the cells (Beissert, Tim et al. Molecular Therapy (2020) 28:119-128). The present disclosure provides mRNAs which are few hundred nucleotides long to several thousand nucleotides long. State of the art discourages using long mRNAs for vaccines and therapeutics. Longer mRNA molecules are more susceptible to degradation, which can compromise their stability and reduce their effectiveness in experimental and therapeutic context. Besides, longer mRNAs are also harder to transcribe accurately as the RNA polymerase used during the IVT reaction is inherently vulnerable to introduce errors within the transcribed mRNA. Additionally, long mRNA molecules are more prone to form complex secondary and tertiary structures, which can interfere with their intended function, reduce their efficiency, complicates the production process, and may even lead to unintended outcomes. Therefore, longer mRNAs are avoided in the art owing to their inherent complexities and challenges. In some embodiments, mRNA is few hundred nucleotides long to several thousand nucleotides long. In some embodiments, mRNA is about 0.5 kb, 1 kb, 1.5 kb, 2 kb, 2.5 kb, 3 kb, 3.5 kb, 4 kb, 4.5 kb, 5 kb, 5.5 kb, 6 kb, 6.5 kb, 7.0 kb, 7.5 kb, 8 kb, 8.5 kb, 9 kb, 9.5 kb, 10 kb, 10.5 kb, 11 kb, 11.5 kb, 12 kb, 12.5 kb, 13 kb, 13.5 kb, 14 kb, 14.5 kb, 15 kb, 16 kb, 17 kb, 18 kb, 19 kb, 20 kb, 21 kb, 22 kb, 23 kb, 24 kb, 25 kb, 26 kb, 27 kb, 28 kb, 29 PVM-00425 (PVX-PAT-2406-WO) kb, 30 kb in length, or a fraction thereof. In some embodiments, mRNA is about 0.5 to 30 kb, 0.5 to 25 kb, 0.5 to 20 kb in length, or any range therein. In some embodiments, mRNA is about 1 to 20 kb, 1 to 18 kb, 1 to 16 kb, 1 to 14 kb, 1 to 12 kb, 1 to 10 kb, 1 to 9 kb, 1 to 8 kb, 1 to 7 kb, 1 to 6 kb, 1 to 5 kb in length, or any range therein. In some embodiments, mRNA is about 0.5 kb to about 1 kb, about 1 kb to about 2 kb, about 2 kb to about 3 kb, about 3 kb to about 4 kb, about 4 kb to about 5 kb, about 5 kb to about 6 kb, about 6 kb to about 7 kb, about 7 kb to about 8 kb, about 8 kb to about 9 kb, about 9 kb to about 10 kb, about 10 kb to about 11 kb, about 11 kb to about 12 kb, about 12 kb to about 13 kb, about 13 kb to about 14 kb, about 14 kb to about 15 kb, about 15 kb to about 16 kb, about 16 kb to about 17 kb, about 17 kb to about 18 kb, about 18 kb to about 19 kb, about 19 kb to about 20 kb, about 20 kb to about 21 kb, about 21 kb to about 22 kb, about 22 kb to about 23 kb, about 23 kb to about 24 kb, about 24 kb to about 25 kb, about 25 kb to about 26 kb, about 26 kb to about 27 kb, about 27 kb to about 28 kb, about 28 kb to about 29 kb, about 29 kb to about 30 kb in length, or any range therein. Target Sequence and target peptide The multisubunit nucleic acid sequence and the multisubunit peptide includes target sequence and target peptide respectively, wherein the target sequence and target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, target sequence and target peptide contains recurring target sequences and target peptides respectively. In some embodiments, the target sequence is a DNA or an RNA. In another embodiment, the target sequence is an mRNA. In some embodiments, the target sequence is modified or unmodified. The target sequence includes codon optimized sequences, fragments, mutants, variants, comparable equivalents, functional analogs, or a combination thereof. In some embodiments, the target sequence is a sequence of nucleotides that encodes a target peptide obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. PVM-00425 (PVX-PAT-2406-WO) In some embodiments, the target peptide is identical in two or more polypeptides, for example homologous polypeptides. In some embodiments, the target peptide is different in two or more polypeptides, for example as in heterologous polypeptides. In some embodiments, the target peptide is few amino acids long to several hundred amino acids long. Hepacivirus Members of the genus hepacivirus consist of enveloped, single stranded RNA viruses viz., Hepacivirus A (canine hepacivirus, equine hepacivirus), Hepacivirus B (GBV-B), Hepacivirus C (hepatitis C virus), Hepacivirus D (Guereza hepacivirus), Hepacivirus E (rodent hepacivirus-339), Hepacivirus F (rodent hepacivirus- NLR07-oct70), Hepacivirus G (Norway rat hepacivirus 1), Hepacivirus H (Norway rat hepacivirus 2), Hepacivirus I (rodent hepacivirus-SAR-3 / RSA / 2008), Hepacivirus J (rodent hepacivirus-RMU10-3382 / GER / 2010), Hepacivirus K (bat hepacivirus-PDB-829), Hepacivirus L (bat hepacivirus-PDB-112), Hepacivirus M (bat hepacivirus-PDB-491.1), Hepacivirus N (bovine hepacivirus). The single stranded RNA of hepaciviruses encodes a single polyprotein that undergoes proteolytic processing to yield multiple individual proteins. Hepacivirus C or hepatitis C virus (HCV) is the most studied member of the hepacivirus genus. To date eight hepatitis C virus genotypes have been identified viz., genotype 1, genotype 2, genotype 3, genotype 4, genotype 5, genotype 6, genotype 7, and genotype 8. Each genotype has multiple subtypes labelled with letters, for example, genotype 1a, genotype 1b, genotype 1c and so on. The genome of the hepacivirus, including the HCV, encodes a single polyprotein which undergoes proteolytic processing to yield typically 10 individual proteins viz., core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, and NS5B protein. Complete polyprotein sequence (amino acid) of hepatitis C virus genotype 1 showing different proteins (Reference Sequence SEQ ID NO: 87) MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG 60 RRQPIPKARR PEGRTWAQPG YPWPLYGNEG CGWAGWLLSP RGSRPSWGPT DPRRRSRNLG 120 KVIDTLTCGF ADLMGYIPLV GAPLGGAARA LAHGVRVLED GVNYATGNLP GCSFSIFLLA 180 LLSCLTVPAS AYQVRNSSGL YHVTNDCPNS SIVYEAADAI LHTPGCVPCV REGNASRCWV 240 PVM-00425 (PVX-PAT-2406-WO) AVTPTVATRD GKLPTTQLRR HIDLLVGSAT LCSALYVGDL CGSVFLVGQL FTFSPRRHWT 300 TQDCNCSIYP GHITGHRMAW DMMMNWSPTA ALVVAQLLRI PQAIMDMIAG AHWGVLAGIA 360 YFSMVGNWAK VLVVLLLFAG VDAETHVTGG SAGRTTAGLV GLLTPGAKQN IQLINTNGSW 420 HINSTALNCN ESLNTGWLAG LFYQHKFNSS GCPERLASCR RLTDFAQGWG PISYANGSGL 480 DERPYCWHYP PRPCGIVPAK SVCGPVYCFT PSPVVVGTTD RSGAPTYSWG ANDTDVFVLN 540 NTRPPLGNWF GCTWMNSTGF TKVCGAPPCV IGGVGNNTLL CPTDCFRKHP EATYSRCGSG 600 PWITPRCMVD YPYRLWHYPC TINYTIFKVR MYVGGVEHRL EAACNWTRGE RCDLEDRDRS 660 ELSPLLLSTT QWQVLPCSFT TLPALSTGLI HLHQNIVDVQ YLYGVGSSIA SWAIKWEYVV 720 LLFLLLADAR VCSCLWMMLL ISQAEAALEN LVILNAASLA GTHGLVSFLV FFCFAWYLKG 780 RWVPGAVYAF YGMWPLLLLL LALPQRAYAL DTEVAASCGG VVLVGLMALT LSPYYKRYIS 840 WCMWWLQYFL TRVEAQLHVW VPPLNVRGGR DAVILLMCVV HPTLVFDITK LLLAIFGPLW 900 ILQASLLKVP YFVRVQGLLR ICALARKIAG GHYVQMAIIK LGALTGTYVY NHLTPLRDWA 960 HNGLRDLAVA VEPVVFSRME TKLITWGADT AACGDIINGL PVSARRGQEI LLGPADGMVS 1020 KGWRLLAPIT AYAQQTRGLL GCIITSLTGR DKNQVEGEVQ IVSTATQTFL ATCINGVCWT 1080 VYHGAGTRTI ASPKGPVIQM YTNVDQDLVG WPAPQGSRSL TPCTCGSSDL YLVTRHADVI 1140 PVRRRGDSRG SLLSPRPISY LKGSSGGPLL CPAGHAVGLF RAAVCTRGVA KAVDFIPVEN 1200 LETTMRSPVF TDNSSPPAVP QSFQVAHLHA PTGSGKSTKV PAAYAAQGYK VLVLNPSVAA 1260 TLGFGAYMSK AHGVDPNIRT GVRTITTGSP ITYSTYGKFL ADGGCSGGAY DIIICDECHS 1320 TDATSILGIG TVLDQAETAG ARLVVLATAT PPGSVTVSHP NIEEVALSTT GEIPFYGKAI 1380 PLEVIKGGRH LIFCHSKKKC DELAAKLVAL GINAVAYYRG LDVSVIPTSG DVVVVSTDAL 1440 MTGFTGDFDS VIDCNTCVTQ TVDFSLDPTF TIETTTLPQD AVSRTQRRGR TGRGKPGIYR 1500 FVAPGERPSG MFDSSVLCEC YDAGCAWYEL TPAETTVRLR AYMNTPGLPV CQDHLEFWEG 1560 VFTGLTHIDA HFLSQTKQSG ENFPYLVAYQ ATVCARAQAP PPSWDQMWKC LIRLKPTLHG 1620 PTPLLYRLGA VQNEVTLTHP ITKYIMTCMS ADLEVVTSTW VLVGGVLAAL AAYCLSTGCV 1680 VIVGRIVLSG KPAIIPDREV LYQEFDEMEE CSQHLPYIEQ GMMLAEQFKQ KALGLLQTAS 1740 RQAEVITPAV QTNWQKLEVF WAKHMWNFIS GIQYLAGLST LPGNPAIASL MAFTAAVTSP 1800 LTTGQTLLFN ILGGWVAAQL AAPGAATAFV GAGLAGAAIG SVGLGKVLVD ILAGYGAGVA 1860 GALVAFKIMS GEVPSTEDLV NLLPAILSPG ALVVGVVCAA ILRRHVGPGE GAVQWMNRLI 1920 AFASRGNHVS PTHYVPESDA AARVTAILSS LTVTQLLRRL HQWISSECTT PCSGSWLRDI 1980 WDWICEVLSD FKTWLKAKLM PQLPGIPFVS CQRGYRGVWR GDGIMHTRCH CGAEITGHVK 2040 NGTMRIVGPR TCRNMWSGTF PINAYTTGPC TPLPAPNYKF ALWRVSAEEY VEIRRVGDFH 2100 YVSGMTTDNL KCPCQIPSPE FFTELDGVRL HRFAPPCKPL LREEVSFRVG LHEYPVGSQL 2160 PCEPEPDVAV LTSMLTDPSH ITAEAAGRRL ARGSPPSMAS SSASQLSAPS LKATCTANHD 2220 SPDAELIEAN LLWRQEMGGN ITRVESENKV VILDSFDPLV AEEDEREVSV PAEILRKSRR 2280 FARALPVWAR PDYNPPLVET WKKPDYEPPV VHGCPLPPPR SPPVPPPRKK RTVVLTESTL 2340 STALAELATK SFGSSSTSGI TGDNTTTSSE PAPSGCPPDS DVESYSSMPP LEGEPGDPDL 2400 SDGSWSTVSS GADTEDVVCC SMSYSWTGAL VTPCAAEEQK LPINALSNSL LRHHNLVYST 2460 TSRSACQRQK KVTFDRLQVL DSHYQDVLKE VKAAASKVKA NLLSVEEACS LTPPHSAKSK 2520 FGYGAKDVRC HARKAVAHIN SVWKDLLEDS VTPIDTTIMA KNEVFCVQPE KGGRKPARLI 2580 VFPDLGVRVC EKMALYDVVS KLPLAVMGSS YGFQYSPGQR VEFLVQAWKS KKTPMGFSYD 2640 TRCFDSTVTE SDIRTEEAIY QCCDLDPQAR VAIKSLTERL YVGGPLTNSR GENCGYRRCR 2700 ASGVLTTSCG NTLTCYIKAR AACRAAGLQD CTMLVCGDDL VVICESAGVQ EDAASLRAFT 2760 EAMTRYSAPP GDPPQPEYDL ELITSCSSNV SVAHDGAGKR VYYLTRDPTT PLARAAWETA 2820 RHTPVNSWLG NIIMFAPTLW ARMILMTHFF SVLIARDQLE QALNCEIYGA CYSIEPLDLP 2880 PVM-00425 (PVX-PAT-2406-WO) PIIQRLHGLS AFSLHSYSPG EINRVAACLR KLGVPPLRAW RHRARSVRAR LLSRGGRAAI 2940 CGKYLFNWAV RTKLKLTPIA AAGRLDLSGW FTAGYSGGDI YHSVSHARPR WFWFCLLLLA 3000 AGVGIYLLPN R 3011 The different bolded, underlines, and italicized sequences correspond to core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, and NS5B protein of hepatitis C virus genotype 1 in this order. In some embodiments, the target peptide is obtained or derived core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus, including mutants, derivatives, variants, comparable equivalents, or functional analogs. Core Protein Core protein is one of the structural proteins of hepatitis C virus. It is the first protein to be translated from the HCV genome. Immature core protein is about 191 amino acid long, which undergoes cleavage by signal peptide peptidase to release C-terminal E1 signal sequence resulting in about 177 amino acid long mature core protein with a molecular weight of approximately 21 kDa. Core protein form the viral capsid enclosing the viral RNA. The mature core protein is involved in RNA binding, and interaction with lipid membrane. In some embodiments, the target peptide is obtained or derived from core protein of a hepacivirus. In some embodiments, the core protein is obtained or derived from hepatitis C virus genotype 1, hepatitis C virus genotype 2, hepatitis C virus genotype 3, hepatitis C virus genotype 4, hepatitis C virus genotype 5, hepatitis C virus genotype 6, hepatitis C virus genotype 7, or hepatitis C virus genotype 8. In some embodiments, the target protein is a full length core protein or a fragment thereof of a hepacivirus or comparable equivalents, including mutants, derivatives, variants, or functional analogs thereof. Exemplary core protein includes, but not limited to, the one represented by the amino acid sequences having SEQ ID NOs: 88-353 or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. PVM-00425 (PVX-PAT-2406-WO) In some embodiments, the core protein shares at least 50% identity with the sequences described herein or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the amino acid sequences of the core protein, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above core protein. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the core protein is encoded by a target sequence which may be either a DNA, an RNA, or an mRNA. E1 protein The envelope protein of HCV consists of two proteins viz., E1 and E2. Envelope protein (E1) is a type I transmembrane protein which is glycosylated. It is about 192 amino acid long with a molecular weight of approximately 31-35 kDa. It is associated with E2 protein forming a heterodimer. Most of the immunogenic domains of E1 protein are hidden under E2 because of E1-E2 heterodimerization. E1 plays a role in attachment, endosome-lipid membrane fusion, and assembly during the HCV replication cycle. E1 facilitates E2 as it binds with host receptors by maintaining an E1-E2 structural confirmation favourable for receptor binding. E1 protein is also believed to interact with several other viral proteins to facilitate HCV assembly process. In some embodiments, the target peptide is obtained or derived from E1 protein of a hepacivirus. In some embodiments, the E1 protein is obtained or derived from hepatitis C virus genotype 1, hepatitis C virus genotype 2, hepatitis C virus genotype 3, hepatitis C virus genotype 4, hepatitis C virus genotype 5, hepatitis C virus genotype 6, hepatitis C virus genotype 7, or hepatitis C virus genotype 8. In some embodiments, the target protein is a full length E1 protein or a fragment thereof of a hepacivirus or comparable equivalents, including mutants, derivatives, variants or functional analogs thereof. Exemplary E1 protein includes, but not limited to, the one represented by the amino acid sequences having SEQ ID NOs: 354-959 or 12121, or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. PVM-00425 (PVX-PAT-2406-WO) In some embodiments, the E1 protein shares at least 50% identity with the sequences described herein, including their codon optimized nucleic acid sequences, fragments, mutants, variants, comparable equivalents, or functional analogs thereof. Given the amino acid sequences of the E1 protein, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above E1 protein. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the E1 protein is encoded by a target sequence which may be either a DNA, an RNA, or an mRNA. E2 protein The envelope protein (E2) is also a type I transmembrane protein which is glycosylated. It is about 363 amino acid long with a molecular weight of approximately 70 kDa. It is associated with E1 protein forming a heterodimer. It is involved in host receptor binding, entry, and fusion with the endosomal membrane. In some embodiments, the target peptide is obtained or derived from E2 protein of a hepacivirus. In some embodiments, the E2 protein is obtained or derived from hepatitis C virus genotype 1, hepatitis C virus genotype 2, hepatitis C virus genotype 3, hepatitis C virus genotype 4, hepatitis C virus genotype 5, hepatitis C virus genotype 6, hepatitis C virus genotype 7, or hepatitis C virus genotype 8. In some embodiments, the target protein is a full length E2 protein or a fragment thereof of a hepacivirus or comparable equivalents, including mutants, derivatives, variants or functional analogs thereof. Exemplary E2 protein includes, but not limited to, the one represented by the amino acid sequences having SEQ ID NOs: 960-1582 or 12122, or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. In some embodiments, the E2 protein shares at least 50% identity with the sequences described herein or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the amino acid sequences of the E2 protein, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above E2 protein. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some PVM-00425 (PVX-PAT-2406-WO) embodiments, the E2 protein is encoded by a target sequence which may be either a DNA, an RNA, or an mRNA. P7 protein P7 protein is one of the non-structural proteins of about 63 amino acid long with a molecular weight of approximately 7 kDa. P7 protein is believed to play a role in viral assembly and release in concert with other viral proteins. It has the ability to oligomerize to form ion channels in host cell membrane. Heptameric and hexameric oligomers of P7 have been identified so far. In some embodiments, the target peptide is obtained or derived from P7 protein of a hepacivirus. In some embodiments, the P7 protein is obtained or derived from hepatitis C virus genotype 1, hepatitis C virus genotype 2, hepatitis C virus genotype 3, hepatitis C virus genotype 4, hepatitis C virus genotype 5, hepatitis C virus genotype 6, hepatitis C virus genotype 7, or hepatitis C virus genotype 8. In some embodiments, the target protein is a full length P7 protein or a fragment thereof of a hepacivirus or comparable equivalents, including mutants, derivatives, variants or functional analogs thereof. Exemplary P7 protein includes, but not limited to, the one represented by the amino acid sequences having SEQ ID NOs: 1583-2026 or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. In some embodiments, the P7 protein shares at least 50% identity with the sequences described herein or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the amino acid sequences of the P7 protein, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above P7 protein. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the P7 protein is encoded by a target sequence which may be either a DNA, an RNA, or an mRNA. NS2 protein PVM-00425 (PVX-PAT-2406-WO) NS2 protein is one of the non-structural proteins of about 217 amino acid long with a molecular weight of approximately 23 kDa. NS2 protein functions as a cysteine protease and also as assists in the viral assembly process along with other viral proteins. In some embodiments, the target peptide is obtained or derived from NS2 protein of a hepacivirus. In some embodiments, the NS2 protein is obtained or derived from hepatitis C virus genotype 1, hepatitis C virus genotype 2, hepatitis C virus genotype 3, hepatitis C virus genotype 4, hepatitis C virus genotype 5, hepatitis C virus genotype 6, hepatitis C virus genotype 7, or hepatitis C virus genotype 8. In some embodiments, the target protein is a full length NS2 protein or a fragment thereof of a hepacivirus or comparable equivalents, including mutants, derivatives, variants or functional analogs thereof. Exemplary NS2 protein includes, but not limited to, the one represented by the amino acid sequences having SEQ ID NOs: 2027-2651 or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. In some embodiments, the NS2 protein shares at least 50% identity with the sequences described herein or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the amino acid sequences of the NS2 protein, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above NS2 protein. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the NS2 protein is encoded by a target sequence which may be either a DNA, an RNA, or an mRNA. NS3 protein NS3 is one of the non-structural proteins of about 631 amino acid long with a molecular weight of approximately 70 kDa. It has two major domains viz., serine protease domain and an RNA helicase domain. The former is responsible for cleaving the viral polyprotein at specific sites during viral polyprotein processing, while the latter is involved in unwinding of the RNA facilitating RNA replication. NS3 protein is also associated with NS4A protein together forming the NS3-4A complex. In some embodiments, the target peptide is obtained or derived from NS3 protein of a hepacivirus. In some embodiments, the NS3 protein is obtained or derived from PVM-00425 (PVX-PAT-2406-WO) hepatitis C virus genotype 1, hepatitis C virus genotype 2, hepatitis C virus genotype 3, hepatitis C virus genotype 4, hepatitis C virus genotype 5, hepatitis C virus genotype 6, hepatitis C virus genotype 7, or hepatitis C virus genotype 8. In some embodiments, the target protein is a full length NS3 protein or a fragment thereof of a hepacivirus or comparable equivalents, including mutants, derivatives, variants or functional analogs thereof. Exemplary NS3 protein includes, but not limited to, the one represented by the amino acid sequences having SEQ ID NOs: 2652-3284 or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. In some embodiments, the NS3 protein shares at least 50% identity with the sequences described herein or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the amino acid sequences of the NS3 protein, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above NS3 protein. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the NS3 protein is encoded by a target sequence which may be either a DNA, an RNA, or an mRNA. NS4A protein NS4A is one of the non-structural proteins of about 54 amino acid long with a molecular weight of approximately 8 kDa. It acts as a cofactor for NS3 serine protease. It is associated with NS3 protein forming NS3-4A complex. In some embodiments, the target peptide is obtained or derived from NS4A protein of a hepacivirus. In some embodiments, the NS4A protein is obtained or derived from hepatitis C virus genotype 1, hepatitis C virus genotype 2, hepatitis C virus genotype 3, hepatitis C virus genotype 4, hepatitis C virus genotype 5, hepatitis C virus genotype 6, hepatitis C virus genotype 7, or hepatitis C virus genotype 8. In some embodiments, the target protein is a full length NS4A protein or a fragment thereof of a hepacivirus or comparable equivalents, including mutants, derivatives, variants thereof. Exemplary NS4A protein includes, but not limited to, the one represented by the amino acid sequences having SEQ ID NOs: 3285-3462 or comparable equivalents, PVM-00425 (PVX-PAT-2406-WO) including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. In some embodiments, the NS4A protein shares at least 50% identity with the sequences described herein or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the amino acid sequences of the NS4A protein, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above NS4A protein. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the NS4A protein is encoded by a target sequence which may be either a DNA, an RNA, or an mRNA. NS4B protein NS4B is one of the non-structural proteins of about 261 amino acid long with a molecular weight of approximately 27 kDa. NS4B is an integral membrane protein and plays an important role in the formation of replication complex thereby facilitating viral RNA replication. In some embodiments, the target peptide is obtained or derived from NS4B protein of a hepacivirus. In some embodiments, the NS4B protein is obtained or derived from hepatitis C virus genotype 1, hepatitis C virus genotype 2, hepatitis C virus genotype 3, hepatitis C virus genotype 4, hepatitis C virus genotype 5, hepatitis C virus genotype 6, hepatitis C virus genotype 7, or hepatitis C virus genotype 8. In some embodiments, the target protein is a full length NS4B protein or a fragment thereof of a hepacivirus or comparable equivalents, including mutants, derivatives, variants or functional analogs thereof. Exemplary NS4B protein includes, but not limited to, the one represented by the amino acid sequences having SEQ ID NOs: 3463-4004 or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. In some embodiments, the NS4B protein shares at least 50% identity with the sequences described herein or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the amino acid sequences of the NS4B protein, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above PVM-00425 (PVX-PAT-2406-WO) NS4B protein. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the NS4B protein is encoded by a target sequence which may be either a DNA, an RNA, or an mRNA. NS5A protein NS5A protein is one of the non-structural proteins of about 447 amino acid long with a molecular weight of approximately 56-58 kDa. NS5A exists in two isoforms depending upon the degree of phosphorylation viz., the basally phosphorylated isoform exists as 56 kDa protein, whereas the hyper phosphorylated isoform exists as a 58 kDa protein. It does not have any apparent enzymatic activity, but interacts with other viral proteins and host cells proteins to regulate viral replication and assembly, in addition to modulation of cell signalling pathways, response to interferon etc. In some embodiments, the target peptide is obtained or derived from NS5A protein of a hepacivirus. In some embodiments, the NS5A protein is obtained or derived from hepatitis C virus genotype 1, hepatitis C virus genotype 2, hepatitis C virus genotype 3, hepatitis C virus genotype 4, hepatitis C virus genotype 5, hepatitis C virus genotype 6, hepatitis C virus genotype 7, or hepatitis C virus genotype 8. In some embodiments, the target protein is a full length NS5A protein or a fragment thereof of a hepacivirus or comparable equivalents, including mutants, derivatives, variants, or functional analogs thereof. Exemplary NS5A protein includes, but not limited to, the one represented by the amino acid sequences having SEQ ID NOs: 4005-4627 or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. In some embodiments, the NS5A protein shares at least 50% identity with the sequences described herein or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the amino acid sequences of the NS5A protein, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above NS5A protein. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the NS5A protein is encoded by a target sequence which may be either a DNA, an RNA, or an mRNA. PVM-00425 (PVX-PAT-2406-WO) NS5B protein NS4B protein is one of the non-structural proteins of about 591 amino acid long with a molecular weight of approximately 68 kDa. It is an RNA dependent RNA polymerase (RdRp) playing a vital role in replication of HCV. In some embodiments, the target peptide is obtained or derived from NS5B protein of a hepacivirus. In some embodiments, the core protein is obtained or derived from hepatitis C virus genotype 1, hepatitis C virus genotype 2, hepatitis C virus genotype 3, hepatitis C virus genotype 4, hepatitis C virus genotype 5, hepatitis C virus genotype 6, hepatitis C virus genotype 7, or hepatitis C virus genotype 8. In some embodiments, the target protein is a full length NS5B protein or a fragment thereof of a hepacivirus or comparable equivalents, including mutants, derivatives, variants thereof. Exemplary NS5B protein includes, but not limited to, the one represented by the amino acid sequences having SEQ ID NOs: 4628-5247 or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. In some embodiments, the NS5B protein shares at least 50% identity with the sequences described herein or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the amino acid sequences of the NS5B protein, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above NS5B protein. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the NS5B protein is encoded by a target sequence which may be either a DNA, an RNA, or an mRNA. B cell epitope In some embodiments, the target peptide is obtained or derived from B cell epitope of a hepacivirus, including a fragment, mutant, derivative or variant thereof. In some embodiments, the B cell epitopes are obtained or derived from a hepatitis C virus, for example, hepatitis C virus genotype 1, hepatitis C virus genotype 2, hepatitis C virus genotype 3, hepatitis C virus genotype 4, hepatitis C virus genotype 5, hepatitis C virus genotype 6, hepatitis C virus genotype 7, or hepatitis C virus genotype 8. PVM-00425 (PVX-PAT-2406-WO) Exemplary B cell epitopes include, but not limited to, the one represented by the amino acid sequences having SEQ ID NOs: 5248-10039 or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. In some embodiments, the B cell epitopes share at least 50% identity with the sequences described herein or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the amino acid sequences of the B cell epitopes, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above B cell epitopes. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the B cell epitopes are encoded by a target sequence which may be either a DNA, an RNA, or an mRNA. T cell epitope In some embodiments, the target peptide is obtained or derived from T cell epitope of a hepacivirus, including a fragment, mutant, derivative or variant thereof. In some embodiments, the T cell epitopes are obtained or derived from a hepatitis C virus, for example, hepatitis C virus genotype 1, hepatitis C virus genotype 2, hepatitis C virus genotype 3, hepatitis C virus genotype 4, hepatitis C virus genotype 5, hepatitis C virus genotype 6, hepatitis C virus genotype 7, or hepatitis C virus genotype 8. Exemplary T cell epitopes include, but not limited to, the one represented by the amino acid sequences having SEQ ID NOs: 10040-12111 or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. In some embodiments, the T cell epitopes share at least 50% identity with the sequences described herein or comparable equivalents, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the amino acid sequences of the T cell epitopes, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above T cell epitopes. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the T cell epitopes are encoded by a target sequence which may be either a DNA, an RNA, or an mRNA. PVM-00425 (PVX-PAT-2406-WO) Self-assembling sequence and self-assembling peptide The multisubunit nucleic acid sequence and multisubunit peptide includes self- assembling sequence and self-assembling peptide respectively. The self-assembling sequence comprises of a sequence of nucleotides, either deoxyribonucleotides or ribonucleotides, that encodes a self-assembling peptide. The self-assembling sequence includes codon optimized sequences, fragments, mutants, variants, comparable equivalents, functional analogs, or a combination thereof. In some embodiments, the self- assembling sequence is a DNA, an RNA, or an mRNA. Any self-assembling peptide that is capable of self-assembling into a polypeptide nanoparticle can be employed in accordance with the present disclosure. In some embodiments self-assembling peptide is a full-length protein or its fragment, mutants, or variant thereof. In some embodiments, the self-assembling peptide includes, but not limited to, lumazine synthase, MS2 coat protein, hepatitis B surface antigen (HBsAg) from Hepatitis B Virus, hepatitis B core antigen (HbcAg) from Hepatitis B virus, human papillomavirus L1 (HPV L1) protein, matrix protein M1 from influenza A virus, ferritin, riboflavin synthase, dihydrolipoyl acetyltransferase (E2p), or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, comparable equivalent, or functional analogs thereof. In some embodiments, the self-assembling peptide is a ferritin peptide. Ferritin is one of the ubiquitous proteins found in nature. It is produced by all living organisms including archaea, bacteria, algae, higher plants, and animals. Each ferritin protein is generally composed of 12 or 24 subunits or peptides which self- assembles into a ferritin nanoparticle. In some aspects, the multisubunit nucleic acid sequence and multisubunit peptide includes ferritin sequence and ferritin peptide respectively. The ferritin sequence comprises of a sequence of nucleotides, either deoxyribonucleotides or ribonucleotides, that encodes a ferritin peptide. In some embodiments, the ferritin sequence is a DNA or an RNA or an mRNA. Any ferritin peptide that is capable of self-assembling into a nanoparticle can be employed in accordance with the present disclosure. In some embodiments, the ferritin peptide is obtained or derived from Helicobacter pylori ferritin, including their codon optimized nucleic acid sequences, fragments, mutants, variants, comparable equivalents, or PVM-00425 (PVX-PAT-2406-WO) functional analogs thereof. In some embodiments a ferritin peptide is obtained or derived from Listeria innocua ferritin, including their codon optimized nucleic acid sequences, fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the self-assembling peptide is lumazine synthase. In some embodiments, the lumazine synthase is obtained or derived from Aquifex species (for example, Aquifex aeolicus) or Bacillus species (for example, Bacillus subtilis), including their codon optimized nucleic acid sequences, fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the self-assembling peptide is dihydrolipoyl acetyltransferase (E2p). In some embodiments, the dihydrolipoyl acetyltransferase (E2p) is obtained or derived from Bacillus stearothermophilus, including their codon optimized nucleic acid sequences, fragments, mutants, variants, comparable equivalents, or functional analogs thereof. In some embodiments, the self-assembling peptide is MS2 coat protein. In some embodiments, the self-assembling peptide is MS2 coat protein obtained or derived from Emesvirus zinderi, including their codon optimized nucleic acid sequences, fragments, mutants, variants, comparable equivalents, or functional analogs thereof. Exemplary self-assembling peptides includes, but not limited to, the ones represented by the following amino acid sequences or comparable equivalents, or a combination thereof, including codon optimized sequences, fragments, mutants, variants, or functional analogs thereof: LSKDIIKLLNEQVNKEMNSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAK KLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDH ATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGI (SEQ ID NO: 1); LSKDIIKLLNEQVNKEMNSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAK KLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDH ATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIRRKR (SEQ ID NO: 2); LSKDIIKLLNEQVNKEMNSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAK KLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDH ATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS (SEQ ID NO: 3); PVM-00425 (PVX-PAT-2406-WO) MQIYEGKLTAEGLRFGIVASRFNHALVDRLVEGAIDCIVRHGGREEDITLVRVPGS WEIPVAAGELARKEDIDAVIAIGVLIRGATPHFDYIASEVSKGLANLSLELRKPITFG VITADTLEQAIERAGTKHGNKGWEAALSAIEMANLFKSLR (SEQ ID NO: 4); MTKKVGIVDTTFARVDMASIAIKKLKELSPNIKIIRKTVPGIKDLPVACKKLLEEEG CDIVMALGMPGKAEKDKVCAHEASLGLMLAQLMTNKHIIEVFVHEDEAKDDKEL DWLAKRRAEEHAENVYYLLFKPEYLTRMAGKGLRQGFEDAGPARE (SEQ ID NO: 5); MTEKEKMLAEKWYDANFDQYLINERARAKDICFELNHTRPSATNKRKELIDQLFQ TTTDNVSISIPFDTDYGWNVKLGKNVYVNTNCYFMDGGQITIGDNVFIGPNCGFY TATHPLNFHHRNEGFEKAGPIHIGSNTWFGGHVAVLPGVTIGEGSVIGAGSVVTKD IPPHSLAVGNPCKVVRKIDNDLPSETLNDETIK (SEQ ID NO: 6); MENTTSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFQGGAPTCPGQNSQSPT SNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLLPGTSTT GTGPCRTCTIPAQGTSMFPSCCCTKPSDGNCTCIPIPSSWAFARFLWEWASVRFSW LSLLVPFVQWFAGLSPTVWLSVIWMMWYRGPSLYNTLSPFLPLLPISFCLWVYI (SEQ ID NO: 7); MIFVLGGCRHKLVCSPAPCNFFHLCLIISCSCPTVHASKLCLGWLWGMHIDPYKEF GASVELLSFLPSDFFPSIRDLLDTASALYREALESPEHCSPHHTALRQAILCWGELM NLATWVGSNLEDPASRELVVSYVNVNMGLKIRQLLWFHISCLTFGRETVLEYLVS FGVWIRTPPAYRPPNAPILSTLPETTVVRRRGRSPRRRTPSPRRRRSQSPRRRRSQSR ESQC (SEQ ID NO: 8); MSLWLPSEATVYLPPVPVSKVVSTDEYVARTNIYYHAGTSRLLAVGHPYFPIKKP NNNKILVPKVSGLQYRVFRIHLPDPNKFGFPDTSFYNPDTQRLVWACVGVEVGRG QPLGVGISGHPLLNKLDDTENASAYAANAGVDNRECISMDYKQTQLCLIGCKPPI GEHWGKGSPCTNVAVNPGDCPPLELINTVIQDGDMVDTGFGAMDFTTLQANKSE VPLDICTSICKYPDYIKMVSEPYGDSLFFYLRREQMFVRHLFNRAGAVGENVPDDL YIKGSGSTANLASSNYFPTPSGSMVTSDAQIFNKPYWLQRAQGHNNGICWGNQLF VTVVDTTRSTNMSLCAAISTSETTYKNTNFKEYLRHGEEYDLQFIFQLCKITLTAD VMTYIHSMNSTILEDWNFGLQPPPGGTLEDTYRFVTSQAIACQKHTPPAPKEDPLK KYTFWEVNLKEKFSADLDQFPLGRKFLLQAGLKAKPKFTLGKRKATPTTSSTSTT AKRKKRKL (SEQ ID NO: 9); MSLLTEVETYVLSIVPSGPLKAEIAQRLEDVFAGKNTDLEALMEWLKTRPILSPLT KGILGFVFTLTVPSERGLQRRRFVQNALNGNGDPNNMDRAVKLYRKLKREITFHG PVM-00425 (PVX-PAT-2406-WO) AKEIALSYSAGALASCMGLIYNRMGAVTTEVAFGLVCATCEQIADSQHRSHRQM VTTTNPLIRHENRMVLASTTAKAMEQMAGSSEQAAEAMEVASQARQMVQAMRA IGTHPRSSAGLKDDLLENLQAYQKRMGVQMQRFK (SEQ ID NO: 10); AAAKPATTEGEFPETREKMSGIRRAIAKAMVHSKHTAPHVTLMDEADVTKLVAH RKKFKAIAAEKGIKLTFLPYVVKALVSALREYPVLNTAIDDETEEIIQKHYYNIGIA ADTDRGLLVPVIKHADRKPIFALAQEINELAEKARDGKLTPGEMKGASCTITNIGS AGGQWFTPVINHPEVAILGIGRIAEKPIVRDGEIVAAPMLALSLSFDHRMIDGATAQ KALNHIKRLLSDPELLLM (SEQ ID NO: 11); ASNFTQFVLVDNGGTGDVTVAPSNFANGVAEWISSNSRSQAYKVTCSVRQSSAQ NRKYTIKVEVPKVATQTVGGVELPVAAWRSYLNMELTIPIFATNSDCELIVKAMQ GLLKDGNPIPSAIAANSGIY (SEQ ID NO: 12112); QIYEGKLTAEGLRFGIVASRFNHALVDRLVEGAIDCIVRHGGREEDITLVRVPGSW EIPVAAGELARKEDIDAVIAIGVLIRGATPHFDYIASEVSKGLAQLSLELRKPITFGV ITADTLEQAIERAGTKHGNKGWEAALSAIEMANLFKSLR (SEQ ID NO: 12113); NIIQGNLVGTGLKIGIVVGRFNDFITSKLLSGAEDALLRHGVDTNDIDVAWVPGAF EIPFAAKKMAETKKYDAIITLGTVIRGATTHYDYVCNEAAKGIAQAAQTTGVPVIF GIVTTENIEQAIETAGTKAGNKGVDCAVSAIEMANLQRSFE (SEQ ID NO: 12114); KTINSVDTKEFLNHQVANLNVFTVKIHQIHWYMRGHNFFTLHEKMDDLYSEFGE QMDEVAERLLAIGGSPFSTLKEFLENASVEEAPYTKPKTMDQLMEDLVGTLELLR DEYKQGIELTDKEGDDVTNDMLIAFKASIDKHIWMFKAFLGKAPLE (SEQ ID NO: 12115). In some embodiments, the self-assembling peptide shares at least 50% identity with the sequences described herein above or comparable equivalents, or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the disclosed amino acid sequences of the self-assembling peptides, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above self-assembling peptides. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the self-assembling peptide is encoded by the self-assembling sequence which may be either a DNA, an RNA, or an mRNA. Linker sequence and linker peptide PVM-00425 (PVX-PAT-2406-WO) The multisubunit nucleic acid sequence and multisubunit peptide includes linker sequence and linker peptide respectively. The linker sequence comprises a sequence of nucleotides, either deoxyribonucleotides or ribonucleotides, that encodes a linker peptide. The linker sequence includes codon optimized sequences, fragments, mutants, variants, comparable equivalents, functional analogs, or a combination thereof. In some embodiments, the linker sequence is a DNA, an RNA, or an mRNA. In some embodiments, the linker peptide connects the target peptide with the self- assembling peptide in a polypeptide. In some embodiments, the linker peptide connects the signal peptide with a polypeptide. In some other embodiments, the linker peptide connects the signal peptide with the first polypeptide. In some embodiments, one linker peptide connects the cleavage peptide with the target peptide and another linker peptide connects the target peptide with the self-assembling peptide in a polypeptide. In some embodiments, the linker peptide connects two cleavage peptides. Any suitable linker peptides can be employed in accordance with the present disclosure. In some embodiments, the linker peptide is an amino acid linker, a zipper motif, a foldon, a scaffold, or a combination thereof. In some embodiments, the linker peptide is an amino acid linker. In some embodiments, the linker peptide is a zipper motif. In some embodiments, the linker peptide is a foldon. In some embodiments the linker peptide is a scaffold. In some embodiments, the linker peptide comprises a combination of an amino acid linker and a zipper motif. In some embodiments, the linker peptide comprises a combination of an amino acid linker and a foldon. In some embodiments, the linker peptide comprises a combination of an amino acid linker and a scaffold. In some embodiments, the linker peptide comprises a combination of a zipper motif and a foldon. In some embodiments, the linker peptide comprises a combination of a zipper motif and a scaffold. In some embodiments, the linker peptide comprises a combination of a foldon and a scaffold. In some embodiments, the linker peptide comprises a combination of an amino acid linker, a zipper motif, and a foldon. In some embodiments, the linker peptide comprises a combination of an amino acid linker, a zipper motif, and a scaffold. In some embodiments, the linker peptide comprises a combination of an amino acid linker, a foldon, and a scaffold. In some embodiments, the linker peptide comprises a combination of a zipper motif, a foldon, and a scaffold. In some embodiments, the linker peptide comprises a combination of an amino acid linker, a zipper motif, a foldon, and a scaffold. PVM-00425 (PVX-PAT-2406-WO) In some embodiments, the amino acid linker comprises of about 2-49 amino acids, 2-40 amino acids, 2-30 amino acids, 2-20 amino acids, 2-15 amino acids, or 2-10 amino acids. In some embodiments, the amino acid linker comprises a glycine serine linker, a glycine proline linker, a glycine threonine linker, an alanine serine linker, any combination of two amino acids, or a combination thereof. The glycine proline linker comprises of glycine (G) and proline (P) amino acids consecutively without any preference of order of appearance of either glycine or proline. In some embodiments, the glycine proline linker is 2-49 amino acids in length. The glycine threonine linker comprises of glycine (G) and threonine (T) amino acids consecutively without any preference of order of appearance of either glycine or threonine. In some embodiments, the glycine threonine linker is 2-49 amino acids in length. The alanine serine linker comprises of alanine (A) and serine (S) amino acids consecutively without any preference of order of appearance of either alanine or serine. In some embodiments, the alanine serine linker is 2-49 amino acids in length. The glycine serine linker comprises of glycine (G) and serine (S) amino acids consecutively without any preference of order of appearance of either glycine or serine. In some embodiments, the glycine serine linker is 2-49 amino acids in length. Exemplary amino acid linkers include, but not limited to, the ones represented by the following amino acid sequences or comparable equivalents, or their combinations, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof: GSG (SEQ ID NO: 12); GSGG (SEQ ID NO: 13); GGSGG (SEQ ID NO: 14); GGSGGGGSGG (SEQ ID NO: 15); GGSGGGGSGGGGSGG (SEQ ID NO: 16); SGGSGG (SEQ ID NO: 17); GGGGSGGGGS (SEQ ID NO: 18); GGGGSGGGGSGGGGS (SEQ ID NO: 19); PGG (SEQ ID NO: 12116). In some embodiments, the amino acid linkers share at least 50% identity with the sequences described herein above or comparable equivalents, or a combination thereof, PVM-00425 (PVX-PAT-2406-WO) including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the disclosed amino acid sequences of the amino acid linkers, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above amino acid linkers. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the amino acid linker is encoded by an amino acid linker sequence which may be either a DNA, an RNA, or an mRNA. In some embodiments, linker peptide is a zipper motif. A zipper motif comprises of a sequence of amino acids encoded by a zipper sequence. Zipper motifs are generally a class of protein-protein interaction domains that facilitates formation of a complex i.e., enables two, three, four, five, or six homologous or heterologous polypeptides to associate themselves into a polypeptide cluster. In some embodiments, the zipper motif is a leucine zipper, an isoleucine zipper, or any synthetic zipper. Exemplary zipper motifs include, but not limited to, the ones represented by the following amino acid sequences or comparable equivalents, or a combination thereof, including codon optimized sequences, fragments, mutants, variants, or functional analogs thereof: RIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNY (SEQ ID NO: 12117); LTDTLQAETDQLEDKKSALQTEIANLLKEKEKLEFILAAY (SEQ ID NO: 12118); RNAYLRKKIARLKKDNLQLERDEQNLEKIIANLRDEIARLENEVA (SEQ ID NO: 12119); LVAQLENEVASLENENETLKKKNLHKKDLIAYLEKEIANLRKKIE (SEQ ID NO: 12120). In some embodiments, the zipper motif shares at least 50% identity with the sequences described herein above or comparable equivalents, or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the disclosed amino acid sequences of the zipper motifs, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above zipper motifs. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the zipper motif is encoded by a zipper sequence which may be either a DNA, an RNA, or an mRNA. PVM-00425 (PVX-PAT-2406-WO) In some embodiments, the linker peptide is a foldon. A foldon comprises of a sequence of amino acids encoded by a foldon sequence. The foldon sequence includes codon optimized sequences, fragments, mutants, variants, comparable equivalent, functional analogs, or a combination thereof. A foldon enables two or more homologous polypeptides to organise to form an oligomeric complex. In some embodiments, foldon also helps in orientation of a polypeptide such that the domains or epitopes on the target peptide are exposed or displayed for interaction or communication with cells or biomolecules or immune system. Exemplary foldons includes, but not limited to, the ones represented by the following amino acid sequences or comparable equivalents, or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof: YIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO: 20); HENEISHHAKEIERLQKEIERHKQSIKKLKQSE (SEQ ID NO: 21). In some embodiments, the foldon shares at least 50% identity with the sequences described herein above or comparable equivalents, or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the disclosed amino acid sequences of the foldons, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above foldons. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the foldon is encoded by a foldon sequence which may be either a DNA, an RNA or an mRNA. In some embodiments, the linker peptide is a scaffold. A scaffold comprises of a sequence of amino acids encoded by a scaffold sequence. The scaffold sequence includes codon optimized sequences, fragments, mutants, variants, comparable equivalent, functional analogs, or a combination thereof. A scaffold provides structural and / or functional integrity or support to the target peptide and may also help in orientation of target peptide such that the domains or epitopes of the target peptide are exposed or displayed for interaction or communication with cells or biomolecules or immune system. PVM-00425 (PVX-PAT-2406-WO) Exemplary scaffolds include, but not limited to, the ones represented by the following amino acid sequences or comparable equivalents, or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof: VDNKFNKEMRNAYWEIALLPNLNNQQKRAFIRSLYDDPSQSANLLAEAKKLNDA QAPK (SEQ ID NO: 22); QDSTSDLIPAPPLSKVPLQQNFQDNQFHGKWYVVGKAGNHDLREDKDPRKMQAT IYELKEDKSYNVTNVRFVHKKCNYRIWTFVPGSQPGEFTLGNIKSWPGLTSWLVR VVSTNYNQHAMVFFKRVYQNRELFEITLYGRTKELTNELKENFIRFSKSLGLPENH IVFPVPIDQCIDGSAWSHPQFEK (SEQ ID NO: 23); VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKST ATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRT (SEQ ID NO: 24); GCPRILMRCKQDSDCLAGCVCGPNGFCG (SEQ ID NO: 25); MRGSHHHHHHGSDLGKKLLEAARAGQDDEVRILMANGADVNATDNDGYTPLHL AASNGHLEIVEVLLKNGADVNASDLTGITPLHLAAATGHLEIVEVLLKHGADVNA YDNDGHTPLHLAAKYGHLEIVEVLLKHGADVNAQDKFGKTAFDISIDNGNEDLA EILQ (SEQ ID NO: 26); MRGSHHHHHHGSVKVKFFWNGEEKEVDTSKIVWVKRAGKSVLFIYDDNGKNGY GDVTEKDAPKELLDMLARAEREKKL (SEQ ID NO: 27); MLPAPKNLVVSEVTEDSARLSWDDPAAFYESFLIQYQESEKVGEAIVLTVPGSERS YDLTGLKPGTEYTVSIYGVHNVYKDTNMRGLPLSAIFTTGGHHHHHH (SEQ ID NO: 28); ETDICKLPKDEGTCRDFILKWYYDPNTKSCARFWYGGCGGNENKFGSQKECEKV CAPV (SEQ ID NO: 29); MIPGGLSEAKPATPEIQEIVDKVKPQLEEKTNETYGKLEAVQYKTQVVAGTNYYI KVRAGDNKYMHLKVFKSLPGQNEDLVLTGYQVDKNKDDELTGF (SEQ ID NO: 30); PCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCA (SEQ ID NO: 31); MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLS DYNIQKESTLHLVLRLRGG (SEQ ID NO: 32); MGSIIFLEDRAFQGRIYGCTTDCPNLQPYFSRCNSIVVQSGCWMIYERPNYQGHQY FLRRGEYPDYQQWMGLSDSIRSCCLIPPHSGAYRMKIYDRDELRGQMSELTDDCL PVM-00425 (PVX-PAT-2406-WO) SVQDRFHLTEIHSLNVLEGSWILYEMPNYRGRQYLLRPGEYRRFLDWGAPNAKV GSLRRVMDLYLEHHHHHH (SEQ ID NO: 33); AGHRIAWLLMMGHPRQQLAIIFGIGVSTLYRYFPA (SEQ ID NO: 34); AFSKSEEARHSSLERECIEEICDHAEAWDIMM (SEQ ID NO: 35); RECDYCGTDIEPGTGGMAVHGDGATTHFCSHRCAWDAMMGAEARNLEWTDTA R (SEQ ID NO: 36); CSQNEYFDSLLHACIPCQLRCSGAPHRCAWDCMM (SEQ ID NO: 37); EHIPGTLAARLSHRAAWDLMMHSLDASQGTATGPRGIFTAEDALKLVQLKQTGK TFPTYKCGHRFAWDCMMGSGLNGAACFAVKIADLPVYSCECAIGFMGQRCEYKE (SEQ ID NO: 38); ACYGHRCAWDCMMLGFSSGKCINSKCKCYK (SEQ ID NO: 39); GEYVVEKVLDKRVVKGKVEYLLKWKGFSDEDNTWEPDENLDGHRLAWDFMM ADVYEVEAILADRVNKNGINEYYIKWAGYDWYDNTWEPEQNLFGAGHRLAWW MMR (SEQ ID NO: 40); AGTIKITQTRSAIGRLPAHKATLLGLGLRRIGHTVEREDGHRIAWDIMMVSFMVKV EG (SEQ ID NO: 41); GIPCGESCGSPCISSAIGCSCKLINTNGSWHIVCYRN (SEQ ID NO: 42); GKCPETFDAWYCLNDAHCFAVLINTNGSWHIVYSCECAIGFMGQRCEYKE (SEQ ID NO: 43); QEEADRTVFVGNLEARVREEILYELFLQAGPLTKVTICKDREGKPKSFGFVCFKHP ESVSYAIALAGLINLNGSWIIVSGPSSG (SEQ ID NO: 44); NEEDAGKMFVGGLSWDTSKKDLKDYFTKFGEVVDCTIKMDPNTGRSRGFGFILF KDAASVEKVLDAGLHNLNGSWIIPKKA (SEQ ID NO: 45); SGNIFIKNLDKSIDNKALYDTFSAFGNILSCKVVCDEQGSKGYGFVHFETQEAAER AIAKMGLMNLNGSWVIVGRFKSRKE (SEQ ID NO: 46); PSRVVYLGSIPYDQTEEQILDLCSNVGPVINLKMMFDPQTGRSKGYAFIEFRDLESS ASAVGALGLYNLNGSWLICGYSSNSDISGVSLEHHHH (SEQ ID NO: 47); LAILVFGYPETMANQVIAYFQEFGTILEDFEVLRKPQAMTVGLQDRQFVPIFSGNS WTKITYDNPASAVDALAEGLANFNGSWLLVIPYTKDAVERLQ (SEQ ID NO: 48); RLVNCNGSWLIGLDRPPYPGAKGEDIYNNVSRKAWDEWQKHQTMLINERRLNM MNAEDRKFLQQEMDKFLSGEDY (SEQ ID NO: 49); FAVESIEKLRNRNGSWEILVKWRGWSPKYNTWEPEENIG (SEQ ID NO: 50); PVM-00425 (PVX-PAT-2406-WO) MRDFFVITNSLYNFNGSWYIKGAVLHVSPTQKRAFWVIADQENFIKQVNKNIEYV EKQASPAFLQRIVEIYQVKFEGKNVG (SEQ ID NO: 51). In some embodiments, the scaffold shares at least 50% identity with the sequences described herein above or comparable equivalents, or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the disclosed amino acid sequences of the scaffold, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above scaffold. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the scaffold is encoded by the scaffold sequence which may be either a DNA, an RNA, or an mRNA. In some embodiments, the linker peptide comprises an amino acid linker and a zipper motif. In some embodiments, the linker peptide comprises an amino acid linker followed by a zipper motif. In some embodiments, the linker peptide comprises a zipper motif followed by an amino acid linker. In some embodiments, the linker peptide comprises an amino acid linker followed by a zipper motif and another an amino acid linker. In some embodiments, the linker peptide comprises a zipper motif followed by an amino acid linker, and another zipper motif. In some embodiments, the linker peptide comprises an amino acid linker and a foldon. In some embodiments, the linker peptide comprises an amino acid linker followed by a foldon. In another embodiment, the linker peptide comprises a foldon followed by an amino acid linker. In some embodiments, the linker peptide comprises an amino acid followed by a foldon and another amino acid linker. In some embodiments, the linker peptide comprises a foldon followed by an amino acid linker and another foldon. In some embodiments, the linker peptide comprises an amino acid linker and a scaffold. In some embodiments, the linker peptide comprises an amino acid linker followed by a scaffold. In some embodiments, the linker peptide comprises a scaffold followed by an amino acid linker. In some embodiments, the linker peptide comprises an amino acid linker followed by a scaffold and another amino acid linker. In some embodiments, the linker peptide comprises a scaffold followed by an amino acid linker and another scaffold. PVM-00425 (PVX-PAT-2406-WO) In some embodiments, the linker peptide comprises a zipper motif and a scaffold. In some embodiments, the linker peptide comprises a zipper motif followed by a scaffold. In some embodiments, the linker peptide comprises a scaffold followed by a zipper motif. In some embodiments, the linker peptide comprises a scaffold followed by a zipper motif and another scaffold. In some embodiments, the linker peptide comprises a zipper motif followed by a scaffold and another zipper motif. In some embodiments, the linker peptide comprises a foldon and a scaffold. In some embodiments, the linker peptide comprises a foldon followed by a scaffold. In some embodiments, the linker peptide comprises a scaffold followed by a foldon. In some embodiments, the linker peptide comprises a foldon followed by a scaffold and another foldon. In some embodiments, linker peptide comprises a scaffold followed by a foldon and another scaffold. In some embodiments, the linker peptide comprises an amino acid linker, a zipper motif, and a scaffold. In some embodiments, the linker peptide comprises an amino acid linker followed by a zipper motif, and a scaffold. In some embodiments, the linker peptide comprises a zipper motif followed by an amino acid linker, and a scaffold. In some embodiments, the linker peptide comprises a scaffold followed by an amino acid linker, and a zipper motif. In some embodiments, the linker peptide comprises a first amino acid linker followed by a zipper motif, a second amino acid linker followed by a scaffold, and a third amino acid linker. In some embodiments, the linker peptide comprises a first amino acid linker followed by a scaffold, a second amino acid linker followed by a zipper motif, and a third amino acid linker. In some embodiments, the linker peptide comprises a scaffold followed by a first amino acid linker, and a zipper motif followed by a second amino acid linker. In some embodiments, the linker peptide comprises a first amino acid linker followed by a scaffold, and a second amino acid linker followed by a zipper motif. In some embodiments, the linker peptide comprises an amino acid linker, a foldon and a scaffold. In some embodiments, the linker peptide comprises an amino acid linker followed by a foldon and a scaffold. In some embodiments, the linker peptide comprises a foldon followed by an amino acid linker and a scaffold. In some embodiments, the linker peptide comprises a scaffold followed by an amino acid linker and a foldon. In some embodiments, the linker peptide comprises a first amino acid linker followed by a foldon, a second amino acid linker followed by a scaffold, and a third amino acid linker. In some embodiments, the linker peptide comprises a first amino acid linker followed by a scaffold, PVM-00425 (PVX-PAT-2406-WO) a second amino acid linker followed by a foldon, and a third amino acid linker. In some embodiments, the linker peptide comprises a scaffold followed by a first amino acid linker, and a foldon followed by second amino acid linker. In some embodiments, the linker peptide comprises a first amino acid linker followed by a scaffold, and a second amino acid linker followed by a foldon. Cleavage sequence and cleavage peptide The multisubunit nucleic acid sequence and multisubunit peptide includes cleavage sequence and cleavage peptide respectively. The cleavage sequence comprises of a sequence of nucleotides, either deoxyribonucleotides or ribonucleotides, that encode a cleavage peptide. The cleavage sequence includes codon optimized sequences, fragments, mutants, variants, comparable equivalents, functional analogs, or a combination thereof. In some embodiments, the cleavage sequence is a DNA, an RNA, or an mRNA. The cleavage peptide connects one polypeptide with another polypeptide, for example, the adjacent polypeptide. The cleavage peptide carries one or more cleavage sites. In some embodiments, the cleavage peptide comprises one or more cleavage peptides, for example cleavage peptide-1, cleavage peptide-2 and so on. In some embodiments, the cleavage peptide optionally comprises a linker peptide between two cleavage peptides. In some embodiments, the cleavage peptide facilitates the action of cellular proteases to cleave the multisubunit polypeptide into individual polypeptides or self cleaves into individual polypeptides. In some embodiments, the resulting polypeptides comprises either a target peptide, a linker peptide and a self-assembling peptide or a linker peptide, target peptide, linker peptide and a self-assembling peptide or a combination thereof. In some embodiments, the polypeptide, in addition to these peptides, may also have some residues (amino acids) of cleavage peptide. Any cleavage peptide that is susceptible to the action of cellular proteases or a cleavage peptide that has the ability to undergo self cleavage can be employed in accordance with the present disclosure. In some embodiments, the cleavage peptide is a substrate for cellular proteases. In some embodiments, the cleavage peptide is a substrate for golgi specific proteases. In some embodiments, the cleavage peptide is a self cleaving peptide. In some embodiments, the cleavage peptide comprises two or more cleavage peptides (for example, cleavage peptide-1, cleavage peptide-2 and so on), optionally linked by a linker peptide, wherein PVM-00425 (PVX-PAT-2406-WO) one cleavage peptide is a substrate for cellular proteases and the other cleavage peptide is a self cleaving peptide. In some embodiments, the cleavage peptide is a golgi specific cleavage peptide i.e., susceptible to action of golgi specific proteases. Exemplary cleavage peptide includes, but not limited to, the one represented by the following amino acid sequence or comparable equivalents, or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof: RRKRSVS (SEQ ID NO: 52); GIRRKRSVSH (SEQ ID NO: 53); VQREKRAVGI (SEQ ID NO: 54); SIRHKREPSV (SEQ ID NO: 55); KRRQRRRPPQ (SEQ ID NO: 56); KIRRRRDVVD (SEQ ID NO: 57); HNRTKRSTDG (SEQ ID NO: 58); RKRRKRELET (SEQ ID NO: 59); THRTRRSTSD (SEQ ID NO: 60); SRRKRRSAST (SEQ ID NO: 61); NLRRRRDLVD (SEQ ID NO: 62); LRRRRRDAGN (SEQ ID NO: 63); ATNFSLLKQAGDVEENPGP (SEQ ID NO: 64); EGRGSLLTCGDVEENPGP (SEQ ID NO: 65); QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66). In some embodiments, the cleavage peptide shares at least 50% identity with the sequence described herein above or comparable equivalents, or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the disclosed amino acid sequences of the cleavage peptide, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above cleavage peptide. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the cleavage peptide is encoded by a cleavage sequence which may be either a DNA, an RNA, or an mRNA. PVM-00425 (PVX-PAT-2406-WO) Signal sequence and signal peptide The multisubunit nucleic acid sequence and multisubunit peptide includes a signal sequence and a signal peptide respectively. The signal sequence comprises of a sequence of nucleotides, either deoxyribonucleotides or ribonucleotides, that encodes a signal peptide. The signal sequence includes codon optimized sequences, fragments, mutants, variants, comparable equivalents, functional analogs, or a combination thereof. In some embodiments, the signal sequence is a DNA or an RNA, or an mRNA. The signal peptide is present upstream (N-terminus or amino-terminus) of one or more polypeptides. In some embodiments, the signal peptide is present on the N-terminus of all or some polypeptides. In some embodiments, the signal peptide is present on the N- terminus of the first polypeptide. In some embodiments, the signal peptide is present upstream (N-terminus) of some polypeptides. In some embodiments, the signal peptide is present upstream (N-terminus) of each of the polypeptides. In some embodiments, the signal peptide transports the multisubunit peptide to cell organelles. In some embodiments, the signal peptide transports the multisubunit peptide to golgi body or golgi apparatus / complex. Any signal peptide that transports the multisubunit peptide to golgi bodies can be employed in accordance with the present disclosure. In some embodiments, the signal peptide is a golgi targeting signal peptide i.e., directs the multisubunit peptide to golgi complex. Exemplary signal peptide includes, but not limited to, the one represented by the following amino acid sequence or comparable equivalents, or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof: MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAA (SEQ ID NO: 67); MGSSVSWGILLLAGLCCLVPVSLAEDPQGDAA (SEQ ID NO: 68); MASSVSWGILLLAGLCCLVPVSLAEDPQGDAA (SEQ ID NO: 69); MDMRAPAGIFGFLLVLFPGYRS (SEQ ID NO: 70); MKWVTFISLLFLFSSAYS (SEQ ID NO: 71); MDWTWRVFCLLAVTPGAHP (SEQ ID NO: 72); MAWSPLFLTLITHCAGSWA (SEQ ID NO: 73); MTRLTVLALLAGLLASSRA (SEQ ID NO: 74); MARPLCTLLLLMATLAGALA (SEQ ID NO: 75); MRSLVFVLLIGAAFA (SEQ ID NO: 76); PVM-00425 (PVX-PAT-2406-WO) MSRLFVFILIALFLSAIIDVMS (SEQ ID NO: 77); MGMRMMFIMFMLVVLATTVVS (SEQ ID NO: 78); MRAFLFLTACISLPGVFG (SEQ ID NO: 79); MKFQSTLLLAAAAGSALA (SEQ ID NO: 80); MASSLYSFLLALSIVYIFVAPTHS (SEQ ID NO: 81); MKTHYSSAILPILTLFVFLSINPSHG (SEQ ID NO: 82); MESVSSLFNIFSTIMVNYKSLVLALLSVSNLKYARG (SEQ ID NO: 83); MKAAQILTASIVSLLPIYTSA (SEQ ID NO: 84); MIKLKFGVFFTVLLSSAYA (SEQ ID NO: 85); MGVKVLFALICIAVAEA (SEQ ID NO: 86). In some embodiments, the signal peptide shares at least 50% identity with the sequence described herein above or comparable equivalents, or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, or functional analogs thereof. Given the disclosed amino acid sequences of the signal peptide, a person skilled in the art would be able to deduce all possible DNA or RNA sequences that encodes the above signal peptide. Such DNA or RNA sequences are deemed to be incorporated in this disclosure. In some embodiments, the signal peptide is encoded by a signal sequence which may be either a DNA, an RNA, or an mRNA. Synthesis of multisubunit nucleic acid sequences Multisubunit nucleic acid sequence according to the present disclosure can be either a DNA or an RNA or an mRNA. The multisubunit nucleic acid sequence as described herein can be synthesized by molecular biology or genetic engineering techniques well known in the art, for example, using recombinant expression system, chemical synthesis, or in vitro transcription (IVT). In some embodiments, the multisubunit nucleic acid sequence is obtained through a single IVT process or step. In some embodiments, the multisubunit nucleic acid sequence obtained through single IVT process or step is an mRNA. In some embodiments, the multisubunit nucleic acid sequence is obtained or synthesized through a single in vitro transcription (IVT) process or step. In some embodiments, the multisubunit nucleic acid sequence is a messenger RNA (mRNA). The mRNA encodes a multisubunit peptide as described herein. PVM-00425 (PVX-PAT-2406-WO) Typically, an mRNA includes at least a coding region (which encodes the multisubunit peptide), a 5’ UTR, a 3’ UTR, a 5’ cap and a 3’ poly(A) tail. UTR (untranslated regions) flanks the coding region or open reading frame (ORF). The 5’ UTR and the 3’ UTR are sections of the mRNA before the start codon and after the stop codon respectively. The 5’ UTR has a cap (5’ cap) consisting of altered nucleotides. mRNA also contains a polyadenylated region at its 3’ end having adenine nucleotides called poly(A) tail. In some embodiments, the mRNA is unmodified or modified or a combination of both. The modification may be in the nucleobase of the nucleotide, or sugar moiety of the nucleotide, or the phosphate of the nucleotide. In some embodiments, unmodified mRNA comprises naturally occurring nucleosides, for example, adenosine, guanosine, cytidine, and uridine. mRNA comprises one or more modified nucleosides, for example, adenosine analog, guanosine analog, cytidine analog, or uridine analog. In some embodiments, the one or more modified nucleosides is a nucleoside analog selected from 2-aminoadenosine, 3-methyl adenosine, 7-deazaadenosine, 7- deazaguanosine, 8-oxoadenosine, or 8-oxoguanosine or a combination thereof. In some embodiments, the one or more modified nucleosides is a uridine analog selected from propynyl-uridine, pseudouridine, C5-bromouridine, C5-fluorouridine, C5- iodouridine, C5-propynyl-uridine, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine, 4- thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine, 3-methyl-uridine, 5- carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 1-methyl-3-(3-amino-3- carboxypropyl)pseudouridine, 2-thio-2’-O-methyl-uridine, 5-methoxycarbonylmethyl-2’- O-methyl-uridine, 5-carboxymethylaminomethyl-2’-O-methyl-uridine, 3,2’-O-dimethyl- uridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine, 1- taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurino-4-thio- pseudouridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl- pseudouridine, 1-methyl-1deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydro-uridine, dihydro-pseudouridine, 2-thio-dihydro-uridine, 2-thio-dihydro- pseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, or 4-methoxy-2-thio-pseudouridine, or a combination thereof. In some embodiments, the one or more modified nucleosides is a cytidine analog selected from 5-methylcytidine, C5-propynyl-cytidine, C5-methylcytidine, pseudoisocytidine, 1-methyl-pseudoisocytidine, pyrrolo-pseudoisocytidine, 4-thio- PVM-00425 (PVX-PAT-2406-WO) pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza- pseudoisocytidine, 1-methyl-1-1deaza-pseudoisocytidine, 4-methoxy-1-methyl- pseudoisocytidine, or a combination thereof. Methods for making modified nucleosides are well known in the art. In some embodiments, the modified nucleoside is pseudouridine, for example, 1- methyl-pseudouridine, 1-propynyl-pseudouridine, 1-carboxymethyl-pseudouridine, 1- methyl-3-(3-amino-3-carboxypropyl) pseudouridine, 4-methoxy-pseudouridine, or 4- methoxy-2-thio-pseudouridine 4-thio-pseudouridine, 2-thio-pseudouridine, 4-thio-1- methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, dihydro-pseudouridine, or a combination thereof. In some embodiments, mRNA is produced using recombinant expression system, chemically synthesized, or obtained through in vitro transcription. In some embodiments, the multisubunit nucleic acid sequence is obtained or synthesized through a single IVT process or step. mRNAs according to the present disclosure may be synthesized via in vitro transcription (IVT). Briefly, IVT is typically performed with a DNA template containing a promoter, a pool of ribonucleotide triphosphates, a buffer system that may include DTT and magnesium ions, and an appropriate RNA polymerase (e.g., T3, T7, or SP6 RNA polymerase), DNase I, pyrophosphatase, and / or RNase inhibitor. The exact conditions may vary according to the specific application. Methods of making mRNA through IVT reaction is well known in the art (see for example, Beckert, Bertrand and Masquida, Benoit Methods in Molecular Biology (2011) 703, 29-41; Brunelle, Julie L. and Green Rachel Methods in Enzymology (2013) 530, 101-114; Kamakaka, Rohinton T. and Kraus W. Lee Current Protocols in Cell Biology (1999) 11.6.1-11.6.17; Kanwal, Fariha et al. Cellular Physiology and Biochemistry (2018) 48:1915-1927; WO2018157153; WO2020185811; WO2022082001). In some embodiments, the in vitro transcription occurs in a single batch. In some embodiments, IVT reaction includes capping and tailing reactions either co- transcriptionally or separately. A cap analog is added to the in vitro transcription reaction and will be incorporated at the 5’ end of the mRNA during the reaction. Alternative method of capping involves adding the cap post-transcriptionally through an enzymatic reaction. The poly (A) tail can be incorporated into the DNA template sequence, and thus the poly (A) tail will be incorporated into the mRNA by T7 RNA polymerase during the in PVM-00425 (PVX-PAT-2406-WO) vitro transcription. Alternative method of tailing involves adding the poly (A) tail post- transcriptionally through an enzymatic reaction. In some embodiments, capping and tailing reactions are performed co-transcriptionally i.e., during the IVT reaction. In some embodiments, capping and tailing reactions are performed separately from IVT reaction i.e., post transcriptionally. mRNA produced as a result of IVT reaction may be purified using techniques well known in the art, such as, centrifugation, filtration and / or chromatographic techniques. The purification of mRNA may be accomplished before capping and tailing steps are performed or after capping and tailing. The synthesized mRNA may be purified by ethanol precipitation or filtration or chromatography methods. In some embodiments, tangential flow filtration is used to purify mRNA. In some embodiments, mRNA is purified by chromatographic step. In other embodiments, mRNA is purified by a combination of filtration and chromatography steps. In some embodiments, a suitable mRNA sequence is an mRNA sequence encoding a protein, peptide, polypeptide. In some embodiments, a suitable mRNA sequence is codon optimized for efficient expression in a host cell or organism. Codon optimization typically includes modifying a naturally-occurring or wild-type nucleic acid sequence encoding a peptide, polypeptide, or protein to achieve the highest possible expression of peptide, polypeptide, protein, or an antibody without altering the amino acid sequence. In some embodiments, the mRNA is circular. In other embodiments, the mRNA is linear. In some embodiments, the mRNA is self-amplifying or self-replicating. In some embodiments, mRNA is few hundred nucleotides long to several thousand nucleotides long. In some embodiments, mRNA is about 0.5 kb, 1 kb, 1.5 kb, 2 kb, 2.5 kb, 3 kb, 3.5 kb, 4 kb, 4.5 kb, 5 kb, 5.5 kb, 6 kb, 6.5 kb, 7.0 kb, 7.5 kb, 8 kb, 8.5 kb, 9 kb, 9.5 kb, 10 kb, 10.5 kb, 11 kb, 11.5 kb, 12 kb, 12.5 kb, 13 kb, 13.5 kb, 14 kb, 14.5 kb, 15 kb, 16 kb, 17 kb, 18 kb, 19 kb, 20 kb, 21 kb, 22 kb, 23 kb, 24 kb, 25 kb, 26 kb, 27 kb, 28 kb, 29 kb, 30 kb in length, or a fraction thereof. In some embodiments, mRNA is about 0.5 to 30 kb, 0.5 to 25 kb, 0.5 to 20 kb in length, or any range therein. In some embodiments, mRNA is about 1 to 20 kb, 1 to 18 kb, 1 to 16 kb, 1 to 14 kb, 1 to 12 kb, 1 to 10 kb, 1 to 9 kb, 1 to 8 kb, 1 to 7 kb, 1 to 6 kb, 1 to 5 kb in length, or any range therein. In some embodiments, mRNA is about 0.5 kb to about 1 kb, about 1 kb to about 2 kb, about 2 kb to about 3 kb, about 3 kb to about 4 kb, about 4 kb to about 5 kb, about 5 kb PVM-00425 (PVX-PAT-2406-WO) to about 6 kb, about 6 kb to about 7 kb, about 7 kb to about 8 kb, about 8 kb to about 9 kb, about 9 kb to about 10 kb, about 10 kb to about 11 kb, about 11 kb to about 12 kb, about 12 kb to about 13 kb, about 13 kb to about 14 kb, about 14 kb to about 15 kb, about 15 kb to about 16 kb, about 16 kb to about 17 kb, about 17 kb to about 18 kb, about 18 kb to about 19 kb, about 19 kb to about 20 kb, about 20 kb to about 21 kb, about 21 kb to about 22 kb, about 22 kb to about 23 kb, about 23 kb to about 24 kb, about 24 kb to about 25 kb, about 25 kb to about 26 kb, about 26 kb to about 27 kb, about 27 kb to about 28 kb, about 28 kb to about 29 kb, about 29 kb to about 30 kb in length, or any range therein. The multisubunit nucleic acid sequence as described herein, express multisubunit peptide. Polypeptide nanoparticle The multisubunit peptide, encoded by the multisubunit nucleic acid, comprises multiple repeats of polypeptide comprising either a target peptide, a linker peptide, and a self-assembling peptide or a linker peptide, target peptide, a linker peptide, and a self- assembling peptide, or a combination thereof, interspersed with cleavage peptide (see illustration in figures), wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A, protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In some embodiments, the total number of polypeptides present in a multisubunit peptide are up to 100 polypeptides. In some embodiments, one or more polypeptides in the multisubunit peptide has identical target peptides (homologous polypeptides). In some embodiments, one or more polypeptides in the multisubunit peptide has different target peptides (heterologous polypeptides). A multisubunit peptide as described herein is encoded by the multisubunit nucleic acid sequence as described herein. Each multisubunit peptide comprises two or more polypeptides, wherein some or all polypeptides comprises either a target peptide, a linker peptide, and a self-assembling peptide or a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide or a combination thereof, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. The polypeptides are connected with each other through a cleavage peptide. The multisubunit peptide includes a signal PVM-00425 (PVX-PAT-2406-WO) peptide upstream (N-terminus) of one or more polypeptides. In some embodiments, the multisubunit peptide includes a signal peptide upstream (N-terminus) of each of all or some polypeptides. In some embodiments, the multisubunit peptide optionally includes a signal peptide upstream (N-terminus) of each polypeptide. In some embodiments, the multisubunit peptide includes a signal peptide upstream (N-terminus) of some polypeptides. In some embodiments, the multisubunit peptide includes a signal peptide upstream (N-terminus) of all polypeptides. The signal peptide transports the multisubunit peptide to golgi body or golgi apparatus. The cellular proteases act on the cleavage sites present in the cleavage peptides or the cleavage peptide undergoes self cleavage and cleaves the multisubunit peptide into individual polypeptides comprising either a target peptide, a linker peptide, and a self- assembling peptide, or a linker peptide, a target peptide, a linker peptide, and a self- assembling peptide, or a signal peptide, a target peptide, a linker peptide, and a self- assembling peptide, or a signal peptide, a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, or a combination thereof, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. The polypeptides may additionally also have some residues (amino acids) of the cleavage peptide. In some embodiments, the linker peptide is an amino acid linker, a zipper motif, a foldon, a scaffold, or a combination thereof. In some embodiments, the polypeptides are homologous polypeptides. In some embodiments, two or more homologous polypeptides organise to form an oligomeric complex. In some embodiments, the oligomeric complex comprises at least two homologous polypeptides, at least three homologous polypeptides, at least four homologous polypeptides, at least five homologous polypeptides, or at least six homologous polypeptides and so on. In some embodiments, the polypeptides are heterologous polypeptides. In some embodiments, the homologous polypeptides or the heterologous polypeptides organize to form a polypeptide cluster. A polypeptide nanoparticle is formed by self-assembly of two or more homologous polypeptides, two or more heterologous polypeptides, one or more oligomeric complexes, one or more polypeptide clusters, or their combination. PVM-00425 (PVX-PAT-2406-WO) In some embodiments, a polypeptide nanoparticle comprises homologous polypeptides, heterologous polypeptides, oligomeric complexes, polypeptide clusters, or a combination thereof. In some embodiments, the polypeptide nanoparticles are symmetrical, non- symmetrical, asymmetrical, or a combination thereof. In some embodiments, the polypeptide nanoparticles are icosahedral, helical, spherical, rod-like, or a combination thereof. In some embodiments, the polypeptide nanoparticles are enveloped or non- enveloped or a combination thereof. In some embodiments, the polypeptide nanoparticles are single layered or multi- layered or a combination thereof. In some of the embodiments, the polypeptide nanoparticle comprises at least 2 or up to 500 polypeptides. In some embodiments, the polypeptide nanoparticle comprises polypeptides between 2-5, 2-10, 2-20, 20-40, 40-60, 60-80, 80-100, 100-120, 120-140, 140-160, 160- 180, 180-200, 200-220, 220-240, 240-260, 260-280, 280-300, 300-320, 320-340, 340-360, 360-380, 380-400, 400-420, 420-440, 440-460, 460-480, or 480-500. In some embodiments, the polypeptide nanoparticle comprises polypeptides between 2-5, 2-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, or 90-99. In one of the embodiments, the polypeptide nanoparticle comprises at least 2 or up to 500 homologous polypeptides. In some embodiments, the polypeptide nanoparticle comprises at least 2 or up to 500 heterologous polypeptides. In some embodiments, the polypeptide nanoparticle comprises two or more oligomeric complexes such that the total number of polypeptides in the polypeptide nanoparticle are not more than 500. In some embodiments, the polypeptide nanoparticle comprises two or more polypeptide clusters such that total number of polypeptides in the polypeptide nanoparticle are not more than 500. In some embodiments, the polypeptide nanoparticle comprises some homologous polypeptides and some heterologous polypeptides such that the total number of polypeptides in the polypeptide nanoparticle are not more than 500. PVM-00425 (PVX-PAT-2406-WO) In some embodiments, the polypeptide nanoparticle comprises some homologous polypeptides and some oligomeric complexes such that the total number of polypeptides in the polypeptide nanoparticle are not more than 500. In some embodiments, the polypeptide nanoparticle comprises some heterologous polypeptides and some oligomeric complexes such that the total number of polypeptides in the polypeptide nanoparticle are not more than 500. In some embodiments, the polypeptide nanoparticle comprises some homologous polypeptides and some polypeptide clusters such that the total number of polypeptides in the polypeptide nanoparticle are not more than 500. In some embodiments, the polypeptide nanoparticle comprises some heterologous polypeptides and some polypeptide clusters such that the total number of polypeptides in the polypeptide nanoparticle are not more than 500. In some embodiments, the polypeptide nanoparticle comprises some polypeptide clusters and some oligomeric complexes such that the total number of polypeptides in the polypeptide nanoparticle are not more than 500. In some embodiments, the polypeptide nanoparticle comprises some homologous polypeptides, some heterologous polypeptides, some oligomeric complexes, or their combination such that the total number of polypeptides in the polypeptide nanoparticle are not more than 500. In some embodiments, the polypeptide nanoparticle comprises some homologous polypeptides, some heterologous polypeptides, some polypeptide clusters, or their combination such that the total number of polypeptides in the polypeptide nanoparticle are not more than 500. In some embodiments, the polypeptide nanoparticle comprises some homologous polypeptides, some polypeptide clusters, some oligomeric complexes, or their combination such that the total number of polypeptides in the polypeptide nanoparticle are not more than 500. In some embodiments, the polypeptide nanoparticle comprises some heterologous polypeptides, some polypeptide clusters, some oligomeric complexes, or their combination such that the total number of polypeptides in the polypeptide nanoparticle are not more than 500. In some embodiments, the polypeptide nanoparticle comprises some heterologous polypeptides, some homologous polypeptides, some polypeptide clusters, some oligomeric PVM-00425 (PVX-PAT-2406-WO) complexes, or their combination such that the total number of polypeptides in the polypeptide nanoparticle are not more than 500. Lipid nanoparticles (LNP) composition The multisubunit nucleic acid sequences as described herein may be encapsulated or formulated in a lipid nanoparticle composition. In some embodiments, the lipid nanoparticle composition comprises lipid components, ionizable polymer, or a combination thereof and a multisubunit nucleic acid sequence as described herein. In some embodiments, the lipid nanoparticle composition comprises lipid components such as a cationic lipid, a phospholipid, a sterol, a PEG-lipid and a multisubunit nucleic acid sequence as described herein. In another embodiment, the lipid nanoparticle composition comprises an ionizable polymer, a cationic lipid, a phospholipid, a sterol, a PEG-lipid and a multisubunit nucleic acid sequence as described herein. In some embodiments, a vaccine comprising the lipid nanoparticle composition is provided herein. Lipid Components Lipid components of the lipid nanoparticle compositions may include one or more lipids, such as a cationic lipid, a phospholipid, a sterol, and a PEG-lipid. Cationic lipid Cationic lipid refers to a lipid that has a net positive charge at a selected pH. Cationic lipids generally comprise a hydrophilic head group that carries the charge and a hydrophobic tail. In some embodiments, the cationic lipid is a cationic lipid with an amine head group. The amine head group can be primary, secondary, tertiary or quaternary. The cationic lipid may comprise one (monoamine) or more (polyamine) such amine groups. In some embodiments, the cationic lipids are positively charged at pH below the pKa of the cationic lipid. In certain embodiments, the cationic lipids are neutral i.e., when pH is same or above the pKa of the cationic lipid. In some embodiments, the cationic lipids are positively charged at acidic pH i.e., pH 1.0 to pH 6.9. In certain embodiments, PVM-00425 (PVX-PAT-2406-WO) the cationic lipids are neutral at certain pH i.e., around physiological pH (pH 7.0 to pH 7.5). A cationic lipid that can exist in a positively charged or neutral form depending on the pH is commonly referred to as ionizable lipid. In some embodiments, the cationic lipids are ionizable such that they can exist in a positively charged or neutral form depending on the pH. In some embodiments, the cationic lipids are positively charged irrespective of the pH. In some embodiments, the cationic lipid present in the lipid nanoparticle composition comprises a cationic lipid disclosed in US provisional applications viz., 63 / 575930; 63 / 575934; 63 / 575938; 63 / 575939; and 63 / 575942. In some embodiments, the cationic lipid present in the lipid nanoparticle composition comprises a cationic lipid represented by formula (I) formula (I) or isomer, or salt thereof, wherein: R1and R2are independently chosen from H, -OH, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, saturated or unsaturated C3-10 cycloalkyl, C6-10 aryl, saturated or unsaturated C3-10 heterocycloalkyl containing 1-4 heteroatoms, C5-10 heteroaryl containing 1-4 heteroatoms, -O-L7-R5, and -NR6R7, or R1and R2may combine together to form a saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, or C5-10heteroaryl containing 1-4 heteroatoms; R3and R4are independently chosen from branched or unbranched C1-26alkyl, C2-26alkenyl, C2-26alkynyl, –(CH2)m-A-(CH2)n-(CH3)y, and -CH((CH2)m-A-(CH2)n-(CH3)y)2, wherein each of m, n, and y is independently an integer ranging from 0 to 26; R5, R6, and R7are independently chosen from H, -OH, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, and C5-10 heteroaryl containing 1-4 heteroatoms; PVM-00425 (PVX-PAT-2406-WO) each of L1, L2, L3, L4, L5, L6, and L7is either absent or independently chosen from C1-10alkylene, C2-10alkenylene, and C2-10alkynylene; X1and X2are independently chosen from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, - C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, and - OP(O)(O-)O-; A is H, a bond, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, or C5-10heteroaryl containing 1-4 heteroatoms; C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S, or N provided that when A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, - OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, or S, one of R1 or R2 is absent; and wherein each alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is independently optionally substituted with one or more substituent. In some embodiments, the cationic lipid present in the lipid nanoparticle composition comprises a cationic lipid represented by formula (II) formula (II) or isomer, or salt thereof, wherein: represents either a single bond or a double bond; R1and R2are independently chosen from H, -OH, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, C5-10heteroaryl containing 1-4 heteroatoms, -O-L7-R5, and -NR6R7, or R1and R2may combine together to form a saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, or C5-10heteroaryl containing 1-4 heteroatoms; PVM-00425 (PVX-PAT-2406-WO) R3and R4are independently chosen from, branched or unbranched, C1-26alkyl, C2-26alkenyl, C2-26alkynyl, –(CH2)m-A-(CH2)n-(CH3)y, and -CH((CH2)m-A-(CH2)n-(CH3)y)2, wherein each of m, n, and y is independently an integer ranging from 0 to 26; R5, R6, and R7are independently chosen from H, -OH, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, and C5-10heteroaryl containing 1-4 heteroatoms; each of L1, L2, L3, L4, L5, L6, and L7is either absent or independently chosen from C1-10alkylene, C2-10 alkenylene, and C2-10 alkynylene; X1and X2are independently chosen from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, - C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, and - OP(O)(O-)O-; A is H, a bond, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, or C5-10heteroaryl containing 1-4 heteroatoms; C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S, or N provided that when A1is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, - OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, or S, one of R1or R2is absent; and wherein each alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is independently optionally substituted with one or more substituent. In some embodiments, the cationic lipid present in the lipid nanoparticle composition comprises a cationic lipid represented by formula (III) PVM-00425 (PVX-PAT-2406-WO) or isomer, or salt thereof, wherein: R1and R2are independently chosen from H, -OH, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, C5-10heteroaryl containing 1-4 heteroatoms, -O-L7-R5, and -NR6R7, or R1and R2may combine together to form a saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, or C5-10heteroaryl containing 1-4 heteroatoms; R3 and R4 are independently chosen from branched or unbranched C1-26 alkyl, C2-26 alkenyl, C2-26alkynyl, –(CH2)m-A-(CH2)n-(CH3)y, and -CH((CH2)m-A-(CH2)n-(CH3)y)2, wherein each of m, n, and y is independently an integer ranging from 0 to 26; R5,R6, and R7are independently chosen from H, -OH, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, and C5-10heteroaryl containing 1-4 heteroatoms; each of L1,L2,L3, L4,L5L6, and L7is either absent or independently chosen from C1-10alkylene, C2-10alkenylene, and C2-10alkynylene; X1and X2are independently chosen from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, - C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, and - OP(O)(O-)O-; A is H, a bond, saturated or unsaturated C3-10 cycloalkyl, C6-10 aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatom, or C5-10heteroaryl containing 1-4 heteroatom; C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S, or N provided that when A1is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, - OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, or S, one of R1or R2is absent; and wherein each alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is independently optionally substituted with one or more substituent. In some embodiments, the cationic lipid present in the lipid nanoparticle composition comprises a cationic lipid represented by formula (IV) PVM-00425 (PVX-PAT-2406-WO) formula (IV) or isomer, or salt thereof, wherein: represents either a single bond or a double bond; R1and R2are independently chosen from H, -OH, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, C5-10heteroaryl containing 1-4 heteroatoms, -O-L7-R5, and -NR6R7, or R1and R2may combine together to form a saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, or C5-10heteroaryl containing 1-4 heteroatoms; R3and R4are independently chosen from branched or unbranched C1-26alkyl, C2-26alkenyl, C2-26alkynyl, –(CH2)m-A-(CH2)n-(CH3)y, and -CH((CH2)m-A-(CH2)n-(CH3)y)2, wherein each of m, n, and y is independently an integer ranging from 0 to 26; R5, R6, and R7are independently chosen from H, -OH, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, and C5-10 heteroaryl containing 1-4 heteroatoms; each of L1, L2, L3, L4, L5, L6, and L7is either absent or independently chosen from C1-10alkylene, C2-10alkenylene, and C2-10alkynylene; X1and X2are independently chosen from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, - C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, and - OP(O)(O-)O-; A is H, a bond, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatom, or C5-10heteroaryl containing 1-4 heteroatom; PVM-00425 (PVX-PAT-2406-WO) C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S, or N provided that when A1is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, - OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, or S, one of R1or R2is absent; and wherein each alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is independently optionally substituted with one or more substituent. In some embodiments, the cationic lipid present in the lipid nanoparticle composition comprises a cationic lipid represented by formula (V) formula (V) or isomer, or salt thereof, wherein: R3and R4are independently chosen from branched or unbranched C1-26alkyl, C2-26alkenyl, C2-26alkynyl, –(CH2)m-A-(CH2)n-(CH3)y, and -CH((CH2)m-A-(CH2)n-(CH3)y)2, wherein each of m, n, and y is independently an integer ranging from 0 to 26; (R10)qis chosen from H, -OH, optionally substituted C1-10alkyl, C2-10alkenyl, C2-10alkynyl, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, C5-10 heteroaryl containing 1-4 heteroatoms, -O-L7-R5, and -NR6R7, wherein q is an integer ranging from 0 to 5; R5, R6, and R7are independently chosen from H, -OH, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, and C5-10heteroaryl containing 1-4 heteroatoms; each of L1, L2, L3, L4, and L7is either absent or independently chosen from C1-10alkylene, C2-10alkenylene, and C2-10alkynylene; X1and X2are independently chosen from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, - C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, and - OP(O)(O-)O-; PVM-00425 (PVX-PAT-2406-WO) A is H, a bond, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, or C5-10heteroaryl containing 1-4 heteroatoms; and wherein each alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, aryl, heterocycloalkyl, heteroaryl is independently optionally substituted with one or more substituent. In some embodiments, the cationic lipid present in the lipid nanoparticle composition comprises a cationic lipid represented by formula (VI) formula (VI) or isomer, or salt thereof, wherein: R3and R4are independently chosen from branched or unbranched C1-26alkyl, C2-26alkenyl, C2-26alkynyl, –(CH2)m-A-(CH2)n-(CH3)y, and -CH((CH2)m-A-(CH2)n-(CH3)y)2, wherein each of m, n, and y is independently an integer ranging from 0 to 26; each of L1, L2, L3, and L4 is either absent or independently chosen from C1-10 alkylene, C2- 10 alkenylene, and C2-10 alkynylene; X1and X2are independently chosen from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, - C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, and OP(O)(O-)O-; A is H, a bond, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, or C5-10heteroaryl containing 1-4 heteroatoms; and wherein each alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, aryl, heterocycloalkyl, heteroaryl is independently optionally substituted with one or more substituent. In some embodiments, the cationic lipid present in the lipid nanoparticle composition comprises a cationic lipid represented by formula (VII) PVM-00425 (PVX-PAT-2406-WO) formula (VII) or isomer, or salt thereof, wherein: represents either a single bond or a double bond; R3and R4are independently chosen from, branched or unbranched, C1-26alkyl, C2-26alkenyl, C2-26alkynyl, –(CH2)m-A-(CH2)n-(CH3)y, and -CH((CH2)m-A-(CH2)n-(CH3)y)2, wherein each of m, n, and y is independently an integer ranging from 0 to 26; (R10)qis chosen from H, -OH, -CH2OH, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, C5-10heteroaryl containing 1-4 heteroatoms, -O-L8-R5, and - NR6R7, wherein q is an integer ranging from 0 to 5; R5, R6, and R7 are independently chosen from H, -OH, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, saturated or unsaturated C3-10 cycloalkyl, C6-10 aryl, saturated or unsaturated C3-10 heterocycloalkyl containing 1-4 heteroatoms, and C5-10heteroaryl containing 1-4 heteroatoms; each of L1, L2, L3, L4, L5, L7, and L8is either absent or independently chosen from C1-10alkylene, C2-10alkenylene, and C2-10alkynylene; X1and X2are independently chosen from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, - C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, and - OP(O)(O-)O-; A is H, a bond, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, or C5-10heteroaryl containing 1-4 heteroatoms; Z is -CH2-, O, N, or S; A1is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, - OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S, or N; and wherein each alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is independently optionally substituted with one or more substituent. PVM-00425 (PVX-PAT-2406-WO) In some embodiments, the cationic lipid present in the lipid nanoparticle composition comprises a cationic lipid represented by formula (VIII) formula (VIII) or isomer, or salt thereof, wherein: R3and R4are independently chosen from branched or unbranched C1-26alkyl, C2-26alkenyl, C2-26alkynyl, –(CH2)m-A-(CH2)n-(CH3)y, and -CH((CH2)m-A-(CH2)n-(CH3)y)2, wherein each of m, n, and y is independently an integer ranging from 0 to 26; (R10)qis chosen from H, -OH, -CH2OH, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, C5-10heteroaryl containing 1-4 heteroatoms, -O-L8-R5, and - NR6R7, wherein q is an integer ranging from 0 to 4; R5, R6, and R7 are independently chosen from H, -OH, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, and C5-10heteroaryl containing 1-4 heteroatoms; each of L1, L2, L3, L4, L5, L7, and L8is either absent or independently chosen from C1-10alkylene, C2-10alkenylene, or C2-10alkynylene; X1and X2are independently chosen from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, - C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, and - OP(O)(O-)O-; A is H, a bond, saturated or unsaturated C3-10cycloalkyl, C6-10aryl, saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, or C5-10heteroaryl containing 1-4 heteroatoms; Z is -CH2-, O, N, or S; A1is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, - OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S, or N; and PVM-00425 (PVX-PAT-2406-WO) wherein each alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is independently optionally substituted with one or more substituent. In some embodiments, the cationic lipid represented by formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), or formula (VIII) are substituted with substituents independently chosen from H, OH, Cl, Br, I, O, S, N, P, optionally substituted C1-6alkoxy, optionally substituted C1-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, optionally substituted saturated or unsaturated C3-10 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted saturated or unsaturated C3-10heterocycloalkyl containing 1-4 heteroatoms, optionally substituted C5-10heteroaryl containing 1-4 heteroatoms or combination thereof. In some embodiments, substituent may further be substituted with H, -OH, Cl, Br, I, or C1-6hydroxyalkyl. In some embodiments, N:P ratio or cationic lipid to nucleic acid ratio in LNP formulation is between 1 to 18, between 1 to 17, between 1 to 16, between 1 to 15, between 1 to 14, between 1 to 13, between 1 to 12, between 1 to 11, between 1 to 10, between 1 to 9, between 1 to 8, between 1 to 7, between 1 to 6, between 1 to 5, between 1 to 4, between 1 to 3, between 1 to 2, or any range therein. In some embodiments, N:P ratio or cationic lipid to nucleic acid ratio in LNP formulation is about 18, about 17, about 16, about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, about 1, or any portion or fraction thereof. In some embodiments, other exemplary cationic lipid for use in the lipid nanoparticle compositions include, but are not limited to, N,N-dioleyl-N,N- dimethylammonium chloride (DODAC); N-(2,3-dioleyloxy)propyl)-N,N,N- trimethylammonium chloride (DOTMA); N,N-distearyl-N,N-dimethylammonium bromide(DDAB); N-(2,3dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP); 3-(N—(N’,N’-dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), N-(l- (2,3-dioleoyloxy)propyl)N-2-(sperminecarboxamido)ethyl)-N,N- dimethylammoniumtrifluoracetate (DOSPA), dioctadecylamidoglycyl carboxyspermine (DOGS), 1,2-dioleoyl- 3-dimethylammonium propane (DODAP), N,N-dimethyl-2,3-dioleoyloxy)propylamine (DODMA), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium PVM-00425 (PVX-PAT-2406-WO) bromide (DMRIE), l,2-dilinoleyloxy-N,N-dimethylaminopropane (Dlin-DMA), 3- dimethylamino-2-(cholest-5-en-3-beta-oxybutan-4-oxy)-l-(cis,cis-9,12-oc- tadecadienoxy)propane (Clin-DMA), 2-[5’-(cholest-5-en-3-beta-oxy)-3’-oxapentoxy)-3- dimethyl-l-(cis,cis-9’,12’-octadecadienoxy)propane (CpLin-DMA), 2,3-Dilinoleoyloxy- N,N-dimethylpropylamine (Dlin-DAP), 1,2-N,N’-Dilinoleylcarbamyl-3- dimethylaminopropane (Dlincarb-DAP), l,2-Dilinoleoylcarbamyl-3- dimethylaminopropane (Dlin-CDAP), 2,2-dilinoleyl-4-dimethylaminomethyl-[l,3]- dioxolane (Dlin-K-DMA), heptatriaconta-6,9,28,31-tetraen-19-yl 4- (dimethylamino)butanoate (Dlin-MC3-DMA), heptadecane-9-yl 8-[2-hydroxyethyl-(6- oxo-6-undecoxyhexyl)amino]octanoate (SM-102), 6-[6-(2-hexyldecanoyloxy)hexyl-(4- hydroxybutyl)amino]hexyl 2-hexyldecanoate (ALC-0315), nonyl 8-[(8-heptadecan-9- yloxy-8-oxooctyl)-(2-hydroxyethyl)amino]octanoate (SLP-0001), or a combination thereof. Methods of making cationic lipid and / or ionizable lipid or imparting the cationic lipid the ability to behave as an ionizable lipid are well known in the art (WO2005121348; WO2009127060; WO2009086558; WO2010042877; WO2010144740; WO2011075656; WO2017049245; WO2017075531; WO2018118102; WO2015199952; Reynier P. et al. Journal of Drug Targeting (2004) 12: 25-38; Sabnis, Staci et al. Molecular Therapy (2018) 26: 1509-1519). In some embodiments, the cationic lipid present in the lipid nanoparticle composition comprises a cationic lipid disclosed in published patent application viz., WO2019 / 152557; WO2019 / 232095; WO2021 / 077067; WO2019 / 089828; US2019 / 0240354; US2010 / 0130588; US2021 / 0087135; US2021 / 0128488; US2020 / 0121809; US2013 / 0108685; US2013 / 0195920; US2015 / 0005363; US2014 / 0308304; US2017 / 0210697; and US2013 / 0053572. The proportion of cationic lipid present in the lipid nanoparticle compositions is from about 10 mol % to about 70 mol % or any range therein. In some embodiments, the proportion of cationic lipid present in the lipid nanoparticle compositions is from about 10 mol % to about 70 mol %, from about 10 mol % to about 65 mol %, from about 10 mol % to about 60 mol %, from about 10 mol % to about 55 mol %, from about 10 mol % to about 50 mol %, or any range therein. In some embodiments, the proportion of cationic lipid present in the lipid nanoparticle compositions is about 10 mol %, about 11 mol %, about 12 mol %, about 13 mol %, about 14 mol %, about 15 mol %, about 16 mol %, about 17 mol %, about 18 mol PVM-00425 (PVX-PAT-2406-WO) %, about 19 mol %, about 20 mol %, about 21 mol %, about 22 mol %, about 23 mol %, about 24 mol %, about 25 mol %, about 26 mol %, about 27 mol %, about 28 mol %, about 29 mol %, about 30 mol %, about 31 mol %, about 32 mol %, about 33 mol %, about 34 mol %, about 35 mol %, about 36 mol %, about 37 mol %, about 38 mol %, about 39 mol %, about 40 mol %, about 41 mol %, about 42 mol %, about 43 mol %, about 44 mol %, about 45 mol %, about 46 mol %, about 47 mol %, about 48 mol %, about 49 mol %, about 50 mol %, about 51 mol %, about 52 mol %, about 53 mol %, about 54 mol %, about 55 mol %, about 56 mol %, about 57 mol %, about 58 mol %, about 59 mol %, about 60 mol %, about 61 mol %, about 62 mol %, about 63 mol %, about 64 mol %, about 65 mol %, about 66 mol %, about 67 mol %, about 68 mol %, about 69 mol %, about 70 mol %, or any portion or fraction thereof. In some embodiments, the proportion of cationic lipid present in the lipid nanoparticle compositions is about 10 mol% to about 20 mol%, about 20 mol% to about 30 mol%, about 30 mol% to about 40 mol%, about 40 mol% to about 50 mol%, about 50 mol% to about 60 mol%, about 60 mol% to about 70 mol%, or any range therein. Phospholipids Phospholipid includes a lipid containing a hydrophilic head with a phosphate group and a hydrophobic tail composed of fatty acid chains attached to a glycerol or sphingosine backbone. Exemplary phospholipids for use in the lipid nanoparticle compositions include, but are not limited to, 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2- dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3- phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2- distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero- phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2- di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2- cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OchemsPC), 1-hexadecyl-sn- glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3- phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2- diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero- 3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2- PVM-00425 (PVX-PAT-2406-WO) dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3- phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2- dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), 1-myristoyl-2- stearoyl-sn-glycero-3-phosphocholine (MSPC), 1-palmitoyl-2-myristoyl-sn-glycero-3- phosphocholine (PMPC), 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (PSPC), 1- stearoyl-2-myristoyl-sn-glycero-3-Phosphocholine (SMPC), 1-Stearoyl-2-palmitoyl-sn- glycero-3-phosphocholine (SPPC), 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC), 1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (SDPC), sphingomyelin, or a combination thereof. The proportion of phospholipid present in the lipid nanoparticle compositions is from about 2 mol % to about 65 mol %, from about 5 mol % to about 65 mol %, from about 10 mol % to about 65 mol %, from about 10 mol % to about 55 mol %, from about 10 mol % to about 50 mol %, or any range therein. In some embodiments, the proportion of phospholipid present in the lipid nanoparticle compositions is about 65 mol %, about 60 mol %, about 55 mol %, about 50 mol %, about 45 mol %, about 44 mol %, about 43 mol %, about 42 mol %, about 41 mol %, about 40 mol %, about 39 mol %, about 38 mol %, about 37 mol %, about 36 mol %, about 35 mol %, about 34 mol %, about 33 mol %, about 32 mol %, about 31 mol %, about 30 mol %, about 29 mol %, about 28 mol %, about 27 mol %, about 26 mol %, about 25 mol %, about 24 mol %, about 23 mol %, about 22 mol %, about 21 mol %, about 20 mol %, about 19 mol %, about 18 mol %, about 17 mol %, about 16 mol %, about 15 mol %, about 14 mol %, about 13 mol %, about 12 mol %, about 11 mol %, about 10 mol %, about 9 mol %, about 8 mol %, about 7 mol %, about 6 mol %, about 5 mol %, about 4 mol %, about 3 mol %, about 2 mol %, or any portion or fraction thereof. Sterol Lipid nanoparticle composition disclosed herein may include sterol and / or sterol derivatives. The term “sterol” as used herein include, but not limited to, cholesterol, sitosterol, fecosterol, ergosterol, campesterol, stigmasterol or their derivatives. In some embodiments, lipid nanoparticle composition comprises cholesterol and / or cholesterolderivatives. Non-limiting examples of cholesterol and cholesterol derivatives include 5 -cholestanol, 5 -coprostanol, cholesteryl-(2’-hydroxy)-ethyl ether, cholesteryl-(4’-hydroxy)-butyl ether, 6-ketocholestanol, 5 -cholestane, cholestenone, 5 -cholestanone, PVM-00425 (PVX-PAT-2406-WO)5 -cholestanone, cholesteryl decanoate, or mixtures thereof. Methods of makingcholesterol and cholesterol derivatives are well known in the art. The proportion of sterol present in the lipid nanoparticle compositions may be from about 20 mol % to about 65 mol % or any range therein. In some embodiments, the proportion of sterol present in the lipid nanoparticle compositions is from about 20 mol % to about 65 mol %, from about 25 mol % to about 65 mol %, from about 30 mol % to about 65 mol %, from about 31 mol % to about 60 mol %, from about 32 mol % to about 60 mol %, from about 33 mol % to about 60 mol %, from about 34 mol % to about 60 mol %, from about 35 mol % to about 60 mol %, or any range therein. In some embodiments, the proportion of sterol present in the lipid nanoparticle compositions is about 65 mol %, about 60 mol %, about 55 mol %, about 50 mol %, about 45 mol %, about 44 mol %, about 43 mol %, about 42 mol %, about 41 mol %, about 40 mol %, about 39 mol %, about 38 mol %, about 37 mol %, about 36 mol %, about 35 mol %, about 34 mol %, about 33 mol %, about 32 mol %, about 31 mol %, about 30 mol %, about 29 mol %, about 28 mol %, about 27 mol %, about 26 mol %, about 25 mol %, about 24 mol %, about 23 mol %, about 22 mol %, about 21 mol %, about 20 mol %, or any portion or fraction thereof. PEG-lipid The term PEG-lipid, pegylated lipid, PEG linked lipid, PEG conjugated lipid, PEG- lipid conjugate, PEG modified lipid have been used interchangeably to mean polyethylene glycol linked to a lipid moiety. The lipid moiety may be linked directly to the PEG molecule or through a linker. In some embodiments, a PEG-lipid comprises a PEG- modified phosphatidylethanolamines, PEG-modified phosphatidic acids, PEG-modified ceramides, PEG-modified dialkylamines, PEG-modified diacylglycerols, PEG-modified dialkylglycerols, and / or PEG-modified cholesterol, and / or mixtures thereof. The methods of making PEG-lipid are well known to persons skilled in the art. In some embodiments, PEG-lipid is selected from mPEG-Dimyristoyl glycerol (mPEG-DMG), mPEG-N,N-Ditetradecylacetamide (mPEG-DTA or ALC0159), mPEG- Cholesterol (mPEG-CLS), mPEG-DSPE, mPEG-DMPE, mPEG-DPPE, mPEG-DLPE, mPEG-DOPE, mPEG-DPPC, mPEG-DSPC, 1,2-Distearoyl-sn-Glycero-3- Phosphoethanolamine with conjugated methoxyl poly(ethylene glycol) (mPEG-DSPE), PVM-00425 (PVX-PAT-2406-WO) 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (mPEG2000-DMG), -(3’-{[1,2-di(myristyloxy)propanoxy]carbonylamino}propyl)- -methoxy, polyoxyethylene(mPEG2000C-DMG), or mixtures thereof. The PEG moiety of the PEG-lipid may comprise an average molecular weight ranging from 0.5 kDa to 10 kDa. In some embodiments, the PEG-lipid has an average molecular weight of about 0.5 kDa to 5 kDa, about 0.5 kDa to 4 kDa, 0.5 kDa to 3 kDa, 0.5 kDa to 2 kDa. In preferred embodiments, the PEG-lipid has an average molecular weight of about 0.5 kDa to about 2 kDa. The proportion of PEG-lipid present in the lipid nanoparticle compositions may be from about 0.2 mol % to about 2.0 mol % or any range therein. In some embodiments, the proportion of PEG-lipid present in the lipid nanoparticle compositions is from about 0.2 mol % to about 2.0 mol %, from about 0.2 mol % to about 1.9 mol %, from about 0.2 mol % to about 1.8 mol %, from about 0.2 mol % to about 1.7 mol %, from about 0.2 mol % to about 1.6 mol %, from about 0.2 mol % to about 1.5 mol %, or any range therein. In some embodiments, the proportion of PEG-lipid present in the lipid nanoparticle compositions is about 0.2 mol %, about 0.3 mol %, about 0.4 mol %, about 0.5 mol %, about 0.6 mol %, about 0.7 mol %, about 0.8 mol %, about 0.9 mol %, about 1.0 mol %, about 1.1 mol %, about 1.2 mol %, about 1.3 mol %, about 1.4 mol %, about 1.5 mol %, about 1.6 mol %, about 1.7 mol %, about 1.8 mol %, about 1.9 mol %, about 2.0 mol %, or any portion or fraction thereof. In some embodiments, the lipid nanoparticle composition additionally contains an ionizable polymer. Ionizable polymer As used herein the term “polymer” means a compound formed from a plurality of repeating units called monomers. Polymers are produced through a process called polymerization wherein two or more monomers are linked through chemical bonds to form the polymer. In some embodiments, the polymer is branched or unbranched. In some embodiments, the polymer is homopolymer, i.e., comprising same type of repeat units or monomers, or heteropolymer, i.e., comprising more than one type of repeat units or monomers. The terms heteropolymer and copolymer have been used interchangeably herein. PVM-00425 (PVX-PAT-2406-WO) The term “Ionizable polymer” as used herein means, a polymer that can exist in a positively charged or neutral form depending on the pH of the solution or environment, for example, ionizable polymer will be cationic (positively charged) when pH of the solution is below the pKa of the ionizable polymer and neutral (no charge) when pH of the solution is same or above the pKa of the ionizable polymer. In some embodiments, ionizable polymer is positively charge in acidic pH i.e., pH 1.0 to pH 6.9. In some embodiments, ionizable polymer is neutral (no charge) around physiological pH (pH 7.0 to pH 7.5). In some embodiments, the ionizable polymer is a biocompatible polymer or biodegradable polymer. The term “biocompatible polymer” and “biodegradable polymer” have been used interchangeably to mean a polymer that is substantially free from any deleterious effects when introduced into a living or biological system. Such polymers are capable of undergoing degradation when introduced into the living or biological systems and are not expected to produce significant toxicity or immunological response. In some embodiments, the lipid nanoparticle compositions comprise an ionizable polymer. The ionizable polymer may be selected from a chitosan, chitosan derivatives, cellulose derivatives, a poly-L-lysine (PLL), a protamine, a polyethyleneimine, their derivatives, or a combination thereof. In some embodiments, the ionizable polymer is positively charged at acidic pH i.e., pH 1.0 to 6.9 and is neutral around physiological pH (pH 7.0 to 7.5). The proportion of ionizable polymer present in the lipid nanoparticle compositions may be from about 1 mol % to about 25 mol %. In some embodiments, the proportion of ionizable polymer present in the lipid nanoparticle compositions is from about 1 mol % to about 25 mol %, from about 1 mol % to about 24 mol %, from about 1 mol % to about 23 mol %, from about 1 mol % to about 22 mol %, from about 1 mol % to about 21 mol %, from about 1 mol % to about 20 mol %, from about 1 mol % to about 19 mol %, from about 1 mol % to about 18 mol %, from about 1 mol % to about 17 mol %, from about 1 mol % to about 16 mol %, from about 1 mol % to about 15 mol %, or any range therein. In some embodiments, the proportion of ionizable polymer present in the lipid nanoparticle compositions is about 1 mol %, about 2 mol %, about 3 mol %, about 4 mol %, about 5 mol %, about 6 mol %, about 7 mol %, about 8 mol %, about 9 mol %, about 10 mol %, about 11 mol %, about 12 mol %, about 13 mol %, about 14 mol %, about 15 mol %, about 16 mol %, about 17 mol %, about 18 mol %, about 19 mol %, about 20 mol PVM-00425 (PVX-PAT-2406-WO) %, about 21 mol %, about 22 mol %, about 23 mol %, about 24 mol %, about 25 mol %, or any portion or fraction thereof. In some embodiments, the preferred ionizable polymer comprises a chitosan, chitosan derivatives, cellulose derivatives, a poly-L-lysine (PLL), a protamine, a polyethyleneimine, and / or their derivatives, or a combination thereof. Method of treatment In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof the multisubunit nucleic acid sequence as described herein. In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof the lipid nanoparticle composition comprising a cationic lipid, a phospholipid, a sterol, a PEG-lipid and the multisubunit nucleic acid sequence as described herein. In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof the lipid nanoparticle composition comprising a cationic lipid, a phospholipid, a sterol, a PEG-lipid and the multisubunit nucleic acid sequence as described herein, wherein the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof the lipid nanoparticle composition comprising an ionizable polymer, a cationic lipid, a phospholipid, a sterol, a PEG-lipid and the multisubunit nucleic acid sequence as described herein. In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof the lipid nanoparticle composition comprising an ionizable polymer, a cationic lipid, a phospholipid, a sterol, a PEG-lipid and the multisubunit nucleic acid sequence as described herein, wherein the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof a vaccine comprising the multisubunit nucleic acid as described herein. PVM-00425 (PVX-PAT-2406-WO) In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof a vaccine comprising the lipid nanoparticle composition, wherein the lipid nanoparticle composition comprises a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid as described herein. In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof a vaccine comprising the lipid nanoparticle composition, wherein the lipid nanoparticle composition comprises a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid as described herein, wherein the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof a vaccine comprising the lipid nanoparticle composition, wherein the lipid nanoparticle composition comprises an ionizable polymer, a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid described herein. In some aspects, provided herein is a method of treating or preventing a disease, comprising administering to a subject in need thereof a vaccine comprising the lipid nanoparticle composition, wherein the lipid nanoparticle composition comprises an ionizable polymer, a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid described herein, wherein the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some aspects, the disclosure relates to use of the multisubunit nucleic acid as described herein in the manufacture of a medicament for the treatment or prevention of a disease in a subject. In some aspects, the disclosure relates to use of a lipid nanoparticle composition comprising a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid sequence as described herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject. In some aspects, the disclosure relates to use of a lipid nanoparticle composition comprising a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit PVM-00425 (PVX-PAT-2406-WO) nucleic acid sequence as described herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject, wherein the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some aspects, the disclosure relates to use of a lipid nanoparticle composition comprising an ionizable polymer, a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid sequence as described herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject. In some aspects, the disclosure relates to use of a lipid nanoparticle composition comprising an ionizable polymer, a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid sequence as described herein in the manufacture of a medicament for the treatment or prevention of a disease in a subject, wherein the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some embodiments, the disclosure relates to use of a vaccine comprising the multisubunit nucleic acid as described herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject. In some embodiments, the disclosure relates to use of a vaccine comprising a lipid nanoparticle composition, wherein the lipid nanoparticle composition comprises a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid described herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject. In some embodiments, the disclosure relates to use of a vaccine comprising a lipid nanoparticle composition, wherein the lipid nanoparticle composition comprises a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid described herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject, wherein the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some embodiments, the disclosure relates to use of a vaccine comprising a lipid nanoparticle composition, wherein the lipid nanoparticle composition comprises an ionizable polymer, a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the PVM-00425 (PVX-PAT-2406-WO) multisubunit nucleic acid described herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject. In some embodiments, the disclosure relates to use of a vaccine comprising a lipid nanoparticle composition, wherein the lipid nanoparticle composition comprises an ionizable polymer, a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid described herein, in the manufacture of a medicament for the treatment or prevention of a disease in a subject, wherein the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or a combination thereof. In some embodiments, the disease is hepatitis C infection, hepatitis and hepatocellular carcinoma, liver damage, liver failure, cirrhosis, or liver cancer. In some embodiments, the multisubunit nucleic acid sequence is present in biologically effective amount or therapeutically effective amount. In some embodiments, the biologically effective amount of the multisubunit nucleic acid sequence is between 0.1 μg to 2000 μg, 0.1 μg to 1800 μg, 0.1 μg to 1600 μg, 0.1 μg to 1400 μg, 0.1 μg to 1200 μg, 0.1 μg to 1000 μg, 0.1 μg to 950 μg, 0.1 μg to 900 μg, 0.1 μg to 850 μg, 0.1 μg to 800 μg, 0.1 μg to 750 μg, 0.1 μg to 700 μg, 0.1 μg to 650 μg, 0.1 μg to 600 μg, 0.1 μg to 550 μg, 0.1 μg to 500 μg, 0.1 μg to 450 μg, 0.1 μg to 400 μg, 0.1 μg to 350 μg, 0.1 μg to 300 μg, 0.1 μg to 250 μg, 0.1 to 200 μg, 0.1 to 175 μg, 0.1 to 150 μg, 0.1 to 125 μg, 0.1 to 100 μg, 0.1 μg to 90 μg, 0.1 μg to 80 μg, 0.1 μg to 70 μg, 0.1 μg to 60 μg, 0.1 μg to 50 μg, 0.1 μg to 40 μg, 0.1 μg to 30 μg, 0.1 μg to 20 μg, 0.1 μg to 10 μg, 0.1 μg to 5 μg, or any range therein. In some embodiments, the biologically effective amount of the multisubunit nucleic acid sequence is from about 0.1 μg to 1000 μg, 0.1 μg to 950 μg, 0.1 μg to 900 μg, 0.1 μg to 850 μg, 0.1 μg to 800 μg, 0.1 μg to 750 μg, 0.1 μg to 700 μg, 0.1 μg to 650 μg, 0.1 μg to 600 μg, 0.1 μg to 550 μg, 0.1 μg to 500 μg, or any range therein. In some embodiments, the biologically effective amount of the multisubunit nucleic acid sequence is 0.1 μg, 0.2 μg, 0.3 μg, 0.4 μg, 0.5 μg, 0.6 μg, 0.7 μg, 0.8 μg, 0.9 μg, 1 μg, 2 μg, 3 μg, 4 μg, 5 μg, 6 μg, 7 μg, 8 μg, 9 μg, 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 55 μg, 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg, 100 μg, 110 μg, 120 μg, 130 μg, 140 μg, 150 μg, 160 μg, 170 μg, 180 μg, 190 μg, 200 μg, 220 μg, 240 μg, 260 μg, 280 μg, 300 μg, 350 μg, 400 μg, 450 μg, 500 μg, 600 μg, 700 μg, PVM-00425 (PVX-PAT-2406-WO) 800 μg, 900 μg, 1000 μg, 1100 μg, 1200 μg, 1300 μg, 1400 μg, 1500 μg, 1600 μg, 1700 μg, 1800 μg, 1900 μg, 2000 μg, or any portion or fraction thereof. In one aspect, provided herein is a nucleic acid comprising a plurality of polynucleotide sequences, wherein some or all polynucleotide sequences of the plurality comprises either a target sequence, a linker sequence, and a self-assembling sequence or a linker sequence, a target sequence, a linker sequence and a self-assembling sequence or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In another aspect, provided herein is a multisubunit nucleic acid comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence or a second linker sequence, a second target sequence, a third linker sequence, and a second self-assembling sequence, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence or the second target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In another aspect, provided herein a multisubunit nucleic acid comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In yet PVM-00425 (PVX-PAT-2406-WO) another aspect, provided herein is a multisubunit nucleic acid comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In one aspect, provided herein is a multisubunit nucleic acid comprising a first plurality of polynucleotide sequences and a second plurality of polynucleotide sequences, each polynucleotide sequence of the first plurality comprises a first target sequence, a first linker sequence, and a first self-assembling sequence, wherein each polynucleotide sequence of the second plurality comprises a second linker sequence, a second target sequence, a third linker sequence, and a second self-assembling sequence, wherein each polynucleotide sequence of the first plurality and each polynucleotide sequence of the second plurality is connected to an adjacent polynucleotide sequence of the first plurality or an adjacent polynucleotide sequence of the second plurality by a cleavage sequence, and wherein the first polynucleotide sequence in the multisubunit nucleic acid is a polynucleotide sequence of the first plurality or a polynucleotide sequence of the second plurality, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of the first polynucleotide sequence of the first plurality or the second polynucleotide sequence of the second plurality, or a combination thereof, wherein the first target sequence and the second target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In another aspect, provided herein is a multisubunit nucleic acid encoding a plurality of polypeptides, wherein some or all polypeptides of the plurality comprises either a target peptide, a linker peptide, and a self- assembling peptide or a linker peptide, a target peptide, a linker peptide and a self- assembling peptide or a combination thereof, wherein each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide, and wherein the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of PVM-00425 (PVX-PAT-2406-WO) one or more of the polypeptides of the plurality, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In another aspect, provided herein is a multisubunit nucleic acid encoding a plurality of polypeptides, wherein some or all polypeptides of the plurality comprises either a target peptide, a linker peptide, and a self- assembling peptide or a second linker peptide, a second target peptide, a third linker peptide and a second self-assembling peptide or a combination thereof, wherein each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide, and wherein the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of the first polypeptide of the plurality or the second polypeptide of the plurality or a combination thereof, wherein the target peptide and the second target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In one aspect, provided herein is a multisubunit nucleic acid encoding a plurality of polypeptides, wherein each polypeptide of the plurality comprises a target peptide, a linker peptide, and a self-assembling peptide, wherein each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide, and wherein the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of one or more of the polypeptides of the plurality, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In another aspect, provided herein is a multisubunit nucleic acid encoding a plurality of polypeptides, wherein each polypeptide of the plurality comprises a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, wherein each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide, and wherein the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of one or more of the polypeptides of the plurality, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. In yet another aspect, provided herein is multisubunit nucleic acid encoding a first plurality of PVM-00425 (PVX-PAT-2406-WO) polypeptides and a second plurality of polypeptides, wherein each polypeptide of the first plurality comprises a target peptide, a linker peptide, and a self-assembling peptide, wherein each polypeptide of the second plurality comprises a second linker peptide, a second target peptide, a third linker peptide, and a second self-assembling peptide, wherein each polypeptide of the first plurality and each polypeptide of the second plurality is connected to an adjacent polypeptide of the first plurality or an adjacent polypeptide of the second plurality by a cleavage peptide, and wherein the first polypeptide encoded by the multisubunit nucleic acid is a polypeptide of the first plurality or a polypeptide of the second plurality, and wherein the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of the first polypeptide of the first plurality or the second polypeptide of the second plurality or a combination thereof, wherein the target peptide and the second target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. Embodiments Some of the embodiments of the present disclosure, set out in the following numbered paragraphs, are: 1. A multisubunit nucleic acid comprising a plurality of polynucleotide sequences, wherein some or all polynucleotide sequences of the plurality comprises either a target sequence, a linker sequence, and a self-assembling sequence or a linker sequence, a target sequence, a linker sequence and a self-assembling sequence or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. PVM-00425 (PVX-PAT-2406-WO) A multisubunit nucleic acid comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. A multisubunit nucleic acid comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. The multisubunit nucleic acid according to any one of the preceding paragraphs, wherein the target sequence, the linker sequence, and the self-assembling sequence or the linker sequence, the target sequence, the linker sequence, and the self- assembling sequence are in 5’ to 3’ order. A multisubunit nucleic acid encoding a plurality of polypeptides, wherein some or all polypeptides of the plurality comprises either a target peptide, a linker peptide, and a self-assembling peptide or a linker peptide, a target peptide, a linker peptide and a self-assembling peptide or a combination thereof, wherein each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide, and wherein the multisubunit nucleic acid further encodes a signal peptide PVM-00425 (PVX-PAT-2406-WO) on the amino-terminus of one or more of the polypeptides of the plurality, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. A multisubunit nucleic acid encoding a plurality of polypeptides, wherein each polypeptide of the plurality comprises a target peptide, a linker peptide, and a self- assembling peptide, wherein each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide, and wherein the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of one or more of the polypeptides of the plurality, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. A multisubunit nucleic acid encoding a plurality of polypeptides, wherein each polypeptide of the plurality comprises a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, wherein each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide, and wherein the multisubunit nucleic acid further encodes a signal peptide on the amino- terminus of one or more of the polypeptides of the plurality, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. The multisubunit nucleic acid according to any one of the paragraphs 5-7, wherein the target peptide, the linker peptide, and the self-assembling peptide or the linker peptide, the target peptide, the linker peptide, and the self-assembling peptide are in N-terminus to C-terminus order. PVM-00425 (PVX-PAT-2406-WO) The multisubunit nucleic acid according to any one of the preceding paragraphs, wherein total number of the polynucleotide sequences or the polypeptides are not more than 100. The multisubunit nucleic acid according to paragraph 9, wherein total number of the polynucleotide sequences or the polypeptides are between 2-5, 2-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, or 90-99. The multisubunit nucleic acid according to any one of the preceding paragraphs, wherein the multisubunit nucleic acid is a DNA or an RNA. The multisubunit nucleic acid according to paragraph 11, wherein the RNA is an mRNA. The multisubunit nucleic acid according to paragraph 12, wherein the mRNA is 0.5 kb to 1 kb, 1 kb to 2 kb, 2 kb to 3 kb, 3 kb to 4 kb, 4 kb to 5 kb, 5 kb to 6 kb, 6 kb to 7 kb, 7 kb to 8 kb, 8 kb to 9 kb, 9 kb to 10 kb, 10 kb to 11 kb, 11 kb to 12 kb, 12 kb to 13 kb, 13 kb to 14 kb, 14 kb to 15 kb, 15 kb to 16 kb, 16 kb to 17 kb, 17 kb to 18 kb, 18 kb to 19 kb, 19 kb to 20 kb in length, or any range therein. The multisubunit nucleic acid according to any one of the paragraphs 12-13, wherein the mRNA is obtained through a single IVT process or step. The multisubunit nucleic acid according to any one of the paragraphs 1-4 and 9-14, wherein the linker sequence encodes a linker peptide. The multisubunit nucleic acid according to any one of the paragraphs 5-15, wherein the linker peptide is an amino acid linker, a zipper motif, a foldon, a scaffold, or a combination thereof. The multisubunit nucleic acid according to paragraph 16, wherein the linker peptide is the amino acid linker. PVM-00425 (PVX-PAT-2406-WO) The multisubunit nucleic acid according to paragraph 17, wherein the amino acid linker comprises 2 to 49 amino acids. The multisubunit nucleic acid according to any one of the paragraphs 17-18, wherein the amino acid linker is a glycine serine linker, a glycine proline linker, a glycine threonine linker, an alanine serine linker, any combination of two amino acids, or a combination thereof. The multisubunit nucleic acid according to paragraph 16, wherein the linker peptide is the zipper motif. The multisubunit nucleic acid according to paragraph 16, wherein the linker peptide is the foldon. The multisubunit nucleic acid according to paragraph 16, wherein the linker peptide is the scaffold. The multisubunit nucleic acid according to any one of the paragraphs 16-19, wherein the linker peptide comprises the amino acid linker and the zipper motif. The multisubunit nucleic acid according to any one of the paragraphs 16-19, wherein the linker peptide comprises the amino acid linker and the foldon. The multisubunit nucleic acid according to any one of the paragraphs 16-19, wherein the linker peptide comprises the amino acid linker and the scaffold. The multisubunit nucleic acid according to any one of the paragraphs 16-19, wherein the linker peptide comprises the amino acid linker, the zipper motif, and the scaffold. The multisubunit nucleic acid according to any one of the paragraphs 16-19, wherein the linker peptide comprises the amino acid linker, the foldon, and the scaffold. PVM-00425 (PVX-PAT-2406-WO) The multisubunit nucleic acid according to paragraph 16, wherein the linker peptide comprises the zipper motif and the scaffold. The multisubunit nucleic acid according to paragraph 16, wherein the linker peptide comprises the foldon and the scaffold. The multisubunit nucleic acid according to any one of the paragraphs 5-29, wherein the linker peptide has an amino acid sequence of any one of SEQ ID NOs: 12-51 or 12116-12120. The multisubunit nucleic acid according to any one of the paragraphs 1-4 and 9-30, wherein the self-assembling sequence encodes a self-assembling peptide. The multisubunit nucleic acid according to any one of the paragraphs 5-31, wherein the self-assembling peptide is a lumazine synthase, an MS2 coat protein, a hepatitis B surface antigen (HBsAg) from Hepatitis B Virus, a hepatitis B core antigen (HbcAg) from Hepatitis B virus, a human papillomavirus L1 (HPV L1) protein, a matrix protein M1 from influenza A virus, a ferritin, a riboflavin synthase, a dihydrolipoyl acetyltransferase (E2p), or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, comparable equivalents, or functional analogs thereof. The multisubunit nucleic acid according to any one of the paragraphs 31-32, wherein the self-assembling peptide is a ferritin comprising a ferritin subunit or a ferritin peptide, a dihydrolipoyl acetyltransferase (E2p), a lumazine synthase, an MS2 coat protein, or a combination thereof. The multisubunit nucleic acid according to paragraph 33, wherein the ferritin peptide is obtained or derived from Helicobacter pylori ferritin, Listeria innocua ferritin, the lumazine synthase is obtained or derived from Aquifex aeolicus or Bacillus subtilis, the MS2 coat protein is obtained or derived from Emesvirus zinderi, and the dihydrolipoyl acetyltransferase (E2p) is obtained or derived from Bacillus stearothermophilus. PVM-00425 (PVX-PAT-2406-WO) The multisubunit nucleic acid according to any one of the paragraphs 5-34, wherein the self-assembling peptide has an amino acid sequence of any one of SEQ ID NOs: 1-11 or 12112-12115. The multisubunit nucleic acid according to any one of the paragraphs 1-4 and 9-35, wherein the cleavage sequence encodes one or more cleavage peptides. The multisubunit nucleic acid according to paragraph 36, wherein the one or more cleavage peptides are optionally connected to each other by a linker peptide. The multisubunit nucleic acid according to paragraph 37, wherein the cleavage peptide is a golgi specific cleavage peptide, a self cleaving peptide, or a combination thereof. The multisubunit nucleic acid according to any one of the paragraphs 5-38, wherein the cleavage peptide has an amino acid sequence of any one of SEQ ID NOs: 52-66. The multisubunit nucleic acid according to any one of the paragraphs 1-4, and 9-39, wherein the signal sequence encodes a signal peptide. The multisubunit nucleic acid according to any one of the paragraphs 5-40, wherein the signal peptide is present on the amino-terminus of one or more of the polypeptides of the plurality. The multisubunit nucleic acid according to paragraph 41, wherein the multisubunit nucleic acid further encodes a second signal peptide on the amino-terminus of all or some polypeptides of the plurality. The multisubunit nucleic acid according to any one of the paragraphs 5-42, wherein the signal peptide has an amino acid sequence of any one of SEQ ID NOs: 67-86. PVM-00425 (PVX-PAT-2406-WO) The multisubunit nucleic acid according to any one of the paragraphs 1-4 and 9-43, wherein the target sequence encodes a target peptide. The multisubunit nucleic acid according to any one of the paragraphs 5-44, wherein the target peptide is encoded by a codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof. The multisubunit nucleic acid according to paragraph 45, wherein the target peptide is obtained or derived from core protein of a hepacivirus. The multisubunit nucleic acid according to paragraph 46, wherein the core protein comprises an amino acid sequence of any one of SEQ ID NOs: 88-353. The multisubunit nucleic acid according to paragraph 45, wherein the target peptide is obtained or derived from E1 protein of a hepacivirus. The multisubunit nucleic acid according to paragraph 48, wherein the E1 protein comprises an amino acid sequence of any one of SEQ ID NOs: 354-959 or 12121. The multisubunit nucleic acid according to paragraph 45, wherein the target peptide is obtained or derived from E2 protein of a hepacivirus. The multisubunit nucleic acid according to paragraph 50, wherein the E2 protein comprises an amino acid sequence of any one of SEQ ID NOs: 960-1582 or 12122. The multisubunit nucleic acid according to paragraph 45, wherein the target peptide is obtained or derived from P7 protein of a hepacivirus. The multisubunit nucleic acid according to paragraph 52, wherein the P7 protein comprises an amino acid sequence of any one of SEQ ID NOs: 1583-2026. The multisubunit nucleic acid according to paragraph 45, wherein the target peptide is obtained or derived from NS2 protein of a hepacivirus. PVM-00425 (PVX-PAT-2406-WO) The multisubunit nucleic acid according to paragraph 54, wherein the NS2 protein comprises an amino acid sequence of any one of SEQ ID NOs: 2027-2651. The multisubunit nucleic acid according to paragraph 45, wherein the target peptide is obtained or derived from NS3 protein of a hepacivirus. The multisubunit nucleic acid according to paragraph 56, wherein the NS3 protein comprises an amino acid sequence of any one of SEQ ID NOs: 2652-3284. The multisubunit nucleic acid according to paragraph 45, wherein the target peptide is obtained or derived from NS4A protein of a hepacivirus. The multisubunit nucleic acid according to paragraph 58, wherein the NS4A protein comprises an amino acid sequence of any one of SEQ ID NOs: 3285-3462. The multisubunit nucleic acid according to paragraph 45, wherein the target peptide is obtained or derived from NS4B protein of a hepacivirus. The multisubunit nucleic acid according to paragraph 60, wherein the NS4B protein comprises an amino acid sequence of any one of SEQ ID NOs: 3463-4004. The multisubunit nucleic acid according to paragraph 45, wherein the target peptide is obtained or derived from NS5A protein of a hepacivirus. The multisubunit nucleic acid according to paragraph 62, wherein the NS5A protein comprises an amino acid sequence of any one of SEQ ID NOs: 4005-4627. The multisubunit nucleic acid according to paragraph 45, wherein the target peptide is obtained or derived from NS5B protein of a hepacivirus. The multisubunit nucleic acid according to paragraph 64, wherein the NS5B protein comprises an amino acid sequence of any one of SEQ ID NOs: 4628-5247. PVM-00425 (PVX-PAT-2406-WO) The multisubunit nucleic acid according to paragraph 45, wherein the target peptide is obtained or derived from B cell epitope of a hepacivirus. The multisubunit nucleic acid according to paragraph 66, wherein the B cell epitope comprises an amino acid sequence of any one of SEQ ID NOs: 5248-10039. The multisubunit nucleic acid according to paragraph 45, wherein the target peptide is obtained or derived from T cell epitope of a hepacivirus. The multisubunit nucleic acid according to paragraph 68, wherein the T cell epitope comprises an amino acid sequence of any one of SEQ ID NOs: 10040-12111. The multisubunit nucleic acid according to any one of the paragraphs 5-69, wherein the target peptide has an amino acid sequence of any one of SEQ ID NOs: 88-12111 or 12121-12122. A lipid nanoparticle composition comprising a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid according to any one of the preceding paragraphs. The lipid nanoparticle composition according to paragraph 71, wherein the cationic lipid is present in an amount from 10 mol percent to 70 mol percent. The lipid nanoparticle composition according to paragraph 71, wherein the phospholipid is present in an amount from 2 mol percent to 65 mol percent. The lipid nanoparticle composition according to paragraph 71, wherein the sterol is present in an amount from 20 mol percent to 65 mol percent. The lipid nanoparticle composition according to paragraph 71, wherein the PEG- lipid is present in an amount from 0.2 mol percent to 2.0 mol percent. PVM-00425 (PVX-PAT-2406-WO) The lipid nanoparticle composition according to paragraph 71, additionally comprising an ionizable polymer. The lipid nanoparticle composition according to paragraph 76, wherein the ionizable polymer is present in an amount from 1 mol percent to 25 mol percent. The lipid nanoparticle composition according to any one of the paragraphs 71-77, wherein the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or SM-102, or ALC-0315, or a combination thereof. The lipid nanoparticle composition according to any one of the paragraphs 71-78, wherein the cationic lipid is represented by formula (I). The lipid nanoparticle composition according to any one of the paragraphs 71-78, wherein the cationic lipid is represented by formula (II). The lipid nanoparticle composition according to any one of the paragraphs 71-78, wherein the cationic lipid is represented by formula (III). The lipid nanoparticle composition according to any one of the paragraphs 71-78, wherein the cationic lipid is represented by formula (IV). The lipid nanoparticle composition according to any one of the paragraphs 71-78, wherein the cationic lipid is represented by formula (V). The lipid nanoparticle composition according to any one of the paragraphs 71-78, wherein the cationic lipid is represented by formula (VI). The lipid nanoparticle composition according to any one of the paragraphs 71-78, wherein the cationic lipid is represented by formula (VII). PVM-00425 (PVX-PAT-2406-WO) The lipid nanoparticle composition according to any one of the paragraphs 71-78, wherein the cationic lipid is represented by formula (VIII). A multisubunit peptide encoded by the multisubunit nucleic acid according to any one of the paragraphs 1-70. A multisubunit peptide comprising two or more polypeptides, wherein some or all of the polypeptides comprises either a target peptide, a linker peptide, and a self- assembling peptide, or a linker peptide, a target peptide, a linker peptide, and a self- assembling peptide or a combination thereof, wherein one polypeptide is connected to another polypeptide by a cleavage peptide, wherein the multisubunit peptide includes a signal peptide on the amino-terminus of one or more of the polypeptides, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus. The multisubunit peptide according to paragraph 88, wherein the linker peptide is an amino acid linker, a zipper motif, a foldon, a scaffold, or a combination thereof. The multisubunit peptide according to paragraph 89, wherein the linker peptide is the amino acid linker. The multisubunit peptide according to paragraph 90, wherein the amino acid linker comprises 2-49 amino acids. The multisubunit peptide according to any one of the paragraphs 90-91, wherein the amino acid linker is selected form the group comprising a glycine serine linker, a glycine proline linker, a glycine threonine linker, an alanine serine linker, any combination of two amino acids, or a combination thereof. The multisubunit peptide according to paragraph 89, wherein the linker peptide is the zipper motif. PVM-00425 (PVX-PAT-2406-WO) The multisubunit peptide according to paragraph 89, wherein the linker peptide is the foldon. The multisubunit peptide according to paragraph 89, wherein the linker peptide is the scaffold. The multisubunit peptide according to any one of the paragraphs 89-92, wherein the linker peptide comprises the amino acid linker and the zipper motif. The multisubunit peptide according to any one of the paragraphs 89-92, wherein the linker peptide comprises the amino acid linker and the foldon. The multisubunit peptide according to any one of the paragraphs 89-92, wherein the linker peptide comprises the amino acid linker and the scaffold. The multisubunit peptide according to any one of the paragraphs 89-92, wherein the linker peptide comprises the amino acid linker, the zipper motif, and the scaffold. The multisubunit peptide according to any one of the paragraphs 89-92, wherein the linker peptide comprises the amino acid linker, the foldon, and the scaffold. The multisubunit peptide according to paragraph 89, wherein the linker peptide comprises the zipper motif and the scaffold. The multisubunit peptide according to paragraph 89, wherein the linker peptide comprises the foldon and the scaffold. The multisubunit peptide according to any one of the paragraphs 88-102, wherein the self-assembling peptide is a lumazine synthase, an MS2 coat protein, a hepatitis B surface antigen (HBsAg) from Hepatitis B Virus, a hepatitis B core antigen (HBcAg) from Hepatitis B virus, a human papillomavirus L1 (HPV L1) protein, a matrix protein M1 from influenza A virus, a ferritin, a riboflavin synthase, a dihydrolipoyl PVM-00425 (PVX-PAT-2406-WO) acetyltransferase (E2p), or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, or variants thereof. The multisubunit peptide according to paragraph 103, wherein the self-assembling peptide is a ferritin comprising a ferritin subunit or a ferritin peptide, a dihydrolipoyl acetyltransferase (E2p), a lumazine synthase, an MS2 coat protein, or a combination thereof. The multisubunit peptide according to paragraph 104, wherein the ferritin peptide is obtained or derived from Helicobacter pylori ferritin or Listeria innocua ferritin, the lumazine synthase is obtained or derived from Aquifex aeolicus or Bacillus subtilis, the MS2 coat protein is obtained or derived from Emesvirus zinderi, and the dihydrolipoyl acetyltransferase (E2p) is obtained or derived from Bacillus stearothermophilus. The multisubunit peptide according to any one of the paragraphs 88-105, wherein the cleavage peptide is a golgi specific cleavage peptide, a self cleaving cleavage peptide, or a combination thereof. The multisubunit peptide according to any one of the paragraphs 88-106, wherein the signal peptide is present on the amino-terminus of one or more polypeptides. The multisubunit peptide according to any one of the paragraphs 88-107, wherein the target peptide is obtained or derived from core protein of a hepacivirus. The multisubunit peptide according to paragraph 108, wherein the core protein comprises an amino acid sequence of any one of SEQ ID NOs: 88-353. The multisubunit peptide according to any one of the paragraphs 88-107, wherein the target peptide is obtained or derived from E1 protein of a hepacivirus. The multisubunit peptide according to paragraph 110, wherein the E1 protein comprises an amino acid sequence of any one of SEQ ID NOs: 354-959 or 12121. PVM-00425 (PVX-PAT-2406-WO) The multisubunit peptide according to any one of the paragraphs 88-107, wherein the target peptide is obtained or derived from E2 protein of a hepacivirus. The multisubunit peptide according to paragraph 112, wherein the E2 protein comprises an amino acid sequence of any one of SEQ ID NOs: 960-1582 or 12122. The multisubunit peptide according to any one of the paragraphs 88-107, wherein the target peptide is obtained or derived from P7 protein of a hepacivirus. The multisubunit peptide according to paragraph 114, wherein the P7 protein comprises an amino acid sequence of any one of SEQ ID NOs: 1583-2026. The multisubunit peptide according to any one of the paragraphs 88-107, wherein the target peptide is obtained or derived from NS2 protein of a hepacivirus. The multisubunit peptide according to paragraph 116, wherein the NS2 protein comprises an amino acid sequence of any one of SEQ ID NOs: 2027-2651. The multisubunit peptide according to any one of the paragraphs 88-107, wherein the target peptide is obtained or derived from NS3 protein of a hepacivirus. The multisubunit peptide according to paragraph 118, wherein the NS3 protein comprises an amino acid sequence of any one of SEQ ID NOs: 2652-3284. The multisubunit peptide according to any one of the paragraphs 88-107, wherein the target peptide is obtained or derived from NS4A protein of a hepacivirus. The multisubunit peptide according to paragraph 120, wherein the NS4A protein comprises an amino acid sequence of any one of SEQ ID NOs: 3285-3462. The multisubunit peptide according to any one of the paragraphs 88-107, wherein the target peptide is obtained or derived from NS4B protein of a hepacivirus. PVM-00425 (PVX-PAT-2406-WO) The multisubunit peptide according to paragraph 122, wherein the NS4B protein comprises an amino acid sequence of any one of SEQ ID NOs: 3463-4004. The multisubunit peptide according to any one of the paragraphs 88-107, wherein the target peptide is obtained or derived from NS5A protein of a hepacivirus. The multisubunit peptide according to paragraph 124, wherein the NS5A protein comprises an amino acid sequence of any one of SEQ ID NOs: 4005-4627. The multisubunit peptide according to any one of the paragraphs 88-107, wherein the target peptide is obtained or derived from NS5B protein of a hepacivirus. The multisubunit peptide according to paragraph 126, wherein the NS5B protein comprises an amino acid sequence of any one of SEQ ID NOs: 4628-5247. The multisubunit peptide according to any one of the paragraphs 88-107, wherein the target peptide is obtained or derived from B cell epitope of a hepacivirus. The multisubunit peptide according to paragraph 128, wherein the B cell epitope comprises an amino acid sequence of any one of SEQ ID NOs: 5248-10039. The multisubunit peptide according to any one of the paragraphs 88-107, wherein the target peptide is obtained or derived from T cell epitope of a hepacivirus. The multisubunit peptide according to paragraph 130, wherein the T cell epitope comprises an amino acid sequence of any one of SEQ ID NOs: 10040-12111. The multisubunit peptide according to any one of the paragraphs 88-131, wherein total number of the polypeptides are not more than 100. PVM-00425 (PVX-PAT-2406-WO) The multisubunit peptide according to paragraph 132, wherein total number of the polypeptides are between 2-5, 2-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, or 90-99. A polypeptide nanoparticle comprising at least 2 or up to 500 polypeptides according to any one of the paragraphs 5-70 or 88-133. The polypeptide nanoparticle according to paragraph 134, comprising a homologous polypeptide, a heterologous polypeptide, an oligomeric complex, a polypeptide cluster, or a combination thereof. The polypeptide nanoparticle according to any one of the paragraphs 134-135, wherein the polypeptide nanoparticle is icosahedral, helical, spherical, rod-like, or a combination thereof. A vaccine comprising the multisubunit nucleic acid according to any one of the paragraphs 1-70. A vaccine comprising the lipid nanoparticle composition according to any one of the paragraphs 71-86. A vaccine comprising the multisubunit peptide according to any one of the paragraphs 88-133 or the polypeptide nanoparticle according to any one of the paragraphs 134-136. A method of treating or preventing a disease, comprising administering to a subject in need thereof the multisubunit nucleic acid according to any one of the paragraphs 1-70 or the vaccine according to any one of the paragraphs 137 or 139. A method of treating or preventing a disease, comprising administering to a subject in need thereof the lipid nanoparticle composition according to any one of the paragraphs 71-86 or the vaccine according to paragraph 138. PVM-00425 (PVX-PAT-2406-WO) 142. The method according to any one of the paragraphs 140-141, wherein the disease is hepatitis C infection, hepatitis and hepatocellular carcinoma, liver damage, liver failure, cirrhosis, or liver cancer. 143. Use of the multisubunit nucleic acid according to any one of the paragraphs 1-70 or the vaccine according to any one of the paragraphs 137 or 139, in the manufacture of a medicament for the treatment or prevention of a disease in a subject. 144. Use of the lipid nanoparticle composition according to any one of the paragraphs 71- 86 or the vaccine according to paragraph 138, in the manufacture of a medicament for the treatment or prevention of a disease in a subject. 145. The use according to any one of the paragraphs 143-144, wherein the disease is hepatitis C infection, hepatitis and hepatocellular carcinoma, liver damage, liver failure, cirrhosis, or liver cancer. The present disclosure is further exemplified by the following non limiting examples. It should be understood that the examples are provided to illustrate the disclosure. From the description and the exemplified embodiments and examples, one skilled in the art can make various modifications or adaptations to the disclosure. Such modifications or adaptations are deemed to be within the scope of the spirit of the disclosure. Examples Example 1 (prophetic): Synthesis of multisubunit nucleic acid sequence (mRNA) The plasmid DNA construction, plasmid DNA isolation and linearization, in vitro transcription (IVT), and transfection etc can be accomplished by general teachings available to a person skilled in the art or using the reference procedure described in PCT Application No. PCT / IB2023 / 000787 or Indian provisional patent application IN202421064707 with appropriate adaptations or modifications. Western blot, ELISA and other techniques may be utilized to confirm the expression of the multisubunit peptide. PVM-00425 (PVX-PAT-2406-WO) Analytical or Immunogenicity assays The testing of multisubunit nucleic acid sequence comprises immunizing animals (typically mice) with multisubunit nucleic acid sequence in appropriate formulation following prime-boost immunization strategy at pre-determined dosage amounts. The serum is collected at appropriate intervals and antibody response against the target peptide is measured by ELISA. The efficacy of the multisubunit nucleic acid sequence is evaluated by pseudovirus neutralization assays well known to persons skilled in the art. The method typically involves incubating the pseudovirus in the presence of different concentrations of immunised serum containing the antibody of interest (i.e., antibodies produced against the target peptide) and adding this mixture to the cells and incubating it further to measure luminescence to determine inhibitory or neutralization titre. Example 2: Synthesis of multisubunit nucleic acid (mRNA) encoding multisubunit peptide of SEQ ID NO: 12123 Plasmid DNA Construction The multisubunit nucleic acid sequence encoding the multisubunit peptide of SEQ ID NO: 12123 was codon optimized for human expression. The multisubunit nucleic acid sequence was synthesized at Twist BioScience, USA. The multisubunit nucleic acid comprised of a signal sequence (encoding a signal peptide), two polynucleotide sequences (each encoding a polypeptide) separated by a cleavage sequence (encoding a cleavage peptide). The first polynucleotide sequence comprised a target sequence (encoding a target peptide i.e., E1 protein of HCV), a linker sequence (encoding an amino acid linker, a zipper motif, and an amino acid linker), and a self-assembling sequence (encoding a self- assembling peptide i.e., ferritin peptide). The second polynucleotide sequence comprised a target sequence (encoding a target peptide i.e., E2 protein of HCV), a linker sequence (encoding an amino acid linker, a zipper motif, and an amino acid linker), and a self- assembling sequence (encoding a self-assembling peptide i.e., ferritin peptide).5’ UTR, Cap, and 3’ UTR sequences were also included in the multisubunit nucleic acid sequence. XbaI site was added to the 3’ terminus of the 3’ UTR for vector linearization. The multisubunit nucleic acid sequence construct was inserted between HindIII and BamH1 restriction sites of pTwist Kan High Copy plasmid (Twist BioScience, USA). Amino acid PVM-00425 (PVX-PAT-2406-WO) sequence of the multisubunit peptide encoded by the multisubunit nucleic acid sequence of example 2 is provided in Table 1. Table 1: depicts amino acid sequence of the multisubunit peptide (SEQ ID NO: 12123) encoded by the nucleic acid sequence of example 2. PVM-00425 (PVX-PAT-2406-WO) PVM-00425 (PVX-PAT-2406-WO) Amino acid sequence of different peptides present in the multisubunit peptide encoded by the nucleic acid sequence of example 2 is separately identified in: Complete sequence of the multisubunit peptide encoded by the nucleic acid sequence of example 2 MGVKVLFALICIAVAEAYQVRNSSGLYHVTNDCPNSSIVYEAADAILHTPGCVPC VREGNASRCWVAVTPTVATRDGKLPTTQLRRHIDLLVGSATLCSALYVGDLCGS VFLVGQLFTFSPRRHWTTQDCNCSIYPGHITGHRMAWDMMMNWSPTAALVVAQ LLRIPQAIMDMIAPGGRIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKV MNYGGGGSGGGGSLSKDIIKLLNEQVNKEMNSSNLYMSMSSWCYTHSLDGAGLFLFD HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVD HAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIRRK RSVSGSGATNFSLLKQAGDVEENPGPMGVKVLFALICIAVAEAETHVTGGSAGRT TAGLVGLLTPGAKQNIQLINTNGSWHINSTALNCNESLNTGWLAGLFYQHKFNSS GCPERLASCRRLTDFAQGWGPISYANGSGLDERPYCWHYPPRPCGIVPAKSVCGP VYCFTPSPVVVGTTDRSGAPTYSWGANDTDVFVLNNTRPPLGNWFGCTWMNSTG FTKVCGAPPCVIGGVGNNTLLCPTDCFRKHPEATYSRCGSGPWITPRCMVDYPYR LWHYPCTINYTIFKVRMYVGGVEHRLEAACNWTRGERCDLEDRDRSELSPLLLST TQWQVLPCSFTTLPALSTGLIHLHQNIVDVQYLYGVGSSIASWAIPGGLTDTLQAE TDQLEDKKSALQTEIANLLKEKEKLEFILAAYGGGGSGGGGSLSKDIIKLLNEQV NKEMNSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSI SAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEV LFKDILDKIELIGNENHGLYLADQYVKGIRRKR (SEQ ID NO: 12123) *The different bolded, underlined, and italicized sequences corresponded to the different sequences in Table 1. Plasmid DNA isolation and linearization Plasmid DNA was obtained by standard techniques. Briefly, the plasmid DNA was introduced into E. coli DH5 alpha cells (Takara Stable Competent Cells, catalogue no. 9132, Takara Bio Inc., Japan). The competent cells were thawed on ice and incubated with the plasmid DNA (pDNA) for 15 min on ice. The mixture of competent cells and the plasmid DNA were given a heat shock for 45 sec at 42 °C, followed by a cold shock for 5 min on ice. LB (Luria-Bertani) medium was added to the cells and incubated for 1 h at 37 PVM-00425 (PVX-PAT-2406-WO) °C on an incubator shaker at 600-900 rpm. The cells were recovered and centrifuged at 4000 g for 2 min, the pellet was collected and resuspended in 100 uL of the same medium. Resuspended cells were transferred to an agar plate containing LB medium supplemented with kanamycin, and the cells were spread evenly using sterile glass beads and incubated for 14 to 16 h at 37 °C. Well grown colonies were picked and resuspended in LB medium supplemented with kanamycin and colony PCR was performed to check the presence of the gene of interest. The selected colonies were cultured overnight. NucleoSpin Plasmid Miniprep Kit (catalogue no.740588, Takara Bio Inc.) was used to isolate the plasmid DNA. The pDNA was linearized by digestion with XbaI restriction enzyme (catalogue no. 09520848101, Roche). The pDNA was quantified using Spark® Multimode Microplate Reader (catalogue no.30086376, Tecan). In vitro transcription (IVT) IVT was performed following standard procedure. Briefly, IVT mix containing four ribonucleotide triphosphates (ATP, Me-psUTP, GTP, and CTP - catalogue nos. 06529194103, 09744878103, 06529216103, and 06529208103 respectively, Roche), 1 M Tris (catalogue no. AM9850G, Invitrogen), 1 M magnesium acetate (catalogue no.63052, Sigma), spermidine (catalogue no.85558, Sigma), CleanCap®Reagent AG (3' OMe) (catalogue no. N-7413, TriLink BioTechnologies), DTT (catalogue no.43815-5G, Merck), RNAse inhibitor (catalogue no. G8005B, New England BioLabs Inc.), inorganic pyrophosphate (catalogue no.08140677103, Roche) and T7 RNA polymerase (catalogue no.08140669103, Roche) and linearized plasmid DNA was taken in a PCR tube containing nuclease free sterile water. The mixture was incubated for 3 h at 40 °C, followed by DNase I (catalogue no. M0303S, New England BioLabs Inc.) treatment to degrade any remaining plasmid DNA. The mRNA was purified as per instructions given in Monarch®RNA Cleanup Kit (catalogue no. T2050L, New England BioLabs Inc.). Poly A tail was added to the purified mRNA following standard post tailing procedure using E. coli Poly(A) Polymerase (catalogue no. M0276L, New England BioLabs Inc.). The mRNA with poly A tail was purified using Monarch®RNA Cleanup Kit (catalogue no. T2050L, New England BioLabs Inc.). The mRNA was quantified by Quant-iT™ RiboGreen™ RNA Assay Kit (catalogue no. R11490, Thermo Fisher Scientific) and Spark®Multimode Microplate Reader (catalogue no.30086376, Tecan). PVM-00425 (PVX-PAT-2406-WO) Formulation Lipid nanoparticle formulation or composition containing four lipid components was prepared by formulating the multisubunit nucleic acid (mRNA) obtained from the IVT step. The mRNA was dissolved in aqueous phase containing sodium acetate buffer (25 mM, pH 5.0), and lipid components viz., cationic lipid 50 mol percent (heptadecan-9-yl 8- [2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate [SM102], Sinopeg), phospholipid 10 mol percent (1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC], BOC sciences), cholesterol 38.5 mol percent (Merck), and PEG-lipid 1.5 mol percent (1,2- dimyristoyl-rac-glycero-3-methoxypolytheyleneglycol 2000 [mPEG2000-DMG], Sinopeg) were dissolved in organic phase (IPEC grade 99.5% v / v ethanol). The aqueous phase (continuous) and organic phase (dispersed) were mixed using a dual syringe pump (Microlab 600 Advanced Dual Syringe Diluter, catalogue no. ML625-DIL-BZ, Hamilton Company) in a microfluidic device (AXF Mini, Micropore Technologies). The total flow rate was maintained at 100 mL / min, and a flow rate ratio (FRR) of 3:1 for aqueous phase to organic phase respectively. The lipid nanoparticles were buffer exchanged with Tris- acetate buffer (pH 7.5) by using Amicon®Ultra 15 (catalogue no. UFC910096, Merck) filters. The retentate was collected and 8.7% sucrose was added to the lipid nanoparticle composition, followed by sterile filtration using 0.22 micron PES filters (catalogue no. SF- 13-100NO, HiMedia Laboratories) to obtain the lipid nanoparticle formulation or composition. Transfection HEK293T cells (catalogue no. CRL3216, ATCC, USA) were seeded at 0.1x106cells per well in a 24 well plate containing Gibco DMEM medium, high glucose, pyruvate (catalogue no.11995065, Thermo Fisher Scientific) supplemented with 10% fetal bovine serum and 100 units / mL penicillin-streptomycin and cultured to achieve 70-80% confluency.0.5 μg of mRNA formulated lipid nanoparticle obtained from the previous step was added to each well, and cells were incubated for 12-16 hours. Spent media was collected by aspiration, and cells were collected with ice-cold 1x PBS (1 mL) with hard pipetting. The cells were centrifuged at 4000 g for 5 min at 4 °C and excess PBS was aspirated. The cells were suspended gently in 150 μL of Pierce RIPA lysis buffer (catalogue no.89900, Thermo Scientific) with protease inhibitors and kept on ice for 20 PVM-00425 (PVX-PAT-2406-WO) min. The lysate was centrifuged at 21,000 g for 20 min at 4 °C. The supernatant was collected into microtubes. Western Blot A western blot was performed on cell lysate, obtained in the previous step, using Jess instrument (an automated western blot system catalogue no.004-650, ProteinSimple, Bio-Techne). The cell lysate was diluted and combined with 1part 5x fluorescent master mix (component of Separation Module compatible with Jess, catalogue no. SM-W001, ProteinSimple, Bio-Techne) and heated for 5 min at 95 °C to denature the protein. The following were loaded in the designated wells of the microplate provided by the manufacturer as per manufacturer’s protocol: 1. sample 2. antibody diluent (provided by manufacturer) 3. primary antibody (anti-ferritin antibody, catalogue no. CSB-PA009053ZA01HUV, CusaBio), diluted to 1:100 ratio 4. secondary antibody (HRP ready anti-rabbit antibody, catalogue no. DM-001, Protein Simple, Bio-Techne), and 5. chemiluminescent substrate (luminol-peroxide complex) The plate was then inserted into the Jess instrument where samples, antibodies, and substrate were drawn into individual capillaries located on a 25-capillary cassette (12-230 kDa Separation Module catalogue no. SM-W001, ProteinSimple, Bio-Techne). Electrophoresis and immunodetection were conducted in automated manner by the Jess instrument. The data was obtained by using the Compass software associated with the Jess system. The results are shown in figure 3. Example 3: ELISA A group of 6 mice (3 males and 3 females) were immunized with the multisubunit nucleic acid (mRNA) of example 2 in lipid nanoparticle formulation, prepared according to one of the previous steps (formulation step), intramuscularly (5 g in 100 L volume per animal, 50 L on each thigh). Additionally, a group of 6 mice (3 males and 3 females) PVM-00425 (PVX-PAT-2406-WO) were also injected with phosphate buffered saline (PBS), pH 7.4, which served as a vehicle control. ELISA was performed on day 21 pooled sera samples to detect the antibodies. Plate preparation: ELISA plate (Maxisorp 96-well plate, Nunc) was coated with lectin (5 μg / mL in 1x PBS, pH 7.4), 100 μL per well, and incubated overnight at 4 °C. Unbound lectin was washed three times with wash buffer (200 μL PBS with 0.05% (v / v) Tween 20, pH 7.4). Hepatitis C virus (HCV) antigens (E1 protein and E2 protein) were expressed recombinantly, and the cell lysate was used to coat the ELISA plate (100 μL per well) and incubated at room temperature for 2 hours. ELISA plate was washed with wash buffer and blocked with a blocking solution (5% NFDM (catalogue no. sc-2325, Santa Cruz) in 200 μL 1x PBS, pH 7.4), and incubated at room temperature for 60 minutes. Unbound antigen was washed three times with the wash buffer. Sample preparation: Serum sample was serially diluted (3-fold) with dilution buffer (1% NFDM in PBS, pH 7.4) in a dilution plate. Testing: The diluted serum sample (100 μL per well) was transferred to ELISA plate and incubated at room temperature for 1 h. ELISA plate was washed five times with wash buffer.100 μL of secondary antibody (anti-mouse IgG, catalogue no.7076-S, Cell Signalling Technologies), dilution ratio 1:5000, was added to the wells of the ELISA plate and incubated for 1 h at room temperature. ELISA plate was washed with wash buffer, and 100 μL of TMB substrate (catalogue no. TMBW-1000-01, Thermo Scientific) was added to each well, and incubated for 15 min. The enzyme substrate reaction was stopped by adding 50 μL 1 N HCl to each well. The ELISA plate was read at 450 nm, with 630 nm as reference using spectrophotometer (Spectramax MS microplate reader, Tecan). Endpoint titre was determined based on the mean OD value of plate blank and multiplied by dilution factor. The ELISA data is represented in log scale. The results are shown in figure 4. Example 4 (prophetic): Pseudovirus neutralization To measure the neutralization antibody titers, pseudovirus neutralization assay is performed. A pseudovirus carrying the target peptide (E1 protein or E2 protein) on a genetically crippled virus harbouring a reporter gene is generated by using standard techniques. For example, Lenti X™ 293T cells (catalogue no.632180, Takara Bio Inc., Japan) or any other appropriate cell line is transfected with plasmid vector carrying a gene for the target peptide and a reporter (for example, luciferase or GFP etc) plasmid with PVM-00425 (PVX-PAT-2406-WO) transfecting agent (for example, Lipofectamine™ 3000 Transfection Reagent using serum free medium (for example, Opti-MEM). After 12-16 hours of incubation at 37 ºC and 5% CO2, the transfection media is replaced with seeding medium (for example, DMEM+10% FBS). The supernatant containing pseudovirus particles is collected at appropriate interval (for example 48 to 72 hours) post transfection. The supernatant containing pseudoviruses is centrifuged, filtered, aliquoted in appropriate volume, and stored at -80 ºC for further use. A pseudovirus neutralization assay is performed to evaluate neutralizing antibodies in sera (pooled or individual mice sera). Briefly, in tissue culture-treated white opaque 96 well plates, permissive cell line that supports replication of target pathogen (HCV) are plated and incubated overnight at 37 ºC with 5% CO2. The sera samples are serially diluted (for example, 2 or 3 fold or as appropriate) in suitable medium and mixed in a 1:1 ratio with the respective pseudoviruses. The mixture is incubated at 37 ºC for one hour and added to the wells (containing permissive cells) of the plate, and the plate is incubated at 37 ºC with 5% CO2for appropriate duration (for example 48 to 72 hours). Appropriate luminescence substrate (for example, luciferase or GFP etc) is added to the wells of the plate. The luminescence activity is measured by using a luminometer. Percentage neutralization is calculated by normalizing the test RLU (relative luminescence units) with virus control and cell-only control RLU. The pseudovirus neutralization reciprocal IC50(half-maximal inhibitory concentration) titres is calculated using a non-linear regression curve fit ‘log(inhibitor) vs. response -- Variable slope (four parameters)’. Example 5 (Prophetic): Synthesis of multisubunit nucleic acid sequence (mRNA) – bivalent, trivalent, tetravalent, and pentavalent constructs Plasmid DNA construction The multisubunit nucleic acid sequence comprising at least two (bivalent), three (trivalent), four (tetravalent), or five (pentavalent) polynucleotide sequences, each separated by one or more cleavage sequences, is codon optimized for human expression. Each polynucleotide sequence comprises either a target sequence (encoding a target peptide), a linker sequence (encoding a linker peptide) and a self-assembling sequence (encoding a self-assembling peptide) or a linker sequence (encoding a linker peptide), a target sequence (encoding a target peptide), a linker sequence (encoding a linker peptide) and a self-assembling sequence (encoding a self-assembling peptide) or their combination. PVM-00425 (PVX-PAT-2406-WO) Such a multisubunit nucleic acid sequence is synthesized by techniques well known in the art or ordered from gene synthesis companies such as Twist Bioscience, USA. A signal sequence (encoding signal peptide) is included upstream of the first polynucleotide sequence, and optionally, ups...

Claims

1. PVM-00425 (PVX-PAT-2406-WO) What is claimed:

1. A multisubunit nucleic acid comprising a plurality of polynucleotide sequences, wherein some or all polynucleotide sequences of the plurality comprises either a target sequence, a linker sequence, and a self-assembling sequence or a linker sequence, a target sequence, a linker sequence and a self-assembling sequence or a combination thereof, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus.

2. A multisubunit nucleic acid comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a target sequence, a linker sequence, and a self-assembling sequence, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus.

3. A multisubunit nucleic acid comprising a plurality of polynucleotide sequences, wherein each polynucleotide sequence of the plurality comprises a linker sequence, a target sequence, a linker sequence, and a self-assembling sequence, wherein each polynucleotide sequence of the plurality is connected to an adjacent polynucleotide sequence of the plurality by a cleavage sequence, and wherein the multisubunit nucleic acid further comprises a signal sequence upstream of one or more of the polynucleotide sequences of the plurality, wherein the target sequence is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein,PVM-00425 (PVX-PAT-2406-WO) NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus.

4. The multisubunit nucleic acid according to any one of the preceding claims, wherein the target sequence, the linker sequence, and the self-assembling sequence or the linker sequence, the target sequence, the linker sequence, and the self-assembling sequence are in 5’ to 3’ order.

5. A multisubunit nucleic acid encoding a plurality of polypeptides, wherein some or all polypeptides of the plurality comprises either a target peptide, a linker peptide, and a self-assembling peptide or a linker peptide, a target peptide, a linker peptide and a self- assembling peptide or a combination thereof, wherein each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide, and wherein the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of one or more of the polypeptides of the plurality, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus.

6. A multisubunit nucleic acid encoding a plurality of polypeptides, wherein each polypeptide of the plurality comprises a target peptide, a linker peptide, and a self- assembling peptide, wherein each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide, and wherein the multisubunit nucleic acid further encodes a signal peptide on the amino-terminus of one or more of the polypeptides of the plurality, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus.

7. A multisubunit nucleic acid encoding a plurality of polypeptides, wherein each polypeptide of the plurality comprises a linker peptide, a target peptide, a linker peptide, and a self-assembling peptide, wherein each polypeptide of the plurality is connected to an adjacent polypeptide of the plurality by a cleavage peptide, and wherein the multisubunitPVM-00425 (PVX-PAT-2406-WO) nucleic acid further encodes a signal peptide on the amino-terminus of one or more of the polypeptides of the plurality, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus.

8. The multisubunit nucleic acid according to any one of the claims 5-7, wherein the target peptide, the linker peptide, and the self-assembling peptide or the linker peptide, the target peptide, the linker peptide, and the self-assembling peptide are in N-terminus to C- terminus order.

9. The multisubunit nucleic acid according to any one of the preceding claims, wherein total number of the polynucleotide sequences or the polypeptides are not more than 100.

10. The multisubunit nucleic acid according to claim 9, wherein total number of the polynucleotide sequences or the polypeptides are between 2-5, 2-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, or 90-99.

11. The multisubunit nucleic acid according to any one of the preceding claims, wherein the multisubunit nucleic acid is a DNA or an RNA.

12. The multisubunit nucleic acid according to claim 11, wherein the RNA is an mRNA.

13. The multisubunit nucleic acid according to claim 12, wherein the mRNA is 1 to 20 kb, 1 to 18 kb, 1 to 16 kb, 1 to 14 kb, 1 to 12 kb, 1 to 10 kb, 1 to 9 kb, 1 to 8 kb, 1 to 7 kb, 1 to 6 kb, 1 to 5 kb in length, or any range therein.

14. The multisubunit nucleic acid according to any one of the claims 12-13, wherein the mRNA is obtained through a single IVT process or step.

15. The multisubunit nucleic acid according to any one of the claims 1-4 and 9-14, wherein the linker sequence encodes a linker peptide.PVM-00425 (PVX-PAT-2406-WO) 16. The multisubunit nucleic acid according to any one of the claims 5-15, wherein the linker peptide is an amino acid linker, a zipper motif, a foldon, a scaffold, or a combination thereof.

17. The multisubunit nucleic acid according to claim 16, wherein the linker peptide is the amino acid linker.

18. The multisubunit nucleic acid according to claim 17, wherein the amino acid linker comprises 2 to 49 amino acids.

19. The multisubunit nucleic acid according to any one of the claims 17-18, wherein the amino acid linker is a glycine serine linker, a glycine proline linker, a glycine threonine linker, an alanine serine linker, any combination of two amino acids, or a combination thereof.

20. The multisubunit nucleic acid according to claim 16, wherein the linker peptide is the zipper motif.

21. The multisubunit nucleic acid according to claim 16, wherein the linker peptide is the foldon.

22. The multisubunit nucleic acid according to claim 16, wherein the linker peptide is the scaffold.

23. The multisubunit nucleic acid according to any one of the claims 16-19, wherein the linker peptide comprises the amino acid linker and the zipper motif.

24. The multisubunit nucleic acid according to any one of the claims 16-19, wherein the linker peptide comprises the amino acid linker and the foldon.

25. The multisubunit nucleic acid according to any one of the claims 16-19, wherein the linker peptide comprises the amino acid linker and the scaffold.PVM-00425 (PVX-PAT-2406-WO) 26. The multisubunit nucleic acid according to any one of the claims 16-19, wherein the linker peptide comprises the amino acid linker, the zipper motif, and the scaffold.

27. The multisubunit nucleic acid according to any one of the claims 16-19, wherein the linker peptide comprises the amino acid linker, the foldon, and the scaffold.

28. The multisubunit nucleic acid according to claim 16, wherein the linker peptide comprises the zipper motif and the scaffold.

29. The multisubunit nucleic acid according to claim 16, wherein the linker peptide comprises the foldon and the scaffold.

30. The multisubunit nucleic acid according to any one of the claims 5-29, wherein the linker peptide has an amino acid sequence of any one of SEQ ID NOs: 12-51 or 12116- 12120.

31. The multisubunit nucleic acid according to any one of the claims 1-4 and 9-30, wherein the self-assembling sequence encodes a self-assembling peptide.

32. The multisubunit nucleic acid according to any one of the claims 5-31, wherein the self-assembling peptide is a lumazine synthase, an MS2 coat protein, a hepatitis B surface antigen (HbsAg) from Hepatitis B Virus, a hepatitis B core antigen (HbcAg) from Hepatitis B virus, a human papillomavirus L1 (HPV L1) protein, a matrix protein M1 from influenza A virus, a ferritin, a riboflavin synthase, a dihydrolipoyl acetyltransferase (E2p), or a combination thereof, including their codon optimized nucleic acid sequences, fragments, mutants, variants, comparable equivalents, or functional analogs thereof.

33. The multisubunit nucleic acid according to any one of the claims 31-32, wherein the self-assembling peptide is a ferritin comprising a ferritin subunit or a ferritin peptide, a dihydrolipoyl acetyltransferase (E2p), a lumazine synthase, an MS2 coat protein, or a combination thereof.PVM-00425 (PVX-PAT-2406-WO) 34. The multisubunit nucleic acid according to claim 33, wherein the ferritin peptide is obtained or derived from Helicobacter pylori ferritin, Listeria innocua ferritin, the lumazine synthase is obtained or derived from Aquifex aeolicus or Bacillus subtilis, the MS2 coat protein is obtained or derived from Emesvirus zinderi, and the dihydrolipoyl acetyltransferase (E2p) is obtained or derived from Bacillus stearothermophilus.

35. The multisubunit nucleic acid according to any one of the claims 5-34, wherein the self-assembling peptide has an amino acid sequence of any one of SEQ ID NOs: 1-11 or 12112-12115.

36. The multisubunit nucleic acid according to any one of the claims 1-4 and 9-35, wherein the cleavage sequence encodes one or more cleavage peptides.

37. The multisubunit nucleic acid according to any one of the claims 5-36, wherein the one or more cleavage peptides are optionally connected to each other by a linker peptide.

38. The multisubunit nucleic acid according to claim 37, wherein the cleavage peptide is a golgi specific cleavage peptide, a self cleaving peptide, or a combination thereof.

39. The multisubunit nucleic acid according to any one of the claims 5-38, wherein the cleavage peptide has an amino acid sequence of any one of SEQ ID NOs: 52-66.

40. The multisubunit nucleic acid according to any one of the claims 1-4 and 9-39, wherein the signal sequence encodes a signal peptide.

41. The multisubunit nucleic acid according to any one of the claims 5-40, wherein the signal peptide is present on the amino-terminus of one or more of the polypeptides of the plurality.

42. The multisubunit nucleic acid according to claim 41, wherein the multisubunit nucleic acid further encodes a second signal peptide on the amino-terminus of all or some polypeptides of the plurality.PVM-00425 (PVX-PAT-2406-WO) 43. The multisubunit nucleic acid according to any one of the claims 5-42, wherein the signal peptide has an amino acid sequence of any one of SEQ ID NOs: 67-86.

44. The multisubunit nucleic acid according to any one of the claims 1-4 and 9-43, wherein the target sequence encodes a target peptide.

45. The multisubunit nucleic acid according to any one of the claims 5-44, wherein the target peptide is encoded by a codon optimized nucleic acid sequence, or fragments, mutants, variants, comparable equivalents, or functional analogs thereof.

46. The multisubunit nucleic acid according to claim 45, wherein the target peptide is obtained or derived from core protein of a hepacivirus.

47. The multisubunit nucleic acid according to claim 46, wherein the core protein comprises an amino acid sequence of any one of SEQ ID NOs: 88-353.

48. The multisubunit nucleic acid according to claim 45, wherein the target peptide is obtained or derived from E1 protein of a hepacivirus.

49. The multisubunit nucleic acid according to claim 48, wherein the E1 protein comprises an amino acid sequence of any one of SEQ ID NOs: 354-959 or 12121.

50. The multisubunit nucleic acid according to claim 45, wherein the target peptide is obtained or derived from E2 protein of a hepacivirus.

51. The multisubunit nucleic acid according to claim 50, wherein the E2 protein comprises an amino acid sequence of any one of SEQ ID NOs: 960-1582 or 12122.

52. The multisubunit nucleic acid according to claim 45, wherein the target peptide is obtained or derived from P7 protein of a hepacivirus.

53. The multisubunit nucleic acid according to claim 52, wherein the P7 protein comprises an amino acid sequence of any one of SEQ ID NOs: 1583-2026.PVM-00425 (PVX-PAT-2406-WO) 54. The multisubunit nucleic acid according to claim 45, wherein the target peptide is obtained or derived from NS2 protein of a hepacivirus.

55. The multisubunit nucleic acid according to claim 54, wherein the NS2 protein comprises an amino acid sequence of any one of SEQ ID NOs: 2027-2651.

56. The multisubunit nucleic acid according to claim 45, wherein the target peptide is obtained or derived from NS3 protein of a hepacivirus.

57. The multisubunit nucleic acid according to claim 56, wherein the NS3 protein comprises an amino acid sequence of any one of SEQ ID NOs: 2652-3284.

58. The multisubunit nucleic acid according to claim 45, wherein the target peptide is obtained or derived from NS4A protein of a hepacivirus.

59. The multisubunit nucleic acid according to claim 58, wherein the NS4A protein comprises an amino acid sequence of any one of SEQ ID NOs: 3285-3462.

60. The multisubunit nucleic acid according to claim 45, wherein the target peptide is obtained or derived from NS4B protein of a hepacivirus.

61. The multisubunit nucleic acid according to claim 60, wherein the NS4B protein comprises an amino acid sequence of any one of SEQ ID NOs: 3463-4004.

62. The multisubunit nucleic acid according to claim 45, wherein the target peptide is obtained or derived from NS5A protein of a hepacivirus.

63. The multisubunit nucleic acid according to claim 62, wherein the NS5A protein comprises an amino acid sequence of any one of SEQ ID NOs: 4005-4627.

64. The multisubunit nucleic acid according to claim 45, wherein the target peptide is obtained or derived from NS5B protein of a hepacivirus.PVM-00425 (PVX-PAT-2406-WO) 65. The multisubunit nucleic acid according to claim 64, wherein the NS5B protein comprises an amino acid sequence of any one of SEQ ID NOs: 4628-5247.

66. The multisubunit nucleic acid according to claim 45, wherein the target peptide is obtained or derived from B cell epitope of a hepacivirus.

67. The multisubunit nucleic acid according to claim 66, wherein the B cell epitope comprises an amino acid sequence of any one of SEQ ID NOs: 5248-10039.

68. The multisubunit nucleic acid according to claim 45, wherein the target peptide is obtained or derived from T cell epitope of a hepacivirus.

69. The multisubunit nucleic acid according to claim 68, wherein the T cell epitope comprises an amino acid sequence of any one of SEQ ID NOs: 10040-12111.

70. The multisubunit nucleic acid according to any one of the claims 5-69, wherein the target peptide has an amino acid sequence of any one of SEQ ID NOs: 88-12111 or 12121- 12122.

71. A lipid nanoparticle composition comprising a cationic lipid, a phospholipid, a sterol, a PEG-lipid, and the multisubunit nucleic acid according to any one of the preceding claims.

72. The lipid nanoparticle composition according to claim 71, wherein the cationic lipid is present in an amount from 10 mol percent to 70 mol percent.

73. The lipid nanoparticle composition according to claim 71, wherein the phospholipid is present in an amount from 2 mol percent to 65 mol percent.

74. The lipid nanoparticle composition according to claim 71, wherein the sterol is present in an amount from 20 mol percent to 65 mol percent.PVM-00425 (PVX-PAT-2406-WO) 75. The lipid nanoparticle composition according to claim 71, wherein the PEG-lipid is present in an amount from 0.2 mol percent to 2.0 mol percent.

76. The lipid nanoparticle composition according to claim 71, additionally comprising an ionizable polymer.

77. The lipid nanoparticle composition according to claim 76, wherein the ionizable polymer is present in an amount from 1 mol percent to 25 mol percent.

78. The lipid nanoparticle composition according to any one of the claims 71-77, wherein the cationic lipid is represented by any one of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), or SM-102, or ALC-0315, or a combination thereof.

79. The lipid nanoparticle composition according to any one of the claims 71-78, wherein the cationic lipid is represented by formula (I).

80. The lipid nanoparticle composition according to any one of the claims 71-78, wherein the cationic lipid is represented by formula (II).

81. The lipid nanoparticle composition according to any one of the claims 71-78, wherein the cationic lipid is represented by formula (III).

82. The lipid nanoparticle composition according to any one of the claims 71-78, wherein the cationic lipid is represented by formula (IV).

83. The lipid nanoparticle composition according to any one of the claims 71-78, wherein the cationic lipid is represented by formula (V).

84. The lipid nanoparticle composition according to any one of the claims 71-78, wherein the cationic lipid is represented by formula (VI).PVM-00425 (PVX-PAT-2406-WO) 85. The lipid nanoparticle composition according to any one of the claims 71-78, wherein the cationic lipid is represented by formula (VII).

86. The lipid nanoparticle composition according to any one of the claims 71-78, wherein the cationic lipid is represented by formula (VIII).

87. A multisubunit peptide encoded by the multisubunit nucleic acid according to any one of the claims 1-70.

88. A multisubunit peptide comprising two or more polypeptides, wherein some or all of the polypeptides comprises either a target peptide, a linker peptide, and a self- assembling peptide, or a linker peptide, a target peptide, a linker peptide, and a self- assembling peptide or a combination thereof, wherein one polypeptide is connected to another polypeptide by a cleavage peptide, wherein the multisubunit peptide includes a signal peptide on the amino-terminus of one or more of the polypeptides, wherein the target peptide is obtained or derived from core protein, E1 protein, E2 protein, P7 protein, NS2 protein, NS3 protein, NS4A protein, NS4B protein, NS5A protein, NS5B protein, B cell epitope, T cell epitope, or a combination thereof of a hepacivirus.

89. A polypeptide nanoparticle comprising at least 2 or up to 500 polypeptides according to any one of the claims 5-70 or 88.

90. The polypeptide nanoparticle according to claim 89, comprising a homologous polypeptide, a heterologous polypeptide, an oligomeric complex, a polypeptide cluster, or a combination thereof.

91. The polypeptide nanoparticle according to any one of the claims 89-90, wherein the polypeptide nanoparticle is icosahedral, helical, spherical, rod-like, or a combination thereof.

92. A vaccine comprising the multisubunit nucleic acid according to any one of the claims 1-70.PVM-00425 (PVX-PAT-2406-WO) 93. A vaccine comprising the lipid nanoparticle composition according to any one of the claims 71-86.

94. A vaccine comprising the polypeptide nanoparticle according to any one of the claims 89-91.

95. A method of treating or preventing a disease, comprising administering to a subject in need thereof the multisubunit nucleic acid according to any one of the claims 1-70 or the vaccine according to any one of the claims 92 or 94.

96. A method of treating or preventing a disease, comprising administering to a subject in need thereof the lipid nanoparticle composition according to any one of the claims 71- 86 or the vaccine according to claim 93.

97. The method according to any one of the claims 95-96, wherein the disease is hepatitis C infection, hepatitis and hepatocellular carcinoma, liver damage, liver failure, cirrhosis, or liver cancer.

98. Use of the multisubunit nucleic acid according to any one of the claims 1-70 or the vaccine according to any one of the claims 92 or 94, in the manufacture of a medicament for the treatment or prevention of a disease in a subject.

99. Use of the lipid nanoparticle composition according to any one of the claims 71-86 or the vaccine according to claim 93, in the manufacture of a medicament for the treatment or prevention of a disease in a subject.

100. The use according to any one of the claims 98-99, wherein the disease is hepatitis C infection, hepatitis and hepatocellular carcinoma, liver damage, liver failure, cirrhosis, or liver cancer.

Images